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ABSTRACT 
 
Lung cancer has the highest mortality rate of any cancer, often due to the fact that it 
is detected at a late stage in its progression when it has already metastasised. The 
levels of certain biomarkers, such as proteins, metabolites and chemokines, in 
biological fluid or tissue could potentially detect cancer at an early stage, determine 
cancer subtype, or monitor the sensitivity to cancer treatment.  
 
Currently available lung cancer markers lack the sensitivity and specificity to be of 
great benefit and there is room for improvement. The research in this thesis aims to 
discover new biomarkers, using proteomic techniques, with the potential to improve 
or supersede those used at present for diagnosis and prognosis of lung cancer. 
 
Discovery phase was performed on conditioned media of lung cancer cell lines 
using 2D-DIGE in the hope it might mimic the serum/plasma environment of lung 
cancer patients. Further discovery phase was performed on serum using 
immunodepletion, proteominer, 2D-DIGE, label-free mass spectrometry followed 
by pathway analysis, metabolomic analysis, and multiplex assay analysis of cancer 
panels and a matrix-metalloproteinase panel. 
 
Validation in serum and plasma was performed using ELISAs, biochemical assays, 
and multiplex platforms, and in tissue using immunohistochemistry. Lung cancer 
subtypes examined in validation phase were squamous cell carcinoma, 
adenocarcinoma, and small cell lung cancer. There were insufficient serum/plasma 
samples to include a large cell carcinoma group. 
 
Potential biomarkers discovered include hnRNPA2B1, pyruvate kinase M2 
(PKM2), HSC70-interacting protein (Hip), tenascin C, vascular endothelial growth 
factor alpha (VEGF-α), MMP-1, MMP-8, MMP-9, 12-HETE, and phenylalanine. 
 
In serum hnRNPA2B1, PKM2, Hip, tenascin C, VEGF-α, MMP-1, -8, and -9, and 
12-HETE were increased in cancer compared to normal. Phenylalanine had similar 
levels in normal and small cell lung cancer but was decreased in non-small cell lung 
cancer. Of those examined in plasma hnRNPA2B1, VEGF-α, MMP-1 and -9, and 
 X
12-HETE were decreased in cancer compared to normal whereas PKM2 and 
tenascin C were increased. Where benign lung disease controls were used the 
markers were present at levels similar to lung cancer except for MMP-9 in plasma, 
VEGF-α in serum, and PKM2 in both serum and plasma. 
 
Immunohistochemistry of tissue showed an overall increase of expression of 
hnRNPA2B1 and HSC70-interacting protein in cancer tissue compared to normal.  
 
Functional assays were performed on hnRNPA2B1 showing its potential role in 
invasion and migration of lung cancer; its knockdown in the DLKP-M lung cancer 
cell line with two siRNA’s showed a 57% and 44% decrease in invasion and a 32% 
and 39% decrease in migration respectively. 
 
The research provided in this thesis demonstrates the importance for intensive 
validation before conclusions can be drawn on the overall usefulness of candidate 
lung cancer markers; a good serum marker does not necessarily make a good 
plasma marker and a marker that differentiates normal conditions from cancer 
conditions does not necessarily differentiate lung diseases/benign tumour from 
cancer. 
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1.1 Cancer Biomarkers 
 
After the genomic revolution science expected great progress to be made in the area 
of biomedical discovery, especially in relation to early diagnosis and identification 
of cancer risk. This has not been the case and the anticipated new range of 
diagnostic tools has been slow to emerge. Biomarkers are often proteins which can 
indicate the presence of a disease relatively early (Etzioni, Urban et al. 2003), and 
can also monitor the progression or recession of a cancer during treatment (Gail, 
Muenz et al. 1988). A biomarker, or more probably a panel of biomarkers (Han, 
Liew et al. 2008, Millar, Graham et al. 2011), ideally can be screened quite easily 
and the presence of these markers in the blood or other biological body fluids would 
allow this (Toyama, Nakagawa et al. 2011). Biological fluids are considered a better 
source of biomarkers than tissue due to several factors, including ease of 
accessibility, avoiding risks of invasive tissue sampling through biopsies, relative 
low cost obtainment, availability of monitoring based on multiple sampling, and the 
potential for large-scale, valuable prognostic/diagnostic tests (Good, 
Thongboonkerd et al. 2007). However, the detection of tissue-specific biomarkers 
in body fluids requires the biomarker to be identified as disease tissue-specific from 
thousands of other proteins in circulation and also requires it to be secreted in the 
first place, whereas tissue can be used to find tumour-specific protein biomarkers 
more directly from the source (Shiwa, Nishimura et al. 2003). 
 
The hunt for blood-based biomarkers (and indeed from other biological fluids) is 
based on the hypothesis that tumours secrete specific proteins (including those 
harbouring characteristic post-translational modifications) that collectively 
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constitute a molecular fingerprint reflecting physiological conditions (Makawita, 
Smith et al. 2011). To be able to read and understand this fingerprint through blood 
samples would allow a non-invasive, unique look into the disease state of a patient.  
 
While blood is a very appropriate non-invasive fluid for monitoring biomarkers 
(Hanash, Baik et al.), the presence of high abundant proteins such as albumin, 
transferrin, fibrinogen and IgGs can mask the presence of important, disease-
specific low abundant proteins (Fountoulakis, Juranville et al. 2004). The most 
abundant blood protein, albumin, is present at 30mg/ml, in contrast to most 
biomarkers which are present in the ng and pg/ml range, meaning a dynamic range 
of detection of up to 12 orders of magnitude is required, whereas most mass 
spectrometry instruments can only measure 3-4 orders of magnitude (Hung and 
Yu). In fact, the 20 most abundant proteins account for 97% of the plasma proteome 
and some sort of fractionation step is needed to remove these proteins in order to 
have a chance of detecting the vast numbers of low abundant proteins (Kim and 
Kim 2007). However, examination of this low-molecular-weight (LMW) range of 
the circulatory proteome, often called the peptidome, due to the profusion of protein 
peptides and fragments, has an additional complexity caused by the binding of these 
disease markers to the high-abundant proteins such as albumin (Rogatsky, Tomuta 
et al. 2007). 
 
To remove and discard the high abundant proteins could mean losing valuable 
diagnostic information (Tirumalai, Chan et al. 2003). Interestingly, by binding to 
albumin these LMW proteins acquire longer half-lives, since albumin protects the 
bound species from kidney clearance (Lowenthal, Mehta et al. 2005), thus 
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increasing the length of time these proteins will circulate in the blood, in turn 
improving the chances they will be detected by a clinical assay or reach their target 
(Dennis, Zhang et al. 2002). In addition to these problems protein concentrations 
are dynamic (Anderson and Anderson 2002), sometimes changing noticeably with 
stress, disease, or treatment, and the proteins themselves can be modified by 
cleavage or by addition of new functional groups (such as phosphorylation or 
glycosylation) which may effect their detection.  
 
 
 
Figure 1.1: Low abundant proteins that may indicate the disease state of a patient 
are found in only one percent of the total protein content of serum 
(http://www.sigmaaldrich.com/life-science/proteomics/mass-spectrometry/protein-
aqua/absolute-quantification-of-serum-proteome.html). 
 
Examination of the low abundant proteins is helped by removal of high abundant 
proteins with the use of multiple affinity removal columns which contain affinity-
purified polyclonal antibodies as seen with immunodepletion, which can be 
combined with other fractionation steps (Dayarathna, Hancock et al. 2008), and also 
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with newer technology such as ProteoMiner, which uses a large library of 
hexapeptide ligands with a limited number of binding sites that act as unique 
binders for proteins (Boschetti and Righetti 2008).  
 
 
Figure 1.2: Proteominer Technology (BioRad) 
 
ProteoMiner technology compresses the dynamic range of protein concentrations in 
complex biological samples such as serum by decreasing high-abundance proteins 
and capturing low-abundance proteins and can be used for quantitative analysis of 
the latter in complex biological samples (Hartwig, Czibere et al. 2009). 
ProteoMiner decreases the amount of high-abundance proteins without 
immunodepletion, preventing the loss of proteins bound to these proteins, which are 
inadvertently lost with immunodepletion and it enriches and concentrates low-
abundance proteins that cannot be detected through traditional methods. It can be 
used to decrease the dynamic range of the protein concentration in a variety of 
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samples and is not dependent on a predefined set of antibodies as are 
immunodepletion columns, and importantly it is compatible with current 
downstream protein analysis techniques. 
 
Studying the peptidome gives important diagnostic information such as; (i) the 
quantity of the peptide itself, (ii) the identity of the parent protein and the peptide 
fragment, and (iii) the nature of the carrier protein to which it is bound. Measuring 
panels of these peptidome markers instead of single markers can overcome 
sensitivity and specificity issues seen with single biomarkers and evaluating this 
combination as a fingerprint of disease is considered the way forward (Petricoin, 
Ardekani et al. 2002, Petricoin, Ornstein et al. 2004). The ability of biomarkers, 
whether single or a panel, to achieve the clinically required level of specificity and 
sensitivity depends on the intended use of the marker. For example, markers used 
for high-risk screening or relapse monitoring can have much lower specificity than 
markers for general population screening for rare diseases, which would require 
almost 100% specificity to be accepted. 
It is clear that body fluids, and blood in particular, potentially harbour many 
markers of different diseases for diagnosis, prognosis and treatment monitoring 
(Hashiguchi, Tanaka et al. 2009, Shen, Tolic et al. 2010) and there are many 
proteomic techniques to make the most of this potential (Conrotto and 
Souchelnytskyi 2008). 
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1.2 Lung Cancer 
 
Lung cancer is the most common cause of cancer-related death in Ireland and 
indeed the world. Between 1994 and 2000 there was a 33% increase in the 
incidence rates of lung cancer in Ireland and it accounts for 20% of all cancer 
deaths. In the United States in 2007, 203,536 people were diagnosed with lung 
cancer and of these 158,683 people died from the disease. The five-year survival 
rate in the U.S. is 49 percent when confined to the lungs, 16 percent when it has 
spread to the chest and as low as 2 percent when it has spread to other organs. 
Women with lung cancer are more likely than men to have adenocarcinoma, to be 
younger at diagnosis, to have smoked less, and to have a first-degree relative with 
lung cancer (Zang and Wynder 1996).  
 
Small cell lung cancer (SCLC) makes up about 15% of lung cancer cases and non-
small lung cancer (NSCLC) makes up the rest. NSCLC is further divided into 
adenocarcinoma (AD), squamous cell carcinoma (SCC), large cell carcinoma 
(LCLC), and bronchioalveolar carcinoma (BAC). A majority of SCLC patients 
present with extensive disease and the survival rate is less than 5% over 5 years. 
The main cause of lung cancer is smoking so it is easily preventable in most cases 
but unfortunately diagnosis generally occurs at a late stage when the cancer has 
metastasised and is therefore difficult to treat effectively. The association of SCLC 
with smoking is so strong that its diagnosis in a non-smoker is considered 
exceptional and would be re-evaluated (Rekhtman). Diagnosis at an early stage is 
essential for improvements in long-term survival.  
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Strategies used to detect lung cancer early include CT scans, bronchoscopy, and 
sputum analysis, though none of them have proven to be effective. 
 
1.2.1  Pathogenesis of Lung Cancer 
Significant strides have been made in understanding the molecular and cellular 
pathogenesis of lung cancer with focus being brought on genetic and epigenetic 
changes of tumour suppressor genes, abnormalitites of protooncogenes, and the role 
of angiogenesis in the many stages of lung cancer development, as well as detection 
of molecular abnormalities in preinvasive respiratory lesions. These findings can 
lead to clinical strategies for risk assessment, chemoprevention, treatment selection, 
early diagnosis and prognosis, and to provide new targets and methods of treatment 
for lung cancer patients. 
 
The autocrine and paracrine systems are cell signalling systems that involve, in 
the former, a cell secreting a hormone or chemical messenger that binds to 
autocrine receptors on the same cell, and in the latter, secreting a hormone or 
chemical messenger which targets a nearby cell. A well-characterised autocrine 
system involves bombesin-like peptides, such as gastrin-releasing peptide (GRP) 
and neuromedin B (NMB). Bombesin-like peptides are important regulators of 
human lung development and in normal tissues stimulate growth of bronchial 
epithelial tissues (Spindel 1996). The family of G protein-coupled bombesin 
receptors mediate the effects of GRP, which includes GRP receptor (GRPR), NMB 
receptor (NMBR), and the bombesin receptor subtype 3 (BRS-3). In NSCLC the 
expression of NMBR is common, whereas that of GRPR and BRS-3 is less frequent 
(DeMichele, Davis et al. 1994). The NMB gene is expressed in all NSCLC and also 
 9
SCLC, and GRP is expressed in 20-60% of SCLC and less frequently in NSCLC. A 
proliferative response of bronchial cells to GRP as well as long-term tobacco use 
have been linked to activation of GRPR and it has been reported that GRPR mRNA 
is more frequently expressed in women than in men in the absence of smoking, and 
in response to tobacco exposure, expression is activated earlier in women (Cuttitta, 
Carney et al. 1985). 
Another growth factor/receptor complex that could be involved in lung cancer 
development is the hepatocyte growth factor (HGF) and its receptor. Epithelial cells 
are stimulated by HGF to proliferate, move, and undergo differentiation. HGF is 
expressed in NSCLC (Harvey, Warn et al. 1996) and is linked with impaired 
survival (Siegfried, Weissfeld et al. 1997). The oncogene MET encodes the HGF 
receptor and is expressed in normal lung epithelium, and in both NSCLC and SCLC 
(Olivero, Rizzo et al. 1996). 
Epidermal growth factor (EGFR) regulates epithelial proliferation and 
differentiation and the EGFR gene was found to be overexpressed in 13% of 
NSCLCs (Reissmann, Koga et al. 1999). 
 
Proto-oncogenes are involved in normal cellular growth and development and their 
expression is tightly regulated. The RAS genes (HRAS, KRAS, NRAS) code for 
guanosine triphosphate (GTP)-binding proteins, and have an important role in 
signal transduction (which is when an extracellular signalling molecule activates a 
surface receptor of a cell). RAS oncogenes have been detected in about 20-30% of 
lung adenocarcinomas and in 15-20% of all NSCLC, and in almost all cases the 
mutation is present in codon 12 of the KRAS gene (Rodenhuis and Slebos 1990). 
Interestingly, RAS point mutations (a single base substitution causing the 
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replacement of a single base nucleotide with another nucleotide of the genetic 
material and can also include insertions or deletions of a single base pair) are never 
found in SCLCs (Zochbauer-Muller, Gazdar et al. 2002). Most KRAS mutations are 
G-T transversions of the type that are associated with carcinogens from cigarette 
smoke (Rodenhuis and Slebos 1990). 
The MYC proto-oncogene family and their unregulated expression have 
involvement in cell proliferation and the formation of cancer. Abnormal MYC 
expression is often observed in SCLCs but less frequently so in NSCLCs 
(Richardson and Johnson 1993). 
The BCL-2 proto-oncogene is involved in the normal pathway for programmed cell 
death. It is negatively regulated by p53 and protects cells from apoptosis. Because 
overexpression of MYC or RAS in fibroblasts can lead to apoptosis it is possible 
tumour cells overexpress BCL-2 to overcome these apoptotic signals, and the BCL-
2 protein is often expressed in SCLCs and NSCLCs as immunohistochemical 
studies have shown (Pezzella, Turley et al. 1993, Kaiser, Schilli et al. 1996).  
Overexpression of Notch-3 is often found in NSCLCs and in metastatic lung 
carcinoma it was found to be translocated from its region on chromosome 19p to 
chromosome 15q (Hibi, Trink et al. 2000). 
As its name suggests, AIS (amplified in squamous cell carcinoma) is often amplified 
in primary lung squamous cell carcinomas. It is a p53 homologue with multiple 
protein products and overexpression of these proteins was observed in SCCs known 
to harbour a high frequency of p53 mutations (Hibi, Trink et al. 2000). 
 
Loss of function of tumour suppressor genes (TSGs) according to Knudson’s 
two-hit hypothesis requires both alleles to be inactivated (Knudson 1971). There 
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must be deactivation of TSGs and activation of oncogenes for cancer to occur. One 
allele could be inactivated by mutation or methylation changes for example, 
whereas the other is inactivated as part of loss of genetic markers by nonreciprocal 
translocation, deletion, or mitotic recombination in the chromosomal region referred 
to as allele loss or loss of heterozygosity (LOH). The presence of one or more TSGs 
in a region of a gene could therefore be assumed if there is consistent LOH for 
genetic markers at a given locus. A search of LOH on SCLCs and NSCLCs was 
performed in order to detect new loci that may harbour TSGs with 13 regions 
showing a preference for SCLC, 7 for NSCLC, and 2 affecting both. Frequent LOH 
occurred in different regions with NSCLC having more regions than SCLC, which 
suggests they undergo different genetic alterations (Girard, Zochbauer-Muller et al. 
2000). 
The most frequent molecular alteration seen in lung cancer is that of the 3p allele 
loss. However this does not only occur in tumours but in epithelium of smokers 
without lung cancer, and also dysplasia, hyperplasias, and carcinoma in situ in the 
respiratory epithelium accompanying lung cancers, linking it to early pathogenesis 
of lung cancer (Wistuba, Behrens et al. 2000). In more than 90% of SCLCs and 
80% of NSCLCs a LOH is found involving markers of 3p (Sekido, Fong et al. 
1998). 
 
The p53 gene encodes a 53-kDa nuclear protein that acts as a transcription factor to 
turn on the expression of a DNA damage response program, stops cells going 
through the late G1 cell cycle phase and triggers apoptosis (Sidransky and Hollstein 
1996). Phosphorylation of p53 is triggered by DNA damage and acts as a specific 
DNA-binding transcription factor for several genes, the activation of which leads to 
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apoptosis, cell cycle arrest, and DNA repair (Sekido, Fong et al. 1998). Some of the 
most common genetic changes seen in cancer are mutations of the p53 gene which 
can cause loss of tumour suppressor function and loss of ability to induce apoptosis. 
Interestingly, p53 mutations were significantly more likely in smokers compared to 
non-smokers (Husgafvel-Pursiainen, Boffetta et al. 2000), although it was also more 
likely in alcohol drinkers who smoke compared with non-drinkers who smoke 
(Ahrendt, Chow et al. 2000). Immunostaining of abnormal p53 expression was seen 
in 40-60% of NSCLCs and 40-70% of SCLCs (Nishio, Koshikawa et al. 1996). 
 
The APC gene (Adenomotous Polyposis Coli) encodes a protein with roles in 
signal transduction, intercellular adhesion mediation, cytoskeleton stabilisation, and 
even perhaps cell cycle and apoptosis regulation (Fearnhead, Britton et al. 2001). In 
primary lung cancer loss of expression of APC is often observed with aberrant 
methylation of APC an important mechanism for inactivation of this gene (Virmani, 
Rathi et al. 2001). 
 
Angiogenesis, the formation of new blood vessels from pre-existing ones, is vital in 
normal growth and development as well as in wound healing. However this 
formation of new blood vessels also allows tumours to metastasise and grow. 
Inducers and inhibitors regulating endothelial cell proliferation and migration 
known as angiogenic factors can affect vasculature growth patterns, formation, and 
permeability as well as influence tumour invasion, metastasis and prognosis. 
Alterations in the oncogenes p53 and RAS are involved in the secretion of 
angiogenic substances by tumour cells and their precursor cells (Rak, Filmus et al. 
1995). The vascular endothelial growth factor (VEGF) is frequently expressed by 
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lung cancers (O'Byrne, Koukourakis et al. 2000). In NSCLC the expression of 
VEGF was linked with the formation of new blood vessels and was an adverse 
prognostic factor in patients with NSCLC (Fontanini, Vignati et al. 1997). 
Activated microvessel density in early operable NSCLC was seen to be lower in the 
normal lung distal to the tumour or the inner tumour areas compared to the invading 
front of the tumours and in normal lung adjacent to the tumours (Koukourakis, 
Giatromanolaki et al. 2000). 
 
Tobacco smoke is the major cause of lung cancer, accounting for about 90% of all 
cases. In tobacco smoke there are three major classes of carcinogens; polycyclic 
hydrocarbons, nitrosamines, and aromatic amines (Gazdar and Minna 1997). 
Subjects sensitive to benzo(a)pyrene (a polycyclic hydrocarbon) -induced damage 
are susceptible to tobacco carcinogen exposure and may be at increased risk of 
developing lung cancer (Li, Firozi et al. 2001). Progressive pathological changes in 
the respiratory epithelium are found in preneoplastic/preinvasive lesions or even the 
in the cytologically normal bronchial epithelium of smokers which can lead to lung 
cancer.  
Mutations of p53 and p16 methylation were found in the bronchial epithelium from 
chronic smokers before any clinical evidence of neoplasia (Kersting, Friedl et al. 
2000).  
The induction of high levels of reactive oxygen species (ROS) after exposure to 
tobacco smoke leads to impairment of epithelial and endothelial cell function as 
well as inflammation (Walser, Cui et al. 2008). 
The capacity of tobacco carcinogens to mutagenise the respiratory epithelium 
extensively has been seen in multifocal premalignant lesions that occur throughout 
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the bronchial tree of tobacco smokers’ respiratory epithelium (Auerbach, Stout et al. 
1961). 
 
1.2.2 Lung Cancer Classification 
Lung cancer, also known as bronchogenic carcinoma, is broadly categorised into 
two types; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). 
The classification into small cell and non-small cell is based upon the microscopic 
appearance of the tumour cells and because they grow, spread, and are treated in 
different ways a distinction between them is important. Carcinomas can be 
described as well-differentiated, moderately differentiated, or poorly differentiated. 
These terms describe how aggressive a carcinoma is likely to be with well-
differentiated carcinomas more likely to grow slowly and have a better prognosis, 
poorly differentiated the most aggressive with a worse prognosis, and moderately 
differentiated falls between these two, with an intermediate prognosis/aggression. In 
this way stage 1 cancer will be well-differentiated, stage 2 will be moderately-
differentiated, and stage 3 will be poorly differentiated. 
 
Differentiation refers to how mature (developed) the cancer cells are in a tumour, 
with differentiated tumour cells resembling normal cells and growing and spreading 
at a relatively slow rate, whereas undifferentiated, or poorly differentiated, cells 
lack the structure and function of normal cells and grow out of control at a much 
faster rate. When a tumour cell becomes poorly differentiated it is therefore more 
difficult to ascertain the original cell type from which it came. Poorly differentiated 
adenocarcinoma for example does not resemble the normal gland cells from which 
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they began and are usually identified by the fact they stain positive for mucin, a 
substance produced in the glands.  
 
 
Figure 1.3: Main histological types of lung cancer; adenocarcinoma, squamous 
carcinoma, large cell carcinoma and small cell carcinoma, as well as carcinoid, a 
type of neuroendocrine tumour, and mesothelioma, a malignant carcinoma arising 
from mesothelial cells of the pleura (Motadi, Misso et al. 2007). 
 
Small cell lung cancer is the most aggressive and rapidly growing lung cancer type 
and comprises about 20% of all lung cancers. It is strongly related to cigarette 
smoking with only 1% of these tumours occurring in patients who do not smoke. 
Because of its ability to rapidly metastasise it has a poorer prognosis than NSCLC 
and is often discovered after it has already spread extensively. It usually starts in the 
bronchi in the centre of the chest.  
The lung is overwhelmingly the most common site of origin of small cell carcinoma 
in the body with more than 95% arising in that location, whereas extra-pulmonary 
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small cell carcinomas such as of bladder, prostate, esophagus, and cervix, are 
extremely rare (Walenkamp, Sonke et al. 2009). SCLC was once referred to as oat 
cell carcinoma, due to the resemblance of the cells to oats when viewed under the 
microscope; the flat cell shape and scanty cytoplasm giving it the oat-like 
appearance. A failure in the mechanism that controls the size of the cells has been 
attributed to the fact small cell carcinomas are smaller than normal cells and have 
little room for cytoplasm (Leslie). SCLC presents as a proliferation of small cells 
with the following morphological features: scant cytoplasm, ill-defined borders, 
finely granular ‘salt and pepper’ chromatin, absent or inconspicuous nucleoli, and a 
high mitotic count. Today SCLC is broken into two main types; 
(1) small cell lung carcinoma 
(2) combined small cell lung carcinoma (c-SCLC) 
 
Small cell lung carcinoma is a neuroendocrine tumour (NET). As the name 
suggests the neuroendocrine system is made up of the nervous system and the 
endocrine system. The endocrine system is involved in the maintenance of 
homeostasis and is the systems of glands which secrete hormones directly into the 
bloodstream. There are four major types of lung neuroendocrine tumours: typical 
carcinoid (TC), atypical carcinoid (AC), small cell lung cancer, and large cell 
neuroendocrine carcinoma (LCNEC) (Rekhtman). As a group these tumours have a 
broad spectrum of clinical behaviour from lethargic in TC to rapidly fatal in SCLC. 
Patients with TC have a survival chance of >87% (Thomas, Tazelaar et al. 2001). 
TC is however defined as a low-grade malignancy because these tumours are 
capable of regional lymph node metastasis in 10-15% of cases and in 3-5% of cases 
distant metastases. AC is more aggressive with higher frequency of nodal (~50%) 
 17
and distant (~20%) metastases, and a 5-year survival rate of 60% (Rekhtman). 
SCLC is the most aggressive with survival measured in months and a 5-year 
survival rate of <5%. Two-thirds of SCLC patients present with distant metastases, 
typically in the brain, liver, adrenal, bone, and bone marrow (Elliott, Osterlind et al. 
1987), and the amount of SCLCs presenting a solitary mass without evidence of 
metastases is very rare, occurring in <5%. 
 
c-SCLC is a small cell carcinoma combined with an additional component 
consisting of any non-small cell histologic type, including adenocarcinoma, 
squamous cell carcinoma and large cell neuroendocrine carcinoma. Approximately 
30% of SCLC will have this non-small cell component. Surgical resection is the 
mainstay for NSCLC and radiation and chemotherapy are used for SCLC so an 
accurate understanding of c-SCLCs is important for treatment strategies. Though at 
present c-SCLC is considered a subset of SCLC by the World health Organisation 
the biologic evidence to support this classification scheme is lacking and the 
validity of the current practice is yet unconfirmed (Wagner, Kitabayashi et al. 
2009). 
 
The three main types of NSCLC are adenocarcinoma (AD), squamous cell 
carcinoma (SCC), and large cell carcinoma (LCC). 
Adenocarcinoma is the most common form of lung cancer, accounting for 
approximately 40%; a total of around 500,000 cases annually. The cells of 
adenocarcinoma resemble gland cells, such as the glands that secrete mucus in the 
lungs. It is the most common type of lung cancer in lifelong non-smokers and it has 
surpassed squamous cell carcinoma as the most common type in smokers. This shift 
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may be related to changes in exposure to tobacco products, dietary factors, 
environmental or occupational carcinogens, and host characteristics (Travis, Travis 
et al. 1995). Most adenocarcinomas arise in the outer, or peripheral, areas of the 
lungs, with a tendency to spread to the lymph nodes and beyond. This peripheral 
location has been attributed to the use of filters in cigarettes which allow smoke to 
be inhaled more deeply into the lungs. The four stages of lung adenocarcinoma are: 
(1) cancer is localised within the lung and has not spread to the lymph nodes (2) 
cancer has spread to lymph nodes or lining of the lungs, or is in the main bronchus 
(3) has spread to tissue close to the lungs, and (4) has metastasised to another part 
of the body. These stages can be applied to all lung cancers.  
 
Squamous cell carcinoma (SCC) were formerly the most common type of lung 
cancer and today still account for 30% of NSCLC cases. They are also referred to as 
epidermoid carcinomas and frequently arise in the central chest area in the bronchi, 
the lung’s major airways. SCC most often stays within the lung, spreads to lymph 
nodes, and grows quite large, forming a cavity. SCC is formed from reserve cells; 
round cells that replaced injured or damaged cells in the lining of the bronchi. SCC 
can spread to bones, adrenal glands, the liver, small intestine, or the brain. It is 
almost always caused by smoking and is a slow-growing cancer that can take years 
to develop from a confined tumour to an invasive one. Symptoms include 
wheezing, shortness of breath, chest pain, bloody sputum and coughing. SCC 
develop slowly, however due to their location are often found earlier than other 
forms of lung cancer. 
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Figure 1.4: WHO and International Association for the Study of Lung cancer 
(IASLC) guidelines for the histologic classification of non-small cell lung cancer 
(www.cancernetwork.com). 
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Epithelia are formed of cells that line the cavities in the body, the epithelial cells 
bound together in sheets of tissue. The whole surface of the body is covered in 
epithelial tissue, which is specialised to form the covering or lining of all internal 
and external body surfaces. Epithelial cells are packed tightly together with almost 
no intercellular spaces. A thin sheet of connective tissue called basement membrane 
separates epithelial tissue from the underlying tissue and provides structural support 
and binds it to neighbouring structures. Squamous cell epithelium has the 
appearance of ‘pavement’. The squamous cells themselves have the appearance of 
thin, flat plates and tend to have horizontal flattened, elliptical nucleus because of 
the thin flattened form of the cell. This nucleus shape usually corresponds to the cell 
form and helps to identify the type of epithelium. Squamous cells form the lining of 
cavities such as the mouth, blood vessels, heart and lungs and make up the outer 
layers of skin. 
 
Large cell lung carcinomas (LCC) are the least common type of NSCLC, 
accounting for 10-15% of all lung cancers, and are often referred to as 
undifferentiated carcinoma. They get their name from the appearance of large round 
cells when examined under the microscope, although the tumours themselves tend 
to be large as well when diagnosed. They generally start in the outer regions of the 
lung and grow quite rapidly. Due to their presence in the outer regions they can 
cause fluid to develop in the space between the tissues that line the lung, a build-up 
that is known as pleural effusion, and invade the chest wall. A patient is generally 
diagnosed with LCC by ‘diagnosis of exclusion’, which is a process of elimination 
whereby the other lung cancer types have been completely ruled out. In this method 
the tumour cells would lack the light microscopic characteristics that would classify 
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a neoplasm as another type of lung cancer. For example it does not have the ‘salt-
and-pepper’ chromatin and has a higher cytoplasmic-to-nuclear size ratio when 
compared to SCLC. One important subtype is large-cell neuroendocrine carcinoma 
(LCNEC) of the lung which displays morphologic and immunohistochemical 
characteristics common to neuroendocrine tumours and morphologic features of 
LCC. Again ‘diagnosis by exclusion’ is used here where LCNEC is diagnosed when 
other neuroendocrine tumours (typical carcinoid, atypical carcinoid, SCLC) have 
been ruled out. LCNEC has a very poor prognosis so there is a need for it to be 
accurately differentiated from other forms of NSCLC (Fernandez and Battafarano 
2006). 
 
1.2.3 Lung Diseases 
The most common causes of lung diseases are smoking, infections, and genetic 
aberrations. Substances in the workplace can lead to lung disease such as dust from 
asbestos, fumes from metals, smoke from burning organic material, gases such as 
nitrogen oxides, vapors such as those given off by solvents, and mists or sprays 
from paint and pesticides. Lung disease incorporates lung cancer but it is a broad 
term that encompasses many afflictions; diseases affecting the airways such as 
asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, 
emphysema, acute bronchitis, and cystic fibrosis; diseases affecting the alveoli such 
as pneumonia, tuberculosis, emphysema, pulmonary edema, acute respiratory 
distress syndrome (ARDS), and pneumoconiosis; diseases affecting the interstitium, 
the microscopically thin, delicate lining between the alveoli such as sarcoidosis, 
idiopathic pulmonary fibrosis, and autoimmune disease; diseases affecting the 
blood vessels such as pulmonary embolism and pulmonary hypertension; diseases 
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affecting the pleura, a thin layer that surrounds the lung and lines the inside of the 
chest wall, such as pleural effusion, pneumothorax, and mesothelioma; and diseases 
affecting the chest wall such as obesity hypoventilation syndrome and 
neuromuscular disorders.  
With so many lung diseases a focus will be brought only to the ones that were used 
in some of the control groups during the biomarker validation phase. 
 
Autoimmune disease is one where an inappropriate immune response occurs in the 
body against substances and tissues normally present in the body. The immune 
system mistakenly attacks and destroys healthy body tissue. Type 1 diabetes 
samples (although not a lung disease) were used as controls in some of our control 
groups. Type-1 diabetes involves the loss of the insulin-producing beta cells of the 
islets of Langerhans in the pancreas, leading to insulin deficiency and is a T-cell-
mediated autoimmune attack (Weigmann, Franke et al.). 
 
Pneumonia is an inflammation of the lung usually caused by an infection. The 
three most common causes are bacteria, viruses, and fungi. Symptoms include 
difficulty breathing, coughing, and a fever, and it can be very dangerous in older 
adults and young children because their immune systems are not as strong. It is 
usually caused by the inhalation of infectious air into the lungs. It can happen if the 
bacteria or virus is not cleared by the lung’s immune system and so can happen to 
healthy people after a viral infection such as influenza which lowers the lung’s 
defence mechanism. The most common cause is from bacteria called streptococcus 
pneumoniae.  
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Bronchitis is an inflammation of the bronchial tubes. Sufferers often have a cough 
which brings up mucus, the slimy substance made by the lining of the bronchial 
tubes. The two main types are acute bronchitis and chronic bronchitis. Acute is a 
short term ailment and chronic is an ongoing, serious condition. Acute bronchitis is 
caused by infections and lung irritants, the same viruses that cause colds and flu, 
such as rhinovirus, adenovirus, and influenza A and B, are the most common cause. 
Chronic bronchitis is a type of COPD, with inflamed bronchi producing a lot of 
mucus, leading to cough and difficulty getting air in and out of the lungs. Smoking 
is the most common cause. 
 
Tuberculosis, or TB, is an infectious disease caused by a bacterium called 
Mycobacterium tuberculosis. It can affect the organs in the central nervous system, 
lymphatic system, and circulatory system, indeed almost any tissue or organ of the 
body, but mainly affects the lungs. Because of the way it ‘consumes’ from within it 
was once called consumption. On infection the bacteria in the lungs multiply and 
cause pneumonia along with chest pain, coughing up blood, and a prolonged cough. 
As it tries to spread to other regions of the body it is attacked by the immune 
system, which forms scar tissue or fibrosis around the TB bacteria. The bacteria will 
often break through the scar tissue and return to active state with pneumonia and 
damage to bones, kidneys, and the meninges that line the spinal cord and brain. 
 
Sarcoidosis is an inflammatory disease which occurs in the lymph nodes, liver, 
eyes, skin, lung, and other tissues. What triggers this inflammation is not known 
and it cannot be caught from, or spread, to other people. It can appear suddenly and 
disappear or develop gradually with symptoms that can last a lifetime, though these 
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may come and go. Granulomas appear in the affected tissue, which are 
lumps/clusters of immune system cells, and if too many form they can affect how 
the organ works, with the resulting symptoms depending on the organ affected, 
though sarcoidosis often has no symptoms. If these granulomas form in the lungs it 
can led to wheezing, coughing, shortness of breath, or chest pain. Sarcoidosis has 
no known cure. 
 
1.2.3.1 Benign lung tumours  
Benign lung tumours are not cancerous as they lack the ability to metastasise. A 
benign tumour is a mass of tissue that serves no useful purpose and though many 
are harmless to human health some can compress on blood vessels, nerves, and the 
brain, and also for example a benign tumour of the endocrine tissue can 
overproduce certain hormones. They tend to grow more slowly than malignant 
tumours and because they stay in one part of the body and do not spread are 
referred to as localised. Benign tumours can of course lead to malignant tumours; 
colon polyps are benign tumours and most colon cancer develops from polyps. 
When benign tumours are surrounded by a fibrous sheath it inhibits their ability to 
become malignant, however many benign tumours can become malignant, 
teratomas in particular are known for this. In many cases benign tumours do not 
need any treatment, but in centralised benign lung tumours preference must be 
given to organ-preserving operations (Ismailov, Shishkin et al. 1993). 
Some benign lung tumours can interfere with the airway and can cause lung 
infections. In turn inflammation from infections can lead to benign lung tumours. 
Hamartomas are a type of benign lung tumour and are firm marble-like tumours 
made up of tissue from the lung’s lining as well as tissue such as fat and cartilage, 
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usually located in the lung periphery. Bronchial adenoma is a tumour in the trachea 
or bronchi that can usually block the airways although with the exception of 
mucous gland adenomas can spread to other areas of the body. There are also 
benign tumours made up of connective tissue or fatty tissue; rare neoplasms such as 
chondromas, fibroma, or lipomas. Despite improvements in diagnosing pulmonary 
nodules, a mass in the lung smaller than 3cm, there are still a significant number of 
cases where surgical resection is needed to differentiate cancer from benign lesions 
(Ohtsuka, Nomori et al. 2003). 
 
1.2.4  Screening 
 
The most significant factor for survival in lung cancer is the stage of disease at 
diagnosis. Lung cancer tends not to cause symptoms in its early stages, whilst in 
patients with more advanced disease the symptoms are non-specific; therefore it is 
classically picked up late in its development. It is estimated that a lung tumour of 
1mm in size is halfway through its growth cycle, and more than three-quarters of 
the way through its growth cycle when it reaches 3-4cms in size (the average size at 
time of diagnosis), and plenty of time will have elapsed for metastatic spread before 
the cancer is diagnosed by conventional methods (Read, Janes et al. 2006). 
Histologic diagnoses of early-stage lung cancers are complicated by a lack of 
agreement among histopathologists on what constitutes a preneoplastic lesion in the 
lung (Price 2004). The first signs of invasive cancer could take 10 to 20 years to 
develop. 
The most common symptom alerting patients and doctors to possible lung cancer is 
bloody sputum and a cough, however a cough is often ignored for a long time 
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before referral to a specialist (Buccheri and Ferrigno 2004). The link between 
abnormal sputum cytology and lung cancer development has been confirmed in 
various studies (Risse, Vooijs et al. 1988, Prindiville, Byers et al. 2003). The 
diagnostic yield of sputum cytology varies in relation to tumour location and 
identifies central tumours confidently but is of little value for identifying peripheral 
cancers, though recent developments in DNA analysis and nuclear image analysis 
show potential to improve or refine diagnosis beyond that achieved with 
conventional sputum cytology examination (Thunnissen 2003). Improvements have 
not been seen in disease-specific survival from screening tests for high-risk 
individuals using chest X-rays or sputum cytology (Marcus, Bergstralh et al. 2006). 
 
Bronchoscopy is a very useful tool in the diagnosis of lung cancer and the 
endoscopic treatment of inoperable lung cancer, and it can improve the diagnosing 
and staging in patients (Herth, Eberhardt et al. 2006). Some epithelial changes, such 
as high-grade dysplasia and carcinoma in situ in the central airways, are early-stage 
squamous cell carcinomas (multidetector CT technology is unable to detect pre-
invasive lesions and less suited to detect early-stage lung cancer in the central 
airways) and the most widely used and investigated technique for the detection of 
this kind of premalignant endobronchial lesion is the light-induced fluorescence 
endoscopy (LIFE) (Kennedy, McWilliams et al. 2007). Bronchoscopy with the help 
of auto-fluorescence bronchoscopy and narrow-band imaging can detect 
preinvasive lesions and early-stage lung cancer in the central airways that cannot be 
detected by CT technology (McWilliams, Lam et al. 2009). 
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X-ray computed tomography (CT) is used to detect early stage lung cancers 
(Swensen, Jett et al. 2005). Screening with low-dose spiral CT in patients at high 
risk for lung cancer may allow detection of many early-stage lung cancers 
(Swensen, Jett et al. 2003). Low radiation dose CT (LDCT) has been shown to have 
a much higher sensitivity for small pulmonary nodules, which are believed to be the 
most common presentation of early lung cancer though it should be noted small 
pulmonary nodules are common and most are not malignant (Diederich, Wormanns 
et al. 2003). LDCT allows a low-resolution image of the thorax to be obtained in a 
single breath-holding, with low radiation exposure (Jain and Arroliga 2001) and 
when compared with chest X-ray is able to detect approximately three to five times 
as many lung cancers and detect tumours with a smaller average size (Sone, 
Takashima et al. 1998). Although LDCT can increase the diagnosis of early stage 
lung cancer it does not show strong evidence of a mortality benefit (Kakinuma, 
Ohmatsu et al. 1999). 
 
Low-dose computed tomography is a promising tool, as seen from preliminary 
screening trials results which employ this technique, but for the future a technique 
called positron emission tomography (PET) with the glucose analogue 18-
fluorodeoxyglucose (FDG) which identifies malignant tumours on the basis of their 
increased metabolic rate is of particular interest, as is the analysis of biomolecule 
markers which can be detected in serum, sputum and exhaled air (Rossi, Maione et 
al. 2005). 
Another approach is the detection and characterisation of circulating tumour cells 
(CTCs). The potential of CTC detection as a diagnostic parameter to distinguish 
malignant from benign lung disease has been evaluated and it was found that the 
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CTC count was higher in patients with lung cancer compared to non-malignant 
patients, however the sensitivity for detecting CTCs was low (Tanaka, Yoneda et al. 
2009). 
 
Routine histopathology is the current standard of lung cancer classification, but this 
method is unreliable. In one study addressing the reproducibility of histopathologic 
classification of resected lung cancers, the central expert pathologist disagreed with 
the regional pathologists in one third of the cases (Stang, Pohlabeln et al. 2006).  
 
1.3 Mechanisms of Invasion and Migration 
 
Migration and invasion mechanisms allow neoplastic cells to enter lymphatic and 
blood vessels for dissemination into the circulation, and then undergo metastatic 
growth in distant organs (Chambers, Groom et al. 2002). This spread of cells from 
the primary neoplasm to distant organs, and the subsequent rapid growth, is the 
main cause of death for cancer patients. The biological processes involved in 
moving tumour cells from their primary site to a distant location can potentially be 
targeted by therapeutic agents, however the molecular events that allow this to 
occur are highly complex and not well understood, and there are no effective 
treatments that target invading tumour cells. The mechanisms used in normal, neo-
plastic cells during physiological processes such as embryonic morphogenesis, 
wound healing and immune-cell trafficking, are quite similar to those used by 
tumour cells to migrate (Friedl and Brocker 2000). 
Cancer cells disseminate from the primary tumour either as individual cells, using 
amoeboid, or mesenchymal-type movement, or as cell sheets, strands and clusters 
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using collective migration, this migration typically regulated by integrins, matrix-
degrading enzymes, cell-cell adhesion molecules and cell-cell communication. 
Cancer therapeutics targeting the migration mechanism have not yet been effective 
in clinical trials, maybe due to the fact that the cancer cell’s migration mechanisms 
can be reprogrammed, allowing it to maintain its invasive properties via 
morphological and functional de-differentiation (Friedl and Wolf 2003). Normal 
cells are anchorage dependent and will undergo apoptosis if detached from cells of 
their own kind; however in tumour cells this regulatory process is disrupted through 
genetic changes, allowing the cancer cell to survive.  
 
The metastatic cascade involves the following steps; cancer cell from primary 
tumour locally invades the surrounding tissue (tumour cells and surrounding 
stromal cells interact and influence one another (Hanahan and Weinberg 2000)), 
enters the microvasculature of the lymph and blood systems (intravasation), 
survives and translocates largely through the bloodstream to microvessels of distant 
tissues, exits the bloodstream (extravasation), survives in the microenvironment of 
distant tissues, and finally adapts to the foreign microenvironment of these tissues 
in ways that facilitate cell proliferation and the formation of a macroscopic 
secondary tumour (Fidler 2003).  
Nutrients for the expanding tumour mass must initially be supplied by simple 
diffusion, however extensive vascularisation must occur if the tumour mass is to 
exceed 1-2mm in diameter, with the synthesis and secretion of angiogenic factors 
establishing a capillary network from the surrounding host tissue (Folkman 1986).  
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Figure 1.5: The main steps in the formation of a metastasis (Fidler 2003). 
 
Local invasion of the host stroma by some tumour cells occurs by several parallel 
mechanisms such as this three-step process; (1) Tumour cell attachment via cell 
surface receptors which specifically bind to components of the matrix such as 
laminin (for basement membrane) and fibronectin (for the stroma), (2) The 
anchored tumour cell next secretes hydrolytic enzymes (or induces host cells to 
secrete enzymes) which can locally degrade the matrix, including degradation of the 
attachment componenets, (3) Tumour cell locomotion into the region of the matrix 
modified by proteolysis, with continued invasion of the matrix taking place by 
cyclic repetition of these three steps (Liotta 1986). 
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Tumour cells are generally heterogenous and contain numerous subpopulations of 
cells that have different biological characteristics including metastatic potential. 
Most primary tumour cells have a low metastatic potential but rare cells (estimated 
at less than one in ten million) within large primary tumour acquire metastatic 
capacity through somatic mutation (Poste and Fidler 1980). Somatic mutations are 
genetic alterations acquired by a cell, frequently caused by environmental factors, 
which can be passed to the progeny of the mutated cells in the course of cell 
division and differ from germ line mutations which are inherited genetic alterations 
that occur in the germ cells. The metastatic phenotype includes the ability to 
migrate from the primary tumour, survive in blood or lymphatic circulation, invade 
distant tissues and establish distant metastatic nodules. However it has been 
suggested that the metastatic potential of human tumours is encoded in the bulk of 
the primary tumour, challenging the notion that metastases arise from rare cells 
within a primary tumour that have the ability to metastasise (Ramaswamy, Ross et 
al. 2003). 
 
1.4 Molecular Targeted Therapies for Lung Cancer 
 
Drugs that specifically target certain molecular pathways leading to lung cancer 
phenotype have been clinically tested and there are others which are in 
development. Gene expression arrays are a genomic technique employed to 
discover changes in the DNA expression that occur in neoplastic transformation and 
have been used for lung cancer, with the goal not only of finding new markers for 
therapy but also to customise therapy based on individual tumour genetic 
composition. Genomic technology can also help with a better understanding of the 
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pathogenesis of lung cancer (molecular changes, pathways), with the ultimate goal 
of discovering genetic transformations that have occurred in a cancer cell that can 
be manipulated to kill the neoplastic cell (Singhal, Miller et al. 2008). 
Small molecules that specifically inhibit the tyrosine kinase (TK) activity of the 
epidermal growth factor receptor (EGFR), such as gefitinib and erlotinib, were the 
first drugs to become clinically available in the treatment of NSCLC (Mitsudomi). 
A somatic mutation of the EGFR gene in Asian women with adenocarcinoma 
showed a tendency of the patients to be sensitive to EGFR-tyrosine kinase 
inhibitors (TKIs), and those with the mutation showed longer survival than those 
with wild-type EGFR (Han, Kim et al. 2005). Evidence that EGFR mutations are 
sensitive and specific predictors of response to single-agent epidermal growth factor 
receptor TKIs in advanced NSCLC has been shown elsewhere (Dahabreh, Linardou 
et al.).  
 
Bevacizumab is a humanized antibody that targets vascular endothelial cell growth 
factor (VEGF), which is thought to play a pivotal role in tumour angiogenesis, 
though in a Phase II trial there was an increased risk of hemorrhage in patients with 
squamous cell carcinomas, especially those with a central location, meaning this set 
of patients was not eligible for subsequent clinical trials (Johnson, Fehrenbacher et 
al. 2004).  
 
DNA synthesized from a mature messenger RNA (mRNA) template in a reaction 
catalyzed by the enzymes reverse transcriptase and DNA polymerase is called 
complementary DNA (cDNA). mRNA is a molecule which serves as a template for 
protein synthesis. On a cDNA array, messenger RNA clones are spotted on arrays 
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in a matrix where one analyzes the relative expression level of a gene by 
determining the amount of mRNA that is present. It allows the analysis of up to tens 
of thousands of genes in a single experiment though the analysis of this data can be 
quite complex and at each step there is the possibility of inheriting variability into 
the detection of the tissues genetic profile (Dobbin, Beer et al. 2005). Even though 
gene expression profiling is a high-throughput method for finding targets it does not 
provide information about whether the changes in gene expression are responsible 
for biological behaviour.  
The principal molecular changes in lung cancer are seen in tumour suppressor 
genes, proto-oncogenes, growth factors, telomerase activity, and methylation status 
of promoters. Well-known agents include angiogenesis-stimulating factors (such as 
vascular endothelial growth factor), as well as factors related to tumour cell 
proliferation and apoptosis (epidermal growth factor receptor, p53, K-ras, 
retinoblastoma and BCL-2), and  though several of these genetic factors have 
already been investigated, no single parameter has yet presented sufficient 
selectivity regarding prognostic value or therapeutic efficacy (Duarte and Paschoal 
2006). The inactivation of p53 tumour suppressor gene is a common genetic event 
in lung cancer (Andjelkovic, Bankovic et al. 2011).  
 
1.4.1 MicroRNAs in Lung Cancer 
MicroRNAs (miRNA) are tiny non-coding RNA molecules which play important 
roles in the epigenetic control of cellular processes by preventing the translation of 
proteins from mRNAs. A single miRNA can target different mRNAs, and an 
mRNA can be targeted by multiple miRNAs, and the target specificity is 
determined by sequence complementarities between the miRNA and mRNA 
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molecules. These complex interplays underlie many molecular pathways in cells 
and changes in miRNA expression have been associated with a wide variety of 
disease states including the diagnosis and prognosis of lung cancer.  
The effect of alteration in the expression of a single miRNA in a cell can depend on 
the concentration of the mRNAs that are targeted by it. miRNAs have been shown 
to control a wide range of biological functions such as cellular proliferation, 
differentiation and apoptosis and it has been suggested that miRNA might function 
as tumour suppressors and oncogenes (Esquela-Kerscher and Slack 2006). These 
alterations can be caused by various mechanisms, including deletions, 
amplifications or mutations involving miRNA loci, epigenetic silencing, or the 
dysregulation of transcription factors that target specific miRNAs.  
As sequences of small RNAs are being explored in more types of cells using 
improved techniques, novel miRNAs are continually being discovered (Creighton, 
Benham et al. 2010). miRNAs have been shown to be remarkably well preserved in 
formalin-fixed, paraffin-embedded (FFPE) tissue, eliminating the need for fresh 
frozen tissue for miRNA expression studies (Szafranska, Davison et al. 2008). 
 
MicroRNAs can be identified in serum or plasma, which has the potential to 
enhance the utility of miRNAs as non-invasive biomarkers of lung cancer. It is 
believed that tumour cells secrete cell membrane-enveloped microvesicles, known 
as exosomes, into the extracellular space allowing them to eventually be detected in 
the blood (Rabinowits, Gercel-Taylor et al. 2009). These exosomes are 30–100nm 
in size and contain proteins, cytosol, mRNA, and miRNAs. Their lipid membrane 
protects them from the circulating ribonucleases present in blood, and microRNAs 
have been shown to be stable in serum stored at 4 °C for up to 4 days (Taylor and 
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Gercel-Taylor 2008). Exosomes can bear cell-surface proteins characteristic of the 
cell of origin, so it may be possible to isolate exosomes in the blood that have 
originated from specific tissue (Mallick, Patnaik et al.).  
 
One study has shown that expression of hsa-miR-205 was restricted to the 
squamous phenotype, and that the measurement of hsa-miR-205 expression was a 
very dependable method of distinguishing lung SCC from adenocarcinomas 
(Lebanony, Benjamin et al. 2009). This provides a rationale for the classification of 
NSCLC based on miRNA expression profiling. 
Two members of the double-stranded RNA-specific endonuclease family, Dicer 
and Drosha, convert precursor forms of microRNA into their mature forms. Dicer, 
an RNAse III enzyme, expression levels are reduced in some lung cancers with a 
significant prognostic impact on the survival of surgically treated cases.  In an 
examination of 67 non-small-cell lung cancer samples it was found that reduced 
expression of Dicer correlates with shortened post-operative survival, which 
indicates that Dicer might be able to prevent the transformation of lung tissue 
(Karube, Tanaka et al. 2005).  
 
1.5 Proteomics in Lung Cancer 
 
Early detection of lung cancer is challenging, due in part to a lack of adequate 
tumour markers. Discovery of biomarkers, and in particular serum biomarkers, that 
could indicate the presence of lung cancer at an early stage would be very beneficial 
and could save lives or lengthen the patient’s survival time from months to years. 
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Even more beneficial would be a panel of biomarkers that diagnosed the particular 
type of lung cancer, allowing for more specific treatment.  
Early detection is not the only area for which biomarkers would be advantageous; 
they could improve diagnosis, predict response after treatment, and monitor 
recurrence after treatment (Gail, Muenz et al. 1988). The clinical usefulness of 
serum biomarkers at present is very limited (McCarthy and Swain 2001). Individual 
studies are often retrospective and lacking statistically, hence, while discovery of 
clinically useful biomarkers is urgently required, larger prospective studies with 
clinically relevant modelling and hypothesis are vital to address the usefulness of 
novel potential tumour biomarkers in the management of lung cancer patients and 
also the treatment strategies must improve to accommodate any improvement in 
biomarker discovery (Bharti, Ma et al. 2007).  
Proteomic-based approaches have greatly improved the data produced relating to 
lung cancer biomarkers but as yet this vast knowledge has not effectively been 
applied to the production of useful clinical assays that can be used on a routine basis 
in the hospital. There is a need to examine the data already available closely for 
trends that may lead to a better understanding of the disease and the pathways 
involved and perhaps then to useful biomarkers yet to be identified by other 
methods. 
 
The general strategy is to analyse serum (indeed any body fluid) or tissue for 
proteins which show a difference in abundance levels between cancer samples and 
samples from healthy individuals or between patients who respond to therapy and 
those who don’t. There have been numerous proteins identified with the potential to 
be useful biomarkers, many indicating high sensitivity and specificity. However, 
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validation by clinical trials in large cohorts of patients is necessary before cancer-
related phenotypes can be translated into the clinic as reliable biomarkers (Cho 
2007) but as this is a very highly regulated, exorbitantly expensive process only a 
few biomarkers are ever brought forward to the validation phase and for this there 
needs to be a high level of statistical confidence in the biomarker/biomarkers of 
choice.  
 
1.5.1 Present state of lung cancer biomarkers 
Some possible biomarkers for lung cancer often mentioned in the literature include 
cytokeratin 19 fragment (CYFRA 21-1), tissue polypeptide antigen (TPA) and 
squamous cell carcinoma antigen (SCCA) for NSCLC, particularly for SCC, 
carcinoembryonic antigen (CEA) and cancer antigen 125 (CA-125) in AD or 
LCLC, and progastrin-releasing peptide (ProGRP) and neuron-specific enolase 
(NSE) in SCLC.  
 
In one study CYFRA 21-1 was investigated in 100 patients with lung cancer and 
detected with an immunoassay in the sera of 60% of patients, showing high 
sensitivity (86.4%) for squamous cell carcinoma and relatively low sensitivity for 
both adenocarcinoma (52.6%) and small cell carcinoma (50%) (Kinoshita, 
Watanabe et al. 1998). In another study CYFR21-1, at a cut-off level of 3.6ng/ml, 
was found to have sensitivity and specificity, respectively, of 56% and 89% for 
NSCLC, 63% and 91% for SCC, and 46% and 89% for SCLC (Pujol, Grenier et al. 
1993). Also it was shown to have, at a cut-off of 3.3ng/ml, sensitivity and 
specificity, respectively, of 59% and 94.4% for NSCLC, 68% and 94.4% for SCC, 
and 19% and 94.4% for SCLC (Wieskopf, Demangeat et al. 1995). Combining 
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telomerase activity with levels of CYFRA 21-1 can increase the sensitivity and 
overall accuracy of differential diagnosis of benign and malignant pleural effusion 
caused by lung cancer (Li, Fu et al.). A decline in CYFRA 21-1, and CEA, during 
chemotherapy can predict response and survival in patients with advanced NSCLC 
(Ardizzoni, Cafferata et al. 2006). CYFRA 21-1 has also been seen to predict 
survival in patients receiving gefitinib as third-line therapy (Barlesi, Tchouhadjian 
et al. 2005).  
CYFRA 21-1 has been shown to be a better marker than SCCA for early prediction 
of squamous cell carcinoma recurrence in the lung (Sun, Hsieh et al. 2000). The use 
of SCCA as a biomarker for NSCLC has been brought into question due to its low 
sensitivity and also by a study in which SCCA was shown to have no additional 
value when used in combination with CYFRA 21-1 (Kagohashi, Satoh et al. 2008).  
CA-125 is more consistently elevated in epithelial ovarian cancer and not lung 
cancer (Bast, Xu et al. 1998) however one study showed that the positive rates of 
CA125 is higher than that of CEA in NSCLC patients, especially in large-cell lung 
cancers and advanced adenocarcinoma, and concluded that CA125 is more useful 
than CEA in diagnosis of NSCLC (Wang, Zhu et al. 2008). 
A study on CEA and CA-125 in bronchoalveolar lavage fluid (BAF) in patients 
with NSCLC used cut-off values of 3ng/ml and 95 IU/ml respectively, and showed 
sensitivity and specificity of 100%, 84% and 92%, 80%, respectively (Dabrowska, 
Grubek-Jaworska et al. 2004).  
The levels of CEA, NSE, CYFRA-21-1, CA-125, and CA 19-9 were noted as being 
significantly higher in patients with pathologically confirmed lung cancer than 
those patients with benign pulmonary disease or control subjects (Li, Asmitananda 
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et al. 2012). CA 15-3, an unspecific marker, showed it may be useful as a marker 
for treatment monitoring (Nutini, Cappelli et al. 1990). 
 
ProGRP and NSE were shown to have complementary roles in diagnosis and 
prognosis of SCLC, indicating that ProGRP is more sensitive than NSE for 
diagnosis, while NSE is superior to ProGRP as a prognostic factor, concluding that 
both ProGRP and NSE are useful tumour markers (Shibayama, Ueoka et al. 2001).  
Detection of ProGRP, CYFRA21-1, NSE and CEA in pleural effusion could be of 
great clinical value in differential diagnosis and histological typing of malignant 
pleural effusion, with ProGRP being the optimal marker for malignant pleural 
effusion caused by SCLC (Liu, Yu et al. 2006).  
 
One study showed TPS, CYFRA21-1 and soluble tumour necrosis factor receptor 
(STNFR) can be used as very useful and sensitive tumour markers in the diagnosis 
of lung cancer, with CYFRA 21-1 considered the most useful tumour marker for 
clinical application (Liao, Li et al. 2005). TPS, along with CYFRA 21-1, could be 
significant prognostic factors and effective monitors of therapy for NSCLC (Liao, 
Li et al. 2005).  
 
Other potential lung cancer markers mentioned in the literature include plasma 
kallikrein, serum amyloid A (SAA), haptoglobin ß chain (Hp ß), and complement 
component 9. High levels of SAA in the sera of lung cancer patients has been 
detected by mass spectrometry, verified by western blot and then quantified by 
ELISA, while the same group demonstrated that the secretion of SAA1 and SAA2 
(isoforms of SAA) stimulates infiltrating macrophages to induce MMP-9, which 
 40
may drive metastasis of cancer cells (Sung, Ahn et al. 2011). High levels of 
haptoglobin in serum have been reported in various cancers such as breast, ovarian, 
pancreatic, and bladder, and the Hp ß chain was suggested as a diagnostic marker 
for lung cancer for both NSCLC and SCLC types (Kang, Sung et al. 2011).  
 
Dihydrodiol dehydrogenase (DDH) over-expression in adenocarcinoma cells has 
been shown to exhibit a much higher resistance to the anticancer drugs doxorubicin 
and cisplatin and to irradiation than cells with lower DDH expression, with the 
isoforms DDH1 and DDH2 mainly responsible for these effects (Hung, Chow et al. 
2006). Over-expression of DDH has been previously shown to be a possible 
prognostic marker of NSCLC (Hsu, Ho et al. 2001) and in serum its level is higher 
in NSCLC patients than non-malignant lung tumours and healthy controls (Huang, 
Chen et al. 2006).  
Pentraxin-3 has recently been highlighted as a new biomarker for lung cancer with 
diagnostic sensitivity and specificity similar to other clinically-used lung cancer 
biomarkers, though it’s own clinical utility has yet to be established (Diamandis, 
Goodglick et al.).  
 
Cigarette smoke, the main cause of lung cancer, induces an accumulation of 
reactive oxygen species which have multiple effects on cell defence, cell 
proliferation, and cell death, therefore compounds involved in the regulation of 
redox balance may play a fundamental role in both carcinogenesis and tumour 
progression. This is why Peroxiredoxins (Prxs), which represent a protein family 
with the capability of breaking down hydrogen peroxide, can participate in cellular 
antioxidant defence and regulate cell proliferation, and also act as indicators of lung 
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cancer (Lehtonen, Svensk et al. 2004). Peroxiredoxin 1 for example may serve as a 
new prognostic biomarker and therapeutic target in NSCLC (Kim, Bogner et al. 
2008).   
 
There are many published papers in the literature with lists showing abundance 
levels of proteins in lung cancer compared to normal, healthy controls, but with no 
clinical validation. These lists, especially when generated from non-serum based 
work such as conditioned media, are relatively obsolete without further validation 
because the expression of these proteins, even ones that have been secreted in cell 
culture for example, does not necessarily relate to their expression in serum. With 
the added difficulties faced when searching in serum for low abundant markers, the 
majority of proteins in these lists would not be viable markers. There is a need now 
for any study involving lung cancer biomarkers to include validation that can be 
considered clinically applicable. For example, a recent study on the conditioned 
media of four lung cancer cell lines included validation in serum, of patients with 
and without lung cancer, using enzyme linked immunosorbent assays (ELISAs) for 
five of their candidate biomarkers, which included pentraxin-3 and soluble tumour 
necrosis factor receptor (Planque, Kulasingam et al. 2009).  
 
1.5.1.1 Preanalytical  Phase 
 
Standardisation and optimisation of the preanalytical conditions for clinical 
specimens is needed for the development of clinically applicable tests. Lack of 
these procedures, as well as specimen acquisition, handling, and storage account for 
more than 90% of the errors within the entire diagnostic process (Lippi, Salvagno et 
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al. 2006). To improve chances of generating validated biomarkers, there needs to be 
greater focus on collection, transport, preparation, and processing of the biological 
sample (Conrads, Hood et al. 2006). Improved quality management in areas such as 
establishment of large biorepositories (biobanks) is needed. Also, depending on the 
phase of biomarker development and validation, the sample needed, and in turn 
sample processing, could be quite different. For example, high-throughput 
proteomic profiling for clinical proteomics has considerably different requirements 
than the subsequent protein identification and in-depth characterisation of single 
protein samples (low-throughput) in the preclinical and discovery phase, and 
differences can arise due to the site of sample collection, the process of 
blood/biofluid collection, the material and liquid content of the sample container, 
the time until sample processing and the temperature (Apweiler, Aslanidis et al. 
2009).  
 
Hemolysis, the release of haemoglobin and other intracellular components from 
erythrocytes to the surrounding plasma following damage or disruption to the cell 
membrane, can influence the accuracy and reliability of laboratory testing. At the 
preanalytical stage there are many parameters related to patient preparation and 
blood collection which can effect this, such as difficulty in locating easy venous 
access, small or fragile veins, application of a negative pressure to the blood in the 
syringe, excessive shaking or mixing of the blood after collection, exposure to 
excessively hot or cold temperatures, and centrifugation at too high speed for a 
prolonged period of time (Lippi, Salvagno et al. 2006).  
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The time of sample collection can have an effect too, as can be seen in particular 
with urine collection where consideration must be given to the time that urine is 
stored in the bladder because due to bacterial contamination there is greater protein 
degradation in first void morning urine compared to urine collected at other times 
(Schaub, Wilkins et al. 2004). 
The protein content can also differ depending on whether it is serum or plasma 
being examined. When serum and plasma are separated from the blood, plasma still 
retains the fibrinogen that helps in clotting while serum is that part of the blood 
after this fibrinogen (clotting factor) is removed. The clotting cascade causes a 
reduction in proteins so generally there are more peptides in plasma than serum, 
however the protein composition in plasma can be affected by the anticoagulant 
used (Tammen, Schulte et al. 2005).  
Storing at -20°C or at -80°C can affect the protein content, although little difference 
was seen between samples frozen for 1-3 months (Hsieh, Chen et al. 2006), 
however this was probably due to the short storage time and greater differences 
would be seen in samples stored for longer periods. Storage conditions can also 
depend on the protein to be examined as one study on the HbA 1C protein showed 
that temperatures of 4°C and -80°C were best for short and long-term storage 
respectively, whereas temperatures of 20°C (room temperature) and -20°C were not 
recommended, even indicating that samples showed earlier degradation at -20°C 
than at 4°C (Szymezak, Lavalard et al. 2009). 
 
The importance of standardisation of the preanalytical process can not be 
overemphasised. The high amount of variables to be taken into account for a 
clinically applicable assay means there is plenty of room for error and to lessen the 
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overall effect of these errors, standard protocols are needed which can be followed 
in all laboratories performing the same tests. Even in a well-used laboratory test 
such as the BCA-assay for measuring protein content, differences can be seen in the 
results depending on the reagents in the lysis buffer used to prepare your protein 
sample, which can interfere with the chemicals in the kit (Krieg, Dong et al. 2005).  
 
1.5.1.2 Serum and Plasma 
Blood is the most common body fluid for biomarker investigation, with both plasma 
and serum used. Plasma is prepared by centrifuging whole blood to remove red and 
white blood cells, with anti-coagulants to prevent clotting used; such as EDTA, 
heparin, and citrate, with EDTA the anticoagulant of choice if delayed blood 
processing is anticipated (Lam, Rainer et al. 2004). Serum is obtained when the 
blood is allowed to clot, the clot is removed by centrifugation, and the light yellow 
supernatant is removed. Serum is basically plasma with the clotting factors removed 
e.g. fibrin. Plasma and serum are a light yellow colour though plasma will tend to 
be cloudier due to the additional proteins.  
It should be noted that a good serum biomarker does not necessarily make a good 
plasma biomarker (and vice versa) and differences are seen in their protein and 
metabolite profiles. One study found reproducibility of metabolite results 
significantly better for plasma than for serum though metabolite concentrations 
were generally higher in serum than in plasma (Yu, Kastenmuller et al. 2011). 
Another study comparing protein profiles of serum and plasma using an antibody 
suspension bead array approach found that while technical variability was equal, 
plasma offered a greater biological variability which gave rise to more potential 
discoveries than serum (Schwenk, Igel et al. 2010). It has been seen that an increase 
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in concentrations of some proteins in serum compared to plasma could be due to the 
stimulation of platelets by the coagulation cascade and the release of platelet 
factors, such as the chemokine NAP-2 which may stimulate leukocytes leading to 
the production of cytokines, growth factors, and other chemokines (Ayache, Panelli 
et al. 2006). 
 
1.5.2 Assays for Detection of Biomarkers in Clinical Samples 
 
1.5.2.1 Enzyme-linked Immunsorbent Assay (ELISA) 
An enzyme-linked immunosorbent assay (ELISA) is used to detect the presence of 
an antigen or antibody in biological fluids such as serum, plasma, saliva, or urine, 
and also in cell culture supernatant and tissue samples, often performed on a 96-
well microtiter plate. The enzyme is conjugated to an antibody which will react 
with a colourless substrate to generate a coloured reaction product, which is 
measured spectrophotometrically. The most commonly used enzymes are 
horseradish peroxidase, alkaline phosphatase, and p-nitrophenyl phosphatase ß 
galactosidase. When mixed with a suitable substrate (for example 3,3’,5,5’-
tetramethylbenzidine (TMB) is a colorimetric substrate for horseradish peroxidase 
enzyme) each of these enzymes generates a coloured reaction product, their 
absorbance read at a particular wavelength on a plate-reader, allowing qualitative 
detection or quantitative measurement of either antigen or antibody. 
An ELISA begins with the generation of antibodies to a particular protein. 
Antibodies (also known as immunoglobulins) are proteins synthesised by an animal 
in response to the presence of a foreign substance (antigen) and normally function 
to protect the animal from infection. They are glycoproteins secreted by specialised 
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B lymphocytes known as plasma cells and are composed of four polypeptides; two 
identical copies of both a heavy (~55 kD) and light (~25 kD) chain are held together 
by disulfide and noncovalent bonds, and the resulting molecule is often represented 
by a schematic Y-shaped molecule of ~150 kD.  
 
Antibodies occur in two forms: a soluble form secreted into the blood and tissue 
fluids, and a membrane-bound form attached to the surface of a B cell that is called 
the B cell receptor (BCR). The BCR allows a B cell to detect when a specific 
antigen is present in the body and triggers B cell activation. When a severe infection 
occurs pathogens spread through the bloodstream and B cells in the blood capture 
the pathogens, via their specific antigen receptors (surface immunoglobulins), then 
present the specific antigen to T cells in the spleen, thus increasing the degree of T-
cell immune responses to systemic infection (Nagafuchi). T cells are a type of white 
blood cells called lymphocytes (as are B cells), the “T” standing for thymus, the 
organ in which their final stage of development occurs. T helper cells help with the 
maturation of B cells into antibody-producing plasma cells and memory B cells 
(which help with the quick response if the antigen invades again and are essential 
for the success of vaccinations) (Esser, Marchese et al. 2003). 
 
Antibodies have specific and high affinity for the antigens that elicited their 
synthesis. The antibody recognises a specific group or cluster of amino acids on a 
large molecule called an antigen determinant, or epitope. Small foreign molecules, 
such as synthetic peptides, can also elicit antibodies, provided that the small 
molecule contains a recognised epitope and is attached to a macromolecular carrier; 
the small foreign molecule is called a hapten. Animals have a large repertoire of 
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antibody-producing cells, each producing an antibody of a single specificity. An 
antigen works by stimulating the proliferation of a small number of cells that were 
already forming an antibody capable of recognising the antigen. Monoclonal 
antibodies will detect only one epitope on an antigen, whereas polyclonal antibodies 
recognise multiple epitopes on any one antigen and are a heterogeneous mixture of 
antibodies of different affinities. Polyclonal antibodies can be produced in a short 
timescale and are relatively inexpensive but are multi-specific and there can often 
be batch-to-batch variability, whereas monoclonal antibodies are expensive with a 
long time scale for production but are mono-specific and once a hybridoma is made 
it is a constant and renewable source of identical batches (Lipman, Jackson et al. 
2005). A hybridoma is an immortal cell line derived from a type of cancer, multiple 
myeloma, a malignant disorder of antibody-producing cells, resulting in a single 
transformed plasma cell dividing uncontrollably, generating a large number of cells 
of a single kind (Ling, Deng et al. 2003).  
 
 
Figure 1.6: Structure of an antibody (www.cartage.org.lb) 
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1.5.2.2 Indirect, sandwich, and competitive ELISA 
The direct method uses a labelled primary antibody that reacts directly with the 
antigen with detection being performed with an antigen that is immobilised on the 
assay plate. This method is not widely used in ELISA but is quite common for 
immunohistochemical staining of tissues and cells. The indirect and the “sandwich” 
methods are commonly used in ELISAs. The indirect method uses a known primary 
antibody to attach to the antigen of interest, which is attached to the well of your 
plate. A conjugated secondary antibody is then added to bind to your primary 
antibody and a substrate added to elicit a readable colour change. A sandwich 
ELISA is similar except that a capture antibody is used to pull out the antigen of 
interest before the primary and conjugated secondary are added. 
 
 
Figure 1.7: Direct, Indirect, and sandwich methods for detection of antigen of 
interest (www.piercenet.com)  
 
A sandwich ELISA is more sensitive than the indirect method. The antigen 
immobilisation in the indirect method is not specific and small concentrations of 
analyte in serum for example must compete with other serum proteins when binding 
to the well surface. The sandwich ELISA provides a solution to this problem with 
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the use of a capture antibody specific for the antigen of interest so that when the 
primary antibody is added in the next step there is only the antigen of interest 
present to bind to. A sandwich ELISA does not need a conjugated secondary if the 
primary antibody is conjugated to an enzyme; however the use of a secondary-
antibody conjugate avoids the expensive process of creating enzyme-linked 
antibodies for every antigen one might want to detect. Without the ‘capture’ 
antibody any proteins in the sample may competitively adsorb to the plate surface, 
lowering the quantity of antigen immobilised. Use of the purified specific antibody 
to attach the antigen to the well eliminates a need to purify the antigen from 
complicated mixtures before the measurement, simplifying the assay, and 
increasing the specificity and sensitivity of the assay. There is also a double-
antibody sandwich ELISA technique which involves, for example, adding the 
samples to be tested (e.g. serum), together with a biotin antibody and streptavidin-
HRP, into the ELISA well coated with capture antibody. 
 
A competitive ELISA involves the initial incubation of unlabelled primary 
antibody with the sample of choice (e.g. serum). The samples, with the bound 
antibody/antigen complexes, are then added to an antigen coated well. The plate is 
washed so that unbound antibody is removed (the antibody/antigen complexes from 
initial incubation will be removed). The more antigen in the serum sample the less 
antibody will be available to bind this antigen, hence the ‘competition’. Next a 
conjugated secondary is added followed by the substrate. The signal produced is 
inversely proportional to the amount of antigen in the sample, i.e. the higher the 
sample antigen concentration the weaker the eventual signal. A competitive ELISA 
allows the use of crude or impure samples and still selectively binds any antigen 
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that may be present. Some competitive ELISA kits include the enzyme-linked 
antigen rather than the enzyme-linked antibody. 
 
 
Figure 1.8: Competitive ELISA: the more antigen in sample the less antibody 
available to bind to antigen coated well, hence signal intensity is inversely 
proportional to antigen concentration in sample. 
 
1.5.2.3 Multiplex Assays 
The simultaneous quantitative assessment of multiple potential biomarkers across 
large cohorts presents a major challenge to the field. Multiplex assays are used for 
measuring the levels of multiple analytes in a single sample. These assays use 
substantially less sample and reagents than the traditional ELISA (which is further 
limited by its ability to measure only a single antigen) and have been shown to be 
reproducible, reliable, robust, and accurate, however their performance has also 
been shown to be analyte, sample type, and concentration dependent, and each 
assay’s dynamic range, linearity, CV (the “coefficient of variation”, describing the 
standard deviation as a percentage of the mean), and percentage recovery are 
important for obtaining accurate and reproducible assay results (Fu, Zhu et al.). 
Virtually all of the commercially available bead array kits are supplied with 
reference standards and thus provide quantitative information. 
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There are several differences between bead array assays and ELISAs. The multiplex 
bead array assays (MBAA) use fluorescence as a reporter system unlike ELISAs 
which use enzyme amplification of a colorimetric substrate. Luminex captures 
ligands onto spherical beads in suspension while ELISAs generally rely upon flat 
surfaces in 96-well plates. The multiplex nature of these assays can invariably lead 
to cross-reactivity, something generally avoided in ELISA methodologies as they 
study one analyte at a time (Elshal and McCoy 2006). A competing technology is 
protein microarray kits which capture antibodies and reporter antibodies in a 
multiplex fashion similar to MBAA, however these assays are relatively new, are 
not widely accepted as a ‘gold standard’ for clinical use, and may also be of limited 
sensitivity (Copeland, Siddiqui et al. 2004). Reliable MBAA results have been seen 
to be obstructed by anti-cytokine antibodies which may cross-react with other 
cytokines (Kellar and Douglass 2003), by cross-species antibodies, as well as by 
other interfering substances (Pang, Smith et al. 2005). It cannot therefore be 
assumed that a reliable single-plex assay can automatically be incorporated into a 
reliable multiplex array and instead each analyte must be tested for non-reactivity 
against all the other antibodies to be used in the multiplex format. Specialised 
platforms such as the Luminex system incorporate software capable of automatic 
gating as well as computation of absolute protein/cytokine levels, and can 
significantly reduce the complexity in performing these assays and also require less 
user interaction. 
 
The Luminex multi-analyte xMAP technology combines advanced fluidics, optics, 
and digital signal processing with a microsphere technology. The microspheres are 
tiny colour-coded polystyrene beads dyed with distinct proportions of red and near-
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infrared fluorophores. Each bead set can be coated with a reagent specific to a 
particular bioassay, allowing the capture and detection of specific analytes from a 
sample. A light source inside the luminex system excites the internal dyes that 
identify each microsphere particle and any reporter dye captured during the assay. 
Up to one hundred different detection reactions can be carried out simultaneously 
on the various bead populations in very small volumes (Earley, Vogt et al. 2002). 
The Luminex-100 for example has a three-colour fluorescence signal-detection 
system with two colours dedicated to microsphere classification and the third colour 
for measurement of the reporter fluorescence intensity. Many readings are made on 
each bead set, which further validates the results. Using the conjugation-ready bead 
sets provided by Luminex it is possible to develop MBAAs within any laboratory. 
Studies that looked at both ELISA and MBAAs demonstrated good correlations but 
often poor concurrence of quantitative values and a comparison of randomly 
selected bead array assays and ELISAs will likely demonstrate substantial 
differences, however if comparisons are made between MBAA and ELISA which 
use identical capture and reporter antibodies, as well as similar diluents and serum 
blockers, variability will be minimised, correlations will be good, and similar 
quantitative values will be achieved (Elshal and McCoy 2006). 
 
1.6 Proteomic Methods 
 
Proteomics has been defined as the study of the proteome, which is composed of the 
total collection of all the cellular proteins present at a given time point and the 
physiological state in a defined biological entity (Bharti, Ma et al. 2007). It has also 
been defined as the global analysis of gene expression at the protein level and 
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comes with the promise of unravelling the cellular mechanisms of diseases with the 
hope of developing reliable markers for disease diagnosis, prognosis, and therapy 
(Mirza and Olivier 2008). 
Proteomics can involve separating proteins from a sample on SDS-PAGE gels 
followed by subsequent identification of the proteins via mass spectrometry, 
however this gives us no information about the differences in protein behaviour 
between normal and disease states and when you take into account the vast number 
of proteins, considered to be a figure of over one million (Jensen 2004) compared to 
gene numbers of between 20,000 and 25,000 (Pertea and Salzberg 2012), there is a 
great need to narrow down this quantity to a workable figure. There have been great 
advances in proteomics to help with this, with many labelling techniques available 
to help with quantitative comparisons between sample sets and there have been vast 
strides made in mass spectrometry methods to complement these techniques. There 
is now a move towards label-free spectrometry, which is less labour intensive and 
less expensive than label-based proteomic techniques and can also remove technical 
issues caused by inefficient labelling, a problem seen with iTRAQ and ICAT (Wu, 
Wang et al. 2006). These techniques, and various other proteomic techniques for 
biomarker discovery, will be examined in detail. 
 
1.6.1 Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) 
The first method used in proteomics, and still used, involves a high-resolution 
separation of proteins based on two properties; two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) separates proteins by their isoelectric point (pI) in the 
first dimension and then by their molecular weight (MW) in the second dimension.  
The combination of two techniques to better resolve proteins has been around for a 
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long time (Poulik and Smithies 1958, O'Farrell 1975). An important step forward 
later on was the development of microanalytical techniques able to identify proteins 
at the amounts seen in 2D gels. Prior to loading samples on a 2D-gel accurate 
protein concentration assays must be performed to determine the amount of protein 
in a sample, which is important for a number of reasons such as ensuring that the 
amount of protein to be separated is appropriate for the gel size and visualization 
method being used, to facilitate comparison among similar samples as image-based 
analysis is simplified when equivalent quantities of proteins have been loaded on 
the gels to be compared, and it is necessary in cases where the protein sample is 
labelled with fluorescent dye before separation as the amount of dye needed is 
relative to the amount of protein in the sample (Berkelman 2008). 
Isoelectric focusing (IEF) is used to separate proteins according to their pI, which is 
the pH at which the electric charge on the protein is neutral, therefore the protein 
carries no net electrical charge and can no longer move in an electrical field. 
Commercial gel strips are available with immobilised pH gradients (IPG) for this 
purpose (Rabilloud 2002). These strips are placed on top of SDS polyacrylamide 
gels and the proteins, via electrophoresis, are separated according to their molecular 
weight, resulting in a two dimensional representation of the proteins contained 
within a gel slab.  
 
A number of staining methods are available to enable visualisation of the proteins in 
the gel such as Coomassie Blue G-250 and more sensitive methods such as silver 
staining when there are only very small quantities of protein available. Coomassie 
Blue staining remains the most used stain for a number of reasons; (i) it is relatively 
cheap, (ii) visible with the eye, (iii) basic desk top scanners can be employed for 
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image acquisition, (iv) better for quantitative analysis than silver staining, (v) 
possible modifications can be performed for fast or highly sensitive staining, and 
(vi) it is compatible with mass spectrometry (Westermeier 2006). However, for 
biomarker protein abundance comparison studies it is relatively ineffective. 
 
1.6.1.1 2D-Difference In-Gel Electrophoresis (2D-DIGE) 
2D-DIGE is a fluorescent dye based protein staining method which can give 
quantitative information on differences between sample sets. It involves covalent 
labelling prior to 2D-PAGE, employing three fluorescent cyanine dyes (Cy2, Cy3, 
and Cy5) which are size and charge matched. Traditional 2D-PAGE is time-
consuming, labour-intensive and, due to the lack of reproducibility between gels, 
leads to significant system variability making it difficult to distinguish between 
system variation and induced biological change, which means that real differences 
between protein abundance attributed to a cancer state can seldom be predicted with 
any real confidence (Marouga, David et al. 2005). 2D-DIGE involves the use of an 
internal standard, included on all gels in the experiment, from which all other gels 
can be normalised against, resulting in accurate reproducibility and protein 
abundance comparisons between gels (Alban, David et al. 2003).  
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Figure 1.9: The workflow for a 2D-DIGE experiment (Andres Ritter). 
 
Computer software such as DeCyder and Progenesis SameSpots are used to match 
gels to a reference image (generally the best resolved gel with the most number of 
protein spots) in order to perform comparison studies and there are statistical 
modules in place to indicate which protein abundance disparities can be examined 
with the most confidence. Coupled with immunodepletion and with subsequent 
mass spectrometry analysis, 2D-DIGE can be used to indicate possible disease 
markers in serum (Dowling, O'Driscoll et al. 2007). 2D-DIGE has also proved 
sensitive enough for proteomic profiling of the mitochondrial proteome of young 
adult rat versus aged rat skeletal muscle to find reliable mitochondrial marker 
candidates that could be used in the establishment of a biomarker signature of 
skeletal muscle aging (O'Connell and Ohlendieck 2009). However, spots on a given 
2D gel often contain more than one protein, making quantification of the protein 
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ambiguous since it is not always clear which protein in the spot has actually 
changed. Also, gel-based methods have a number of restrictions on the proteins 
they can resolve; having difficulty handling or detecting proteins which are 
hydrophobic, have extreme molecular weights and pI values, or in samples with a 
high dynamic range. 
 
1.6.2 Stable Isotope Labelling Proteomics 
 
1.6.2.1 Stable isotope labelling with amino acids in cell culture (SILAC) 
In contrast to other isotope labelling techniques, SILAC is an in vivo labelling 
strategy in which the proteome is labelled as cells grow in culture. SILAC relies on 
the incorporation of amino acids with substituted stable isotopic nuclei (e.g. 
deuterium, 13C, 15N) so that two cell populations can be grown in culture media 
that are identical except that one of them contains a 'light' and the other a 'heavy' 
form of a particular amino acid (e.g. 12C and 13C labelled L-lysine, respectively) 
which can be readily distinguished by mass spectrometry. If the labelled analogue 
of an amino acid is supplied instead of the natural abundant amino acid, it will be 
incorporated into each newly synthesized protein chain (Ong, Blagoev et al. 2002).  
In fact, SILAC has the ability to compare up to five states in a single experiment, 
the number of states restricted by the limited availability of heavy forms of amino 
acids, though it can only be used in metabolically active cells so cannot be used for 
tissue samples (Harsha, Molina et al. 2008). It has been used to study 
posttranslational modifications such as protein phosphorylation and methylation, to 
characterise signalling pathways and to determine specific protein interactions 
(Gruhler and Kratchmarova 2008). The labelling process itself is uncomplicated and 
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highly efficient (100% of sample is available for labelling) and due to the 
combination of unlabelled and labelled samples prior to cell lysis it allows any 
method of protein or peptide purification to be used without introducing error (Ong, 
Foster et al. 2003).  
SILAC has been used for phosphoproteomic analysis (Pimienta, Chaerkady et al. 
2009), to discover differentially expressed plasma membrane proteins in renal cell 
carcinoma (Aggelis, Craven et al. 2009), to identify secreted proteins for pancreatic 
serum biomarker discovery (Yu, Barry et al. 2009), and even to help quantitatively 
identify proteins linked to human embryonic stem cells (Collier, Sarkar et al.), cells 
which could be used in the treatment of numerous medical conditions, showing its 
usefulness as a complementary technique for generating a list of possible protein 
disease markers. 
 
1.6.2.2 Isotope-Coded Affinity Tags 
The isotope coded affinity tag is a chemical modification strategy that allows quick 
and accurate quantification coupled with sequence identification of proteins in a 
complex mixture. Isotope-coded affinity tags (ICAT) and an improved version 
known as isobaric tags for relative and absolute quantification (iTRAQ) are the two 
main methods used. ICAT utilises reagents consisting of three functional groups; a 
sulfhydryl-reactive iodoacetate group, a biotin affinity group, and a linker carrying 
light or heavy isotopes (Sethuraman, McComb et al. 2004). ICAT-labelled peptides 
elute as pairs from a reverse-phase column so by calculating the ratio of the areas 
under the curve for identical peptide peaks labelled with the light and heavy ICAT 
reagent, the relative abundance of that peptide in each sample can be determined, 
which is directly related to the abundance of the corresponding protein. In addition, 
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because the ICAT reagents are specific for cysteinyl residues, the complexity of the 
original peptide mixture is greatly reduced (Li, Steen et al. 2003). Also, because it 
is based on post-isolation stable isotope labelling of proteins it is not limited to cells 
and tissues compatible with metabolic labelling.  
 
The ICAT approach allows quantitative cataloguing and comparison of protein 
expression in a number of states; normal, developmental, and disease, with obvious 
uses in cancer biomarker discovery. The combination of ICAT and 
multidimensional chromatography followed by mass spectrometry of digested 
proteins is able to detect and quantify low abundant proteins in complex mixtures 
(Gygi, Rist et al. 2002).  
There are a number of limitations to ICAT including missed identification of 
proteins with few or no cysteine residues, lost information for post-translational 
modifications (PTM’s), differential reversed-phase elution of identical peptides 
labelled with the hydrogen/deuterium isotope pairs, and complicated interpretation 
of tandem mass spectrometry (MS/MS) spectra due to the addition of the biotin 
group (Goshe and Smith 2003, Leitner and Lindner 2004), however most of these 
problems have been solved by the use of cleavable isotope-coded affinity tags 
(cICAT).  
cICAT involves labelling samples with the isotopically light or heavy cICAT 
reagent, combining them, digesting with a protease, retrieval using an avidin 
affinity column and importantly having the added bonus of being able to remove the 
retrieval ligand prior to MS, and subsequently can be used to reduce the complexity 
of digested proteins and to improve quantification of low-abundant proteins (Qu, 
Jusko et al. 2006). 
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Another method using isotope affinity tags, known as iTRAQ, allows up to eight 
samples to be analysed in a single experiment enabling simultaneous identification 
and quantification, both relative and absolute, using synthetic isobaric peptide 
standards that are indistinguishable by their MS spectra or MS/MS ion series, but 
exhibit intense, low-mass MS/MS signature ions that permit quantitation of 
members of the multiplex set (Ross, Huang et al. 2004). The distribution of isotopes 
in the different tags is such that when the tags fragment a reporter ion is released 
which is tag-specific and the ratio of signal intensities from these tags act as an 
indication of the relative proportions of that peptide between the different labelled 
samples (Unwin). Performed in 4plex or 8plex experiments, the amine specificity of 
the iTRAQ reagents makes most peptides in a sample amenable to this labelling 
strategy.  
iTRAQ, generally in conjunction with either LC-MS/MS or MALDI-TOF/TOF MS 
or a combination of both, has been used to find new and better biomarkers for 
gastric cancer (Chong, Lee et al.), to uncover clinically relevant candidate markers 
for prostate cancer progression (Glen, Evans et al. 2010), to study p53-modulated 
proteins secreted in lung cancer cells (Chenau, Michelland et al. 2009), to identify 
serum biomarkers for oral squamous cell carcinoma (Bijian, Mlynarek et al. 2009), 
to investigate low-grade breast primary tumour tissues with and without metastases 
and metastasis for relevant biomarkers (Bouchal, Roumeliotis et al. 2009), and to 
identify serum biomarkers in brain-injured patients that may predict elevated 
intracranial pressure (Hergenroeder, Redell et al. 2008), to name a few areas of 
biomarker discovery iTRAQ has been used, and is presently used, for.  
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There are however limitations with labelling-based quantification approaches 
including increased time and complexity of sample preparation, requirement for 
higher sample concentration, the high cost of reagents, incomplete labelling, and the 
requirement for specialised computer software for quantification. Also, labelling 
strategies limit the number of samples that can be analysed in a single experiment 
and some labelling strategies can not be applied to all types of samples . 
 
1.6.3  Mass Spectrometry 
Mass spectrometry (MS) is used for peptide fragmentation and protein 
identification. The more common bottom-up mass spectrometry technique involves 
fragmenting peptides in the gas phase after protein digestion with a protease such as 
trypsin. The less common but becoming gradually more popular top-down 
technique involves fragmenting intact proteins directly.  
Identifying proteins using MS requires an interconnected relationship between mass 
spectrometry instrumentation. For example there are differences in how molecules 
are ionised, activated, and detected. Gas-phase peptide chemistry determines which 
bonds are broken, at what rate, the cleavage depending on factors such as 
peptide/protein charge state, size, composition, and sequence. There is a huge 
variety of MS/MS instrument configurations with different aptitudes for speed, 
ionisation method, resolution, sensitivity, and mass/charge range (Wysocki, Resing 
et al. 2005). To identify proteins in complex biological samples, more sensitive 
mass spectrometers are used with low flow, high resolution separation technologies 
but the more sensitive the mass spectrometer generally the more expensive it is. 
There is a vast, and continuously expanding, amount of genome and proteome 
information stored in databases which can be used for MS and MS/MS applications 
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and the lists of peak intensities and mass to charge ratios produced by MS can be 
compared to lists generated from ‘theoretical’ fragmentation of a peptide or 
digestion of a protein to yield protein identifications. 
For biomarker discovery, a benefit of using mass spectrometry is its ability to 
discern structural modifications to proteins (e.g. posttranslational modifications 
such as phosphorylation and glycosylation), and as proteomic techniques improve 
so too will discovery of these changes and whereas it is difficult to build 
conventional assays to such candidates, targeted mass spectrometry (such as 
multiple reaction monitoring (MRM)) can be applied to overcome this problem 
(Wang, Whiteaker et al. 2009).  
 
1.6.3.1 Ionisation 
To analyse a sample by MS it must be first ionised and vaporised. The two main 
ionisation techniques are electrospray ionisation (ESI) and matrix-assisted laser 
desorption/ionisation (MALDI). In ESI, ions are formed at atmospheric pressure, 
while ions in MALDI may be generated either at atmospheric pressure or under 
vacuum conditions (Canas, Lopez-Ferrer et al. 2006). Conventional electrospray 
involves initially dissolving your protein sample in a solvent, meaning it will exist 
in an ionised form, and this solution is pumped through a thin capillary which is 
raised to a high potential forming small charged droplets which are sprayed from 
the ES capillary into a bath gas at atmospheric pressure before travelling down a 
pressure and potential gradient towards an orifice in the MS high-vacuum system 
(Griffiths, Jonsson et al. 2001). As droplets make this journey they become 
desolvated and reduced in size to such an extent that surface-coulombic forces 
overcome surface-tension forces and subsequently the droplets are broken up into 
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even smaller droplets. There are two theories for ion formation in ESI, one being 
that ionised sample molecules are expelled from the droplets (Bakhtiar and Nelson 
2001), the other that individual ionised molecules remain after continuous solvent 
evaporation and droplet fragmentation (Mora, Van Berkel et al. 2000).  
 
In matrix-assisted laser desorption/ionisation the sample is usually embedded in 
an excess of a solid matrix, which, upon laser irradiation, assists in the volatilization 
and ionization of the analytes and additionally, the high matrix/sample ratio reduces 
associations between analyte molecules, and provides protonated and free-radical 
products that ionize the molecules of interest (Marvin, Roberts et al. 2003). The 
matrix is the primary absorber of the UV laser radiation and because it breaks down 
rapidly expanding into the gas phase it is used in high excess compared to the 
sample itself and in this way it minimises sample degradation from the laser 
radiation. The matrix is a crystal-like structure of weak organic acids; examples of 
such include a-Cyano-4-hydroxycinnamic acid (CHCA), Sinapic acid (SA), and 2-
(4-Hydroxyphenylazo) benzoic acid (HABA), and the matrix of choice will have to 
strongly absorb the energy of the laser beam at a wavelength where analytes exhibit 
only weak absorption (Bonk and Humeny 2001).  The sample and the matrix co-
crystallise together on the MALDI plate.  
 
1.6.3.2 Mass Analysis 
ESI and MALDI mass spectrometers are combined in various ways with different 
mass analysers. The mass analysers generally used are quadrupoles, Time of Flight 
(TOF) instruments, and ion traps, either alone or in hybrid systems. One of the most 
important characteristics of mass analysers is their resolution, i.e. their ability to 
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differentiate two close signals. The key parameters for mass analysers in proteomics 
are sensitivity, resolution, mass accuracy, and the ability to generate information-
rich ion mass spectra from peptide fragments (tandem MS or MS/MS spectra) 
(Aebersold and Mann 2003).    
 
In ion trap MS (IT-MS), ions are stored until the trap is full and by varying the 
radio frequency (RF) voltage applied to the ring electrode, ions are ejected out of 
the endcap and are detected by the electron multiplier, however in quadrupole MS 
(Q-MS), ions are continuously formed, accelerated into the quadrupole and mass 
analyzed, consequently, both types of mass spectrometers have specific advantages; 
with IT-MS higher sensitivity is obtained in full scan, whereas ion ratio stability is 
better for Q-MS (Fitzgerald, O'Neal et al. 1997).  
 
MALDI-TOF and the related technique, surface enhanced laser 
desorption/ionisation (SELDI)-TOF both use time-of-flight (TOF), in which a time 
measurement is used to measure ions mass-to-charge ratio. In MALDI-TOF MS, a 
small amount, typically 1 µL, of specimen containing peptides and protein is dried 
on a target plate together with a light-absorbing matrix molecule. The protein/matrix 
sample is vaporised from surface deposits by nanosecond-duration laser pulses 
which release ionized protein molecules, often with a single charge (z =1), which 
are then accelerated in an electric field within a vacuum. Ions with low mass/charge 
ratios (m/z) are accelerated to higher velocities and reach the detector before ions 
with a high m/z. Ions reach the detector over a time span of 0.01–1 ms; the 
millisecond timescale to analyze ions produced by a single laser pulse allows 
acquisition of data from multiple laser pulses for each specimen and provides short 
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analysis time per specimen, and therefore the technique lends itself to high-
throughput analysis (Hortin 2006). MALDI-TOF sample analysis is independent of 
factors other than mass because separations occur in a vacuum. Its ability to desorb 
high-molecular-weight thermolabile molecules, its high accuracy and sensitivity, 
combined with its wide mass range (1-300kDa) makes MALDI-TOF MS a usual 
platform for identification of biomolecules in complex samples (Marvin, Roberts et 
al. 2003).  
 
In SELDI-TOF the sample is spotted onto a protein-chip array, with each spot on 
the chip consisting of a chromatographic surface that allows attachment and 
enrichment of particular proteins under defined conditions from a complex protein 
mixture, such as serum. The surface may consist of various materials of different 
physico-chemical characteristics such as hydrophobic or hydrophilic properties, 
containing metal ions (such as immobilised metal affinity capture: IMAC) or anion 
and cation exchangers (Kiehntopf, Siegmund et al. 2007), or it can be pre-activated 
for the coupling of capture molecules such as protein, DNA, or RNA prior to 
sample loading. After the binding phase of the sample to these surfaces, the 
unbound proteins are washed away while retained molecules are overlaid with a 
laser-absorbing matrix, and then the sample is ionised with a laser and the mass 
spectra is recorded after ions are resolved with the TOF spectrometer. 
 
Protein profiling using SELDI-TOF for biomarker discovery has become more 
popular in recent years. One of the key features of SELDI-TOF MS is its ability to 
provide rapid protein expression profiles from a variety of biological samples with 
minimum requirements for purification and separation of proteins prior to mass 
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spectrometry (De Bock, de Seny et al.). Biofluids used on SELDI chips include 
plasma, serum, saliva, urine, amniotic fluid, and nipple aspirate fluid, however, 
when working with biofluids great care must be taken as non-biological differences 
can be caused by variances in sample collection, processing, storage, and analytical 
techniques. The range detectable by SELDI-TOF and indeed MALDI-TOF is about 
2 orders of magnitude so a complex sample such as serum over at least 9 orders of 
magnitude (Adkins, Varnum et al. 2002) must undergo some fractionation 
procedures before it can be analysed.  
 
An advantage of SELDI-TOF-MS is its relatively high tolerance for salts and other 
impurities, and also sample requirement is low, and can range from 5ul to 400ul 
(Wiesner 2004). The major disadvantage is a lack of protein identification; 
identification by sequencing or peptide fingerprinting involves enrichment and 
purification of the biomarker, which is arduous and time-consuming. To partly 
solve this problem new ProteinChip interface coupled to a tandem mass 
spectrometer was recently developed allowing direct sequencing of peptides <6,000 
Da .  
 
A study to find biomarkers for early detection of ovarian cancer identified three 
biomarkers in serum using SELDI-TOF-MS; apolipoprotein A1, a truncated form of 
transthyretin, and a cleavage fragment of inter-α-trypsin inhibitor heavy chain H4, 
and when combined with a known ovarian cancer biomarker CA125, improve 
significantly on the specificity of CA125 alone while maintaining a relatively high 
sensitivity (Zhang, Bast et al. 2004).  
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1.6.3.3 Label-Free Mass Spectrometry 
Isotope and fluorescent labelling have been widely used for quantitative proteomic 
research however there is a move towards label-free spectrometry as this can yield 
faster, cleaner, and simpler results. As an alternative to 2D-PAGE, two-dimensional 
chromatography coupled to mass spectrometry systems has been used for protein 
identification. This initially focused on protein separation and failed to identify 
large numbers of proteins in a sample. Improvements to this set-up resulted in the 
development of a method called multidimensional protein identification technology 
(MudPIT), which combines multidimensional liquid chromatography with 
electrospray ionization tandem mass spectrometry, and involves loading a complex 
peptide mixture generated from a biological sample on to a biphasic microcapillary 
column packed with reversed phase (RP) and strong cation exchange (SCX) high 
performance liquid chromatography (HPLC) grade materials (Wolters, Washburn et 
al. 2001). In HPLC, the sample is in a liquid phase known as the mobile phase and 
is forced through a column that is packed with a stationary phase composed of 
irregularly or spherically shaped particles, a porous monolithic layer, or a porous 
membrane, at high pressure. MudPIT is an online approach but SCX can also be run 
offline where SCX fractions are generated and then individually subjected to RP 
chromatography into a mass spectrometer, as has been done with a study on the 
proteome of S. cerevisiae (Peng, Elias et al. 2003).   
Label-free spectrometry involves measurements of changes in chromatographic ion 
intensity such as peptide peak areas or peak heights, and also spectral counting of 
identified proteins. Label-free can be broken into two groups; (1) area under the 
curve (AUC) or signal intensity measurement based on precursor ion spectra, and 
(2) spectral counting, which is based on counting the number of peptides assigned 
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to a protein in an MS/MS experiment. Label-free shotgun proteomics produces 
large amounts of data that require meticulous statistical assessment. 
 
The general process of quantitating proteins based on AUC involves the 
measurement of ion abundances at specific retention times for the given ionised 
peptides without the use of a stable isotope standard, which is often referred to as 
ion counts, and as ionised peptides elute from a reversed-phase column into the 
mass spectrometer, their ion intensities can be measured within the given detection 
limits of the experimental setup and differentially expressed peptides can be 
validated by LC-MS/MS identification either subsequently or simultaneously . This 
method requires that all data is collected in data-dependent ‘Triple Play’ mode 
(allowing MS scan, Zoom scan, and MS/MS scan) and these together with 
chromatographic retention time determine the analytical accuracy of protein 
identification and quantification by ion intensity (Higgs, Knierman et al. 2005).  
 
There are concerns with LC signal resolution when peptide signals are spread over a 
large retention time causing overlap and co-eluting peptides, and concerns with 
biological variations resulting in multiple signals for the same peptide as well as 
technical variations in retention time MS intensity, and sample background noise 
from chemical interference. 
 
For spectral counting, the more of a particular protein present in a sample the more 
MS/MS spectra are collected for peptides of that protein, therefore relative 
abundance of that protein can be obtained by comparing the number of MS/MS 
spectra among a set of experiments, the advantage of this being that both protein 
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quantification and identification can be achieved by extensive MS/MS data 
collection across the chromatographic time scale simultaneously (Wang, You et al. 
2008). This method is dependent on the quality of MS/MS peptide identification 
and errors in this can lead to inaccurate protein quantification (Bantscheff, Schirle 
et al. 2007), however the correlation between the amount of protein and number of 
MS/MS spectra can generally be trusted (Gilchrist, Au et al. 2006). The spectral 
counting method has diversified from summing spectra to modifying counts with a 
normalisation factor and, more recently, combining strategies for increased 
accuracy, and many spectral counting strategies and statistical tools for analysing 
spectral count data have emerged in recent years (Lundgren, Hwang et al.).  
 
Label-free quantitative proteomics has been used to find potential biomarkers for 
various conditions and diseases, for example kidney chronic allograft dysfunction 
(Quintana, Campistol et al. 2009), a common chronic liver disease called non-
alcoholic fatty liver disease (Bell, Theodorakis et al.), melanoma tumour 
progression (Huang, Darfler et al. 2009), periodontal disease (Bostanci, Heywood et 
al. 2010), invasive ductal breast carcinoma (Rower, Vissers et al. 2009), and lung 
cancer (Zeng, Hood et al. 2011).  
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Figure 1.10: General approaches of quantitative proteomics. (a) Shotgun isotope 
labelling method. After labelling by light and heavy stable isotope, the control and 
sample are combined and analyzed by LC-MS/MS. The quantification is calculated 
based on the intensity ratio of isotope-labelled peptide pairs. (b) Label-free 
quantitative proteomics. Control and sample are subjected to individual LC-MS/MS 
analysis. Quantification is based on the comparison of peak intensity of the same 
peptide or the spectral count of the same protein (Zhu, Smith et al.). 
 
1.6.3.4 Multiple Reaction Monitoring (MRM)  
Multiple reaction monitoring (also known as selected reaction monitoring) uses 
mass spectrometry for highly sensitive and selective targeted quantitation of 
protein/peptide abundances in complex clinical samples. Untargeted MS-based 
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quantitation work flows concentrate on lengthy, exhaustive prefractionation sample 
methods. These methods involve both the protein and peptide level sometimes with 
the goal of detecting and quantifying an entire proteome. This untargeted approach 
can involve lengthy MS data acquisition and analysis times so can be limited to 
quantifying small sample sets. Therefore there is a need to reduce MS time and 
simplify sample preparation in order to quantitate larger clinical sample sets 
(Kuzyk, Smith et al. 2009). MRM is highly selective and allows the fine-tuning of 
MS instrumentation to specifically look for peptides, or protein fragments, of 
interest and is commonly used for the analysis of small molecules. 
 
Multiple reaction monitoring (MRM) is capable of rapid, sensitive, and specific 
quantitation of analytes in highly complex matrices using tandem MS/MS scan 
mode unique to triple quadrupole MS instrumentation (Hoofnagle, Becker et al.). 
MRM is a targeted approach that requires knowledge of the molecular weight of an 
analyte and its fragmentation behaviour under CID. Electrospray ionisation is 
followed by two stages of mass selection, the first selecting the mass of the intact 
analyte, known as the parent ion, and after fragmentation of this ion by collision 
with gas atoms, the second stage then selects a specific fragment of the parent ion, 
collectively generating a selected reaction monitoring assay (plural MRM). The 
detection and integration of a peak for the selected analyte is possible due to the two 
mass filters producing a very specific and sensitive response in a simple 1D 
chromatographic separation of the sample. This structural specificity for the 
analyte, in combination with appropriate stable isotope-labelled internal standards 
(SISs) can provide absolute quantitation of analyte concentration (Anderson and 
Hunter 2006). These methods are used in the clinical laboratory for the routine 
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measurement of endogenous metabolites, for example immunosuppressants (Streit, 
Armstrong et al. 2002) and screening of newborns for a panel of inborn errors of 
metabolism (Roschinger, Olgemoller et al. 2003). MRM has also been used as a 
powerful analytical method for the prescreening of candidate protein biomarkers in 
serum prior to antibody and immunoassay development (Kuhn, Wu et al. 2004). 
 
1.6.4 Immunohistochemistry 
Immunohistochemistry (IHC) can be used in the routine diagnosis of lung cancer in 
order to identify biological markers. The objective of performing 
immunohistochemistry is to recognize cell antigens on tissue which are then viewed 
under microscopy (the visualization of the antigen-antibody complex is made 
possible through the addition of either a fluorochrome conjugate or an enzyme to 
the antibody) and, consequently, to identify and classify specific cells within a cell 
population whose morphology is heterogenous or apparently homogenous 
(Capelozzi 2009). Standardization of IHC for quantitation is becoming more 
important due to the requirement in translational research for quantitation of the 
differential expression of various prognostic markers for cancer, based on 
retrospective study of clinical cases with known clinical outcomes. 
 
Quantitative evaluation of protein levels in tumour samples is challenging, with 
technical issues arising related to immunohistochemistry procedure and subjectivity 
of assessment. Due to the significant heterogeneity that can be seen in lung cancer 
small tumour specimens, such as those frequently obtained in advanced lung cancer, 
they may not be representative of the tumour itself (Taillade, Penault-Llorca et al. 
2007). There may be as much as a 30% variance seen in protein expression in 
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primary versus metastatic tumour sites, though the clinical significance of this 
difference is unknown. Small samples are more susceptible to the "edge effect" with 
non-specific staining observed in the very edge of the specimen and it should be 
noted that the choice of primary antibody and antigen retrieval (AR) conditions are 
of utmost importance (Szutowicz and Dziadziuszko).  
The antigen retrieval technique is a simple method of boiling archival paraffin-
embedded tissue sections in water to enhance the signal of immunohistochemistry, 
though knowledge of the exact localization of a certain protein in tissue is critical to 
interpret not only the accuracy of IHC staining results but also the reliability of AR 
treatment (Shi, Cote et al. 2001). The heating conditions and the pH value of the 
AR solution are the two major factors that influence the effectiveness of IHC 
staining. The success of AR has shown that the modification of protein structure by 
formalin is reversible under certain conditions, such as high-temperature heating or 
strong alkaline treatment (Morgan, Navabi et al. 1997).  
 
A pathologist performs a quantitative measurement of the observed 
immunostaining, an indication of protein level, with numerous scales and there is 
no consensus which scale is better or more practical, and often percentage of cells 
with positive staining of any intensity is recorded (Szutowicz and Dziadziuszko). 
To account for the protein abundance, the percentage of cells with positive staining 
is multiplied by the staining intensity (graded from 0 to 3 or from 0 to 4) to give the 
staining index (ranging from 0 to 300 or from 0 to 400, respectively) (Cappuzzo, 
Hirsch et al. 2005). In other systems, the staining index is composed of percentage 
of positive cells binned into categories and multiplied by staining intensity (0 to 3 
or 0 to 4 scale) (Olaussen, Dunant et al. 2006). Regardless of which classification 
 74
you use, it is very important to note which part of the cell is stained, whether it’s the 
cell membrane, cytoplasm, or nucleus, or in more than one of these cell 
compartments. Precise quantification of the protein level by the pathologist 
provides accurate data to be analyzed with patient outcome and to select the best 
prognostic or predictive cut-off points of the test. Reproducibility of 
immunohistochemical analysis is highly vulnerable to (i) staining variation as a 
function of tissue preservation and processing, (ii) to disparities in assay protocol 
and reagents, and (iii) to the interpretation bias inherent with observer-based 
assessment devoid of quantitative scoring systems (Taylor and Levenson 2006). 
 
IHC analysis of lung adenocarcinoma was used to indicate paxillin over-expression 
occurs during the earliest stages of lung cancer development (Mackinnon, 
Tretiakova et al. 2011). Protein tyrosine phosphatase (SHP2) expression, with the 
help of IHC staining in the tissue of NSCLC patients who smoke, could play a role 
in the development of lung cancer (Zhan, Dong et al. 2010). IHC was used to 
investigate the expression of tumour necrosis factor-alpha (TNFalpha) in the 
tumour islets and stroma of patients with surgically resected NSCLC and its 
expression is associated with improved survival suggesting a role in the host anti-
tumour immunological response (Ohri, Shikotra et al. 2010).  
 
1.7 Metabolomics 
 
Metabolomics is the global quantitative assessment of metabolites within a 
biological system. It is used to detect metabolites and their changes in biofluids or 
tissue. Like genomics, transcriptomics, and proteomics, metabolomics is a science 
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of systems biology, which is a biology-based inter-disciplinary study field that 
focuses on complex interactions in biological systems. Metabolomics could address 
the limitation associated with transcriptomics and proteomics where changes do not 
always result in altered biochemical phenotypes. Systems biology could be 
indispensible to the future discovery of biomarkers for early detection and diagnosis 
of cancer and for predictive and pharmacodynamic evaluation of drug effect. The 
level of metabolites at any given time represents a composite of both catabolic and 
anabolic processes and presents a snapshot of the metabolome at that particular time 
only, though this can be an advantage as time dependent snapshot sampling will 
reveal directed correlations of metabolic processes (Weckwerth 2003).  
 
Metabolomics involves the detection of metabolites, either individually or grouped 
as a metabolomic profile, and is carried out in cells, tissues, or biofluids by either 
nuclear magnetic resonance (NMR) spectroscopy or mass spectrometry, and when 
used as a translational research tool can provide a link between the laboratory and 
clinic, enabling the discrimination of metabolic markers noninvasively in vivo 
(Spratlin, Serkova et al. 2009).  
Metabolomics involves a number of different analyses, including (i) metabolic 
fingerprinting, which measures a subset of the whole profile with little 
differentiation or quantitation of metabolites (Ryan and Robards 2006); (ii) 
metabolic profiling, the quantitative study of a group of metabolites, known or 
unknown, within or associated with a particular metabolic pathway (Dunn, Bailey et 
al. 2005) and (iii) target isotope-based analysis, which focuses on a particular 
segment of the metabolome by analyzing only a few selected metabolites that 
comprise a specific biochemical pathway (Boros, Lerner et al. 2005).  
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Metabolomics certainly has potential for finding useful biomarkers for cancer. It 
has been used to show that tumours display elevated phospholipid levels and 
increased glycolytic capacity including increased utilization of glucose carbons to 
drive synthetic processes, high glutaminolytic function, and overexpression of 
pyruvate kinase type M2 (Spratlin, Serkova et al. 2009). Using NMR-based 
metabolomics on blood samples it was shown that lipid metabolic profiles were 
83% accurate at discriminating between cancer patients and controls (Bathen, 
Engan et al. 2000).  
 
The urinary profile of lung cancer patients was studied and metabolic alterations 
enabled their discrimination from healthy subjects with high sensitivity and 
specificity (Carrola, Rocha et al. 2011). 
One study using NMR and GC-MS metabolomic analysis compared non-cancerous 
lung and tumour tissues, showing accelerated glycolysis in tumour tissues (Fan, 
Lane et al. 2009). 
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1.8 Aims of Thesis: 
 
The aims of this thesis are as follows: 
 
1. To create lists of potential lung cancer biomarkers from the 2D-DIGE and 
subsequent DeCyder software analysis of conditioned media from the main lung 
cancer types; squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and 
small cell carcinoma. 
 
2. To validate some of the interesting proteins from the 2D-DIGE experiment of 
conditioned media study in serum from lung cancer patients and normal healthy 
patients.  
 
3. To examine the expression of some of the interesting proteins from the 2D-
DIGE experiment of conditioned media study in lung cancer and normal lung tissue 
using immunohistochemistry. 
 
4. To examine the expression of the most interesting protein from the immuno-
histochemistry study in different types of normal and cancer tissue. 
 
5. To determine if the most interesting protein from the validation of the 2D-
DIGE experiment of conditioned media study has any effect on the invasion and 
migration of lung cancer cells. 
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6. To perform 2D-DIGE on immunodepleted serum of lung cancer and healthy 
patients to discover potential lung cancer biomarkers. 
7. To perform label-free mass spectrometry analyses of serum run through 
ProteoMiner columns to discover potential lung cancer biomarkers and subsequently 
validate the most interesting proteins in a larger cohort of serum samples. 
 
8. To use the Luminex Multiplex assay platform to discover potential lung 
cancer biomarkers in serum and subsequently validate the most interesting proteins in 
a larger cohort of serum samples. 
 
9. To use Metabolon diagnostics discovery platform to evaluate metabolites that 
may function as lung cancer biomarkers and subsequently validate the most 
interesting metabolites in a larger cohort of serum samples using ELISAs and 
biochemical assays. 
 
10. To examine in plasma some of the interesting proteins from the serum 
validation phases. 
 
11. To examine some of the interesting proteins from the validation phases in 
ELISAs/assays with the inclusion of a benign lung disease control group. 
 
12. To create a lung cancer biomarker panel combination with high sensitivity and 
high specificity from the list of validated proteins/metabolites.  
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13. To examine, in serum and plasma, well-known cancer biomarkers on the 
Luminex system and compare panel of highest specificity and sensitivity to equivalent 
sized panel using at least one of the new potential lung cancer markers. 
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CHAPTER TWO 
 
MATERIALS AND METHODS 
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2.1 Cell Culture 
 
2.1.1 Preparation of Cell Culture Media 
Ultrapure water (UHP) was purified to a standard of 12-18 M/cm resistance by a 
reverse osmosis system (Millipore MillI-RO 10 Plus, Elgastat UHP). Glassware 
required for cell culture related applications were soaked in a 2% RBS-25 (AGB 
Scientific) for 1 hour, washed in an industrial dishwasher, using Neodisher 
detergent and rinsed twice with UHP. All thermostable solutions, water and 
glassware were sterilised by autoclaving at 121C for 20 minutes at 15 bar 
(Thermolabile solutions were filtered through 0.22 m sterile filters (Millipore, 
Millex-GV SLGV025BS)). 
 
All 1X basal media were prepared in-house as follows: 10X media was added to 
sterile UHP water, buffered with HEPES (N-(2-Hydroxyethyl) piperazine-N-(2-
ethanesulfonic acid) and NaHCO3 as required and adjusted to pH 7.5 using sterile 
1.5 N NaOH or 1.5 N HCl. The media was then filtered through sterile 0.22m bell 
filters (Gelman, 12158) and stored in sterile 500ml bottles at 4C. Sterility checks 
on all media bottles for bacterial, yeast and fungal contamination were made using 
Colombia blood agar (Oxoid, CM217), Sabauraud dextrose (Oxoid, CM217) and 
Thioglycolate broths (Oxoid, CM 173) respectively. All sterility checks were then 
incubated at both 25C and 37C.  
 
Basal media were stored at 4C for up to three months in the dark. Complete media 
was then prepared as follows: supplements of 2mM L-glutamine (Gibco, 11140-
0350) for all basal media and 1ml 100X non-essential amino acids (Gibco, 11140-
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035) and 100mM sodium pyruvate (Gibco, 11360-035) were added to MEM. Other 
components were added as per cell line requirement. Complete media was stored at 
4C for a maximum of one month in the dark. 
 
2.1.2 Cell lines and cell culture 
All cell culture work was carried out in a class II laminar air-flow cabinet (Holten). 
Before and after use the LF cabinet was cleaned with 70% industrial methylated 
spirits (IMS). Any items brought into the cabinet were also swabbed down with 
IMS. At any time only one cell line was used in the LF cabinet and upon 
completion of work with any given cell line, 15 minutes clearance was given to 
eliminate any possibilities of cross-contamination between the various cell lines. 
The cabinet was cleaned weekly with Virkon (Antech International, P0550) and 
IMS. Details pertaining to the cell lines used for the experiments are provided in 
Table 2.1.1. All cells were incubated at 37C and where required, in an atmosphere 
of 5% CO2. Cells were fed with fresh media or subcultured (see section 2.5.1) every 
2-3 days or as required in order to maintain active cell growth.  
 
 
 
 
 
 
 
 
 
 83
Cell line Cell type Source 
DLKP Poorly differentiated squamous cell lung
carcinoma 
NCTCC* 
DLRP Poorly differentiated squamous cell lung
carcinoma 
NCTCC 
SK-MES-1 Squamous cell lung carcinoma NCTCC 
NCI-H226 Squamous cell lung carcinoma NCI** 
A549 Lung adenocarcinoma NCTCC 
CALU-3 Lung adenocarcinoma NCTCC* 
SK-LU-1 Lung adenocarcinoma NCTCC 
NCI-H23 Lung adenocarcinoma NCI 
COR-L23 Lung large cell carcinoma NCTCC 
NCI-H460 Lung large cell carcinoma NCTCC 
NCI-1299 Lung large cell cracinoma NCTCC 
HOP-18 Lung large cell carcinoma NCI 
COR-L24 Small cell lung carcinoma NCTCC 
DMS-53 Small cell lung carcinoma NCTCC 
NCI-H69 Small cell lung carcinoma NCTCC 
DMS-114 Small cell lung carcinoma NCI 
NHBE Normal Human Bronchial/Tracheal 
Epithelial Cell Line 
LONZA 
Table 2.1.1: Description of cell lines used in conditioned media study.  
 
*NCTCC – National Cell and Tissue Culture Centre 
**NCI – National Cancer Institute 
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2.1.3 Subculturing of adherent cell lines 
Waste cell culture medium was removed from the tissue culture flask and discarded 
into a sterile bottle.  The flask was then rinsed out with 1ml of trypsin/EDTA solution 
(0.25% trypsin (Gibco, 043-05090), 0.01% w/v EDTA (Sigma, E9884) solution in 
PBS (Oxoid, BRI4a)) to ensure the removal of any residual media. Depending on the 
size of the flask, 2-5ml of trypsin was then added to the flask, which was then 
incubated at 37C, for approximately 5 minutes, until all of the cells detached from 
the inside surface of the flask monitored by microscopic observation. Adding an 
equal volume of complete media to the flask deactivated the trypsin.  The cell 
suspension was removed from the flask and placed in a sterile universal container 
(Sterilin, 128a) and centrifuged at 170g for 5 minutes.  The supernatant was then 
discarded from the universal and the pellet was suspended gently in complete 
medium. A cell count was performed and an aliquot of cells was used to seed a flask 
at the required density. All cell waste and media exposed to cells were autoclaved 
before disposal. 
 
2.1.4 Subculturing of floating aggregate cell lines 
The cell suspension was removed from the flask and placed in a sterile universal 
container and centrifuged at 170g for 5 minutes. The supernatant was then discarded 
from the universal and the pellet was suspended in complete medium.  The 
aggregates were broken up by gently pipetting the suspension up and down using a 10 
ml pipette. A cell aliquot was used to seed a flask. 
 
2.1.5 Assessment of cell number and viability 
Prior to cell counts, cells were prepared for subculturing as detailed in 2.1.3 or 2.1.4 
depending on adherent or floating aggregates. An aliquot of the cell suspension was 
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then added to trypan blue (Gibco, 525) at a ratio of 5:1. The mixture was incubated 
for 3 minutes at room temperature. An aliquot (10l) was then applied to the 
chamber of a glass coverslip-enclosed haemocytometer. For each of the four grids, 
cells in the 16 squares were counted. The average of the four grids were multiplied 
by a factor of 104 volume of the grid) and the relevant dilution factor to determine 
the average cell number per ml in the original cell suspension. Non-viable cells 
stained blue, while viable cells excluded the trypan blue dye as their membrane 
remained intact and remained unstained. On this basis, percentage viability could be 
calculated. 
2.1.6 Cryopreservation of cells 
Cells for cryopreservation were harvested in the log phase of growth and counted as 
described in Section 2.1.5.  Cell pellets were resuspended in a suitable volume of 
serum. An equal volume of a 10 - 20 % DMSO/serum solution was added dropwise 
with mixing, to the cell suspension. The suspension was then aliqoted in 1 ml 
volumes to cryovials (Greiner, 122278) and immediately placed in the vapour phase 
of a liquid nitrogen container.  After four hours, vials were transferred to the liquid 
phase for long term storage (- 196C). 
 
2.1.7 Thawing of cryopreserved cells  
A volume of 5ml of fresh growth medium was added to a sterile universal. The 
cryopreserved cells were removed from the liquid nitrogen and thawed at 37C 
quickly. The cells were removed from the vials and transferred to the aliquoted 
media.  The resulting cell suspension was centrifuged at 170g for 5 minutes. The 
supernatant was removed and the pellet resuspended in fresh culture medium. An 
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assessment of cell viability on thawing was then carried out (Section 2.1.5).  Thawed 
cells were then added to an appropriately sized tissue culture flask with a suitable 
volume of growth medium and allowed to attach overnight. The following day, flasks 
were re-fed with fresh media to remove any non-viable cells. 
 
2.1.8 Monitoring of sterility of cell culture solutions 
Sterility testing was performed in the case of all cell culture media and cell culture 
related solutions. Samples of prepared basal media were incubated at 37C for a 
period of seven days. This ensured that no bacterial or fungal contamination was 
present in the media or the solutions. 
 
2.1.9 Serum batch testing 
To prevent batch to batch variation (a common problem in foetal calf serum (FCS) 
in cell culture), a range of FCS batches were screened and the most suitable was 
chosen for a block of work (Sigma, F7524). Screening involved growing cells in 
96-well plates and growth was recorded as a percentage of growth of a serum with 
known acceptable growth rate. 
 
2.1.10 Mycoplasma analysis of cell lines 
Mycoplasma testing was carried out in house. Both direct and indirect methods 
were used. In the indirect method, Mycoplasma negative NRK (Normal rat kidney 
fibroblast) cells were exposed to conditioned media of the test sample. Hoechst 
staining specific for DNA shows positive for Mycoplasma when viewed in the 
extracellular spaces. In the direct method, conditioned media were incubated on 
cells specifically to encourage Mycoplasma growth. 
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2.2 Conditioned Media Sample Preparation.  
Cells (3x106) were seeded in four biological replicates in T-175cm2 flasks. Cells 
were allowed to grow until 50-60% confluent. Cells were washed three times with 
10mL of serum-free (SF) basal media and then incubated in 15mL of SF basal 
media for 60 min. After this time, cells were washed again twice with SF basal 
media. 15mL of SF basal media was added to the cells and incubated for 72hrs. 
After such time, conditioned media (CM) was collected, centrifuged for 15min at 
250g, and stored at –800C. 
To concentrate conditioned media samples, 10ml was added to a Sartorius VivaSpin 
20 with a 5,000 molecular weight cut-off and centrifuged at 4°C at 3220g. Samples 
were concentrated down to 200µl before undergoing a clean-up using Bio-Rad 
ReadyPrep 2-D Cleanup kit to remove substances like ionic detergents, salts, 
nucleic acids and lipids which are known to interfere with iso-electric focusing 
(IEF). Proteins were precipitated using ice-cold acetone and the subsequent protein 
pellets were resuspended in lysis buffer (20 mM Tris, 7 M Urea, 2 M Thiourea, 4% 
CHAPS, pH 8.5) prior to labelling. 
 
2.3 Protein Quantification  
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad, 500-
0006) as follows. A 2mg/ml bovine serum albumin (BSA) solution (Sigma, A9543) 
was prepared freshly in lysis buffer. A protein standard curve (0, 0.2, 0.4, 0.6, 0.8 
and 1.0mg/ml) was prepared from the BSA stock with dilutions made in lysis 
buffer.  The Bio-Rad reagent was diluted 1:5 in UHP water.  A 20l volume of 
protein standard dilution or sample (diluted 1:10) was added to 980l of diluted dye 
reagent and the mixture vortexed. All samples were assayed in triplicate. After 5 
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minutes incubation, absorbance was assessed at 570nm.  The concentration of the 
protein samples was determined from the plot of the absorbance at 570nm versus 
the concentration of the protein standard. 
2.4 2D-DIGE Sample Preparation 
2.4.1 Preparation of CyDye DIGE fluor minimal dye stock solution (1 nmol/μl) 
The three CyDye DIGE Fluor Minimal dyes (Cy3, Cy5 and Cy2 (Amersham, 25-
8010-65) were thawed from –20 oC to room temperature for 5 minutes. To each 
microfuge tube dimethylformamide (DMF) (Aldrich, 22,705-6) was added to a 
concentration of 1 nmol/ μl. Each microfuge tube was vortexed vigorously for 30 
seconds to dissolve the dye. The tubes were then centrifuged for 30 seconds at 
18,000g in a microcentrifuge. The reconstituted dyes can be stored at –20 oC for up 
to two months. 
 
2.4.1.1 Preparation of 10 μl working dye solution (200 pmol/μl) 
On thawing, the dye stock solutions were centrifuged in a microcentrifuge for 30 
seconds. To make 10 μl of the three working dye solutions, 8 μl of DMF was added 
to three fresh eppendorfs labelled Cy2, Cy3 and Cy5. 2µl of dye stock was added to 
the 8µl DMF for a 0.2 nmol/μl concentration of each of the reconstituted dye stock 
solutions was added to their respective tubes. The dyes can be stored at -20 oC in 
tinfoil in the dark for 3 months. 
 
2.4.2 Protein sample labelling  
A volume of the protein samples equivalent to 50 μg was placed into eppendorf 
tubes. An eppendorf tube for the Cy2 pool made up from aliquots from each of the 
protein samples contained enough protein for 50µg for each gel. Each tube was 
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mixed by vortexing, centrifuged and then left on ice for 30 minutes in the dark. To 
stop the reaction, 1 μl of 10 mM lysine was added, the tubes were vortexed, 
centrifuged briefly and left on ice for 10 minutes in the dark. The labelled samples 
were stored at –80 oC. To this tube 1 μl of working dye solution was added. 
 
2.4.3 Preparing the labelled samples for the first dimension 
The protein samples labelled with Cy2 (pooled internal standard), Cy3 and Cy5 
were thawed on ice (in the dark), combined by placing into a single eppendorf tube 
and mixed. An equal volume of 2X sample buffer (2.5 ml rehydration buffer stock 
solution (8M urea, 4 % CHAPS), pharmalyte broad range pH 4-7 (2%) (Amersham, 
17-6000-86), DTT (2%) (Sigma, D9163)) was added to the labelled protein 
samples. The mixture was left on ice for at least 10 minutes then applied to 
Immobiline DryStrips for isoelectric focussing. 
 
2.5 First dimension separation - isoelectric focussing methodologies 
Isoelectric focussing of all samples was carried out using immobiline pH gradient 
(IPG) strips.  
 
2.5.1 Strip rehydration using Immobiline DryStrip reswelling tray  
The protective lid was removed from the Immobiline Dry Strip Reswelling tray. 
The tray was levelled using the spirit level. A 350μl volume of rehydration buffer 
solution (with 2 % pharmalyte broad range pH4-7 and 2 % DTT) was slowly 
pipetted into the centre of each slot; all air bubbles generated were removed. The 
cover film from the IPG strip (Amersham, 17-1233-01) was removed and 
positioned with the gel side down and lowered. To ensure the entire strip was 
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evenly coated the strip was gently lifted and lowered onto the entire surface of the 
solution avoiding trapping air bubbles. 
Each strip was overlaid with about 3 ml IPG Cover Fluid (Amersham, 17-1335-01) 
starting on both ends of the strip, moving to the centre. The protective lid was then 
replaced and the strips were left at room temperature to rehydrate overnight (or at 
least 12 hours). 
 
2.5.2 Isoelectric focussing using the IPGphor manifold 
Following the rehydration procedure, the Manifold (Amersham) was placed onto 
the IPGphor unit by inserting the “T” shape into the hollow provided. A 9 ml 
volume of Cover Fluid was placed into each of the twelve lanes in the tray in order 
to cover the surface. Two wicks (Amersham, 80-6499-14) per strip were placed on 
tinfoil and 150 μl of UHP was pipetted onto each one to rehydrate them. The 
rehydrated strips were placed in the correct orientation (+ to anode) and aligned just 
below the indented mark, to allow for the wicks to overlap the strip. The rehydrated 
wicks were then placed over both the cathodic and anodic ends of all the strips. The 
wicks were checked to ensure they were positioned over the gel portion of the strip 
and avoiding the indent in the lane so as to guarantee a good contact with the 
electrodes. The sample cups (Amersham, 80-6498-95) were then positioned 
approximately 1 cm from the cathodic end of the strip and an insertion tool was 
used to securely “click” the cups into place. The electrodes were then fitted with 
their “Cams” open and in direct contact with the wicks. 
 
The amount of protein loaded per strip was 150ug for DIGE or 400µg for spot 
picking. The protein samples were prepared by centrifuging to remove any 
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insoluble material and the appropriate volume was loaded with a pipette tip placed 
just beneath the surface of the cover fluid. The cover of the IPGphor unit was 
closed and the desired programme selected. The temperature was set for 20oC with 
50A/strip. The IEF parameters are as follows: step 1: 300 volts for 3 hours (step-
and-hold), step 2: 600 volts for 3 hours (gradient), step 3 1000 volts for 3 hours 
(gradient), step 4: 8000 volts for 3 hours (gradient). The IEF was left at 8000 volts 
(step-and –hold) until ready for SDS-PAGE step. On completion of the IEF run, the 
strips were drained of the cover fluid and stored in glass tubes at –80oC or used 
directly in the second dimension.  
 
2.6 Second Dimension – SDS polyacrylamide gel electrophoresis 
 
2.6.1 Casting gels in the ETTAN Dalt-12 gel caster 
The 12.5 % acrylamide gel solution was prepared in a glass beaker (acrylamide/bis 
40 %, 1.5 M Tris pH 8.8, 10 % SDS). Prior to pouring, 10 % (w/v) ammonium 
persulfate and 50µl neat TEMED were added.  
Two types of plates were used, low fluorescent for DIGE experiments and hinged 
for preparative and screening silver stained gels. All plates (both normal hinged and 
low fluorescent) and casting equipment were inspected to ensure they were clean. 
The gel caster frame was placed on a level bench leaning on its “legs” so that the 
back of the caster was open and facing the operator. The plates were assembled so 
that the front and back plates were evenly aligned and all seals and hinges in place. 
A thin spacer was placed in the gel caster unit followed by an assembled plate 
followed by a thin spacer then another plate. The plates were positioned in the 
caster unit so that the lower, front plate was the furthest away from the operator and 
the spacers packed with their curved edges to the top. This layering was repeated 
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until all 14 plates and spacers were in place. All plates and spacers were checked to 
ensure they were packed tightly together so as to minimise any gaps and air 
pockets. If all 14 gels were not required, up to 4 dummy plates could be substituted 
instead of the glass plates. When the desired amount of plates had been added, the 
thicker spacers were placed next to bring the level marginally over the edge of the 
back of the caster. The backing plate was then added to the caster frame and 
screwed into place with the 6 screws provided. The silicone tubing was added to the 
outlet of the glass beaker and the glass tube was inserted to the other end of the 
silicone tubing. The glass tube was inserted into the inlet of the reservoir and the 
glass beaker containing the gel solution was then clamped to a retort stand. The gel 
solution was held in place using arterial clamps on the top tube and the tube running 
down from the reservoir to the caster chamber. The top tube was unclamped and the 
gel solution was allowed to fill the tubing and the reservoir drain. Air bubbles that 
had been generated were dislodged by flicking the tube. When all air bubbles had 
been removed the bottom clamp was released allowing the gel solution into the gel 
caster. When the gel solution reached the indicator line across the top of the caster, 
the bottom and top tubes were reclamped. The displacement solution (0.375M Tris-
Cl 1.5M pH8.8, 30% glycerol, UHP and bromophenol blue) was added to the 
reservoir and the glass tubing was slowly removed from the reservoir inlet. The 
clamp was removed from the bottom tube allowing the displacement solution into 
the tube and forcing the remaining gel solution into the gel caster. The gels were 
overlaid with 1 ml saturated butanol or sprayed with 0.1 % SDS solution. The gels 
were left to set for at least three hours at room temperature. Following this, the 
caster was gently unlocked and the gels removed and rinsed with distilled water. If 
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the gels were not used immediately they were stored for up to four days in 1X 
running buffer at 4 oC. 
If gels were to be used for “spot picking” the plates were silanised to stick the 
acrylamide mixture to the plates. A volume of 2ml of (8ml ethanol, 200l glacial 
acetic acid, 10l bind-silane and 1.8ml UHP) was pipetted over the glass plate and 
wiped over with a lint free cloth. This was left to air dry for 15 minutes, after which 
2ml ethanol and 2 ml UHP were each pipetted over the plate and wiped off 
respectively. The plate was left to air dry for approximately 1 hour 30 minutes.  
 
2.6.2 Preparing the ETTAN DALT 12 electrophoresis unit 
The electrophoresis chamber was prepared by adding 6.48 litres of UHP and 720 ml 
of 10X SDS running buffer. The pump was then turned on to cool the system to 10 
oC.  
 
2.6.3 Equilibration and loading of focussed Immobiline DryStrips 
The SDS equilibration buffer (30% glycerol, 6M urea, 50nm 1.5M Tris-Cl pH 8.8, 
2% SDS, bromophenol blue and UHP) which had been prepared, aliquotted into 30 
ml volumes and frozen at –20oC was allowed to thaw to room temperature. Two 
SDS equilibration buffer solutions with DTT (65 mM) or iodoacetamide (240 mM)  
(Sigma, I1149) were then prepared. Using a forceps, the IPG strips* were removed 
from the IPGphor unit, the cover fluid was drained off by holding the strips at an 
angle and they were placed into individual glass tubes with the support film toward 
the wall. Equilibration buffer (10 mls containing DTT) was added to each tube and 
incubated for 15 minutes with gentle agitation using an orbital shaker. During this 
equilibration step, the gel cassettes were rinsed with UHP and then the tops rinsed 
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with 1X running buffer. After the first equilibration, DTT containing equilibration 
solution was removed and 5 mls of the iodoacetamide containing equilibration 
buffer added. The strips were incubated for 10 minutes with gentle agitation. 
During this equilibration step, the agarose overlay solution (0.5% agarose in 
running buffer) was prepared and 50 ml of 1X running buffer was placed in a glass 
tube. 
 *If the strips had been frozen at this stage they were left at room temperature to 
thaw before the DTT-containing equilibration solution was added. 
 
Using a forceps and holding the anode end, the IPG strips were rinsed in 1X SDS 
electrophoresis running buffer and placed between the two glass plates of the gel. 
The strip was pushed down gently using a thin plastic spacer until it came in contact 
with the surface of the gel. Any air bubbles trapped between the gel surface and the 
strip were gently removed. Approximately 1 ml of the 0.5 % agarose overlay 
solution was applied over the IPG strip to seal it in place. 
 
2.6.4 Inserting the gels into the Ettan DALT 12 electrophoresis buffer tank 
When the running buffer reached the desired temperature (10oC) the loaded gel 
cassettes were wetted with UHP and inserted into the tank through the slots 
provided in the same orientation. When all 12 slots were filled the upper chamber 
was filled, 2X running buffer was added to the upper chamber until the mark on the 
side of the chamber was reached. The cover of the unit was replaced and the 
required running conditions selected. The unit was run for 18–24 hours at 1.5 Watts 
per gel at 10°C or until the bromophenol blue dye front reached the bottom of the 
gel. When the run was completed, the gel cassettes were removed from the tank one 
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at a time using the DALT cassette removal tool and rinsed with UHP to remove the 
running buffer.  
 
2.7 Method for scanning DIGE labelled samples 
The Typhoon Variable Mode Imager (GE Healthcare) was turned on and left to 
warm up for 30 minutes prior to scanning. The scanning control software was 
opened and the fluorescence mode was selected. The appropriate emission filters 
and lasers were then selected for the separate dyes (Cy2 520 BP40 Blue (488), Cy3 
580 BP30 Green (532) and Cy5 670 BP 30 Red (633)). The first gel was placed in 
the scanner and pre-scanned at a 1000 pixel resolution in order to obtain the correct 
photo multiplier tube (PMT) value (to prevent saturation of the signal from high 
abundant spots). Once the correct PMT value was found, the gel was scanned at 100 
pixel resolution, resulting in the generation of three images, one each for Cy2, Cy3 
and Cy5. Once the scanning was completed, the gel images were imported into the 
ImageQuant software. All gels were cropped identically to facilitate spot matching 
in the Decyder BVA module. 
 
2.8 Analysis of gel images 
 
2.8.1 Differential in-gel analysis (DIA) 
The DIA module processes a triplet of images from a single gel. The internal 
standard is loaded as the primary image followed by the secondary and tertiary 
image, derived from, for example, a control and treated sample. Spot detection and 
calculation of spots properties were performed for each image from the same gel. 
The software determined the margins of the spots, quantified the spot intensities and 
calculated the relative spot intensity as the ratio between the total intensity of the 
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gel and the intensity of each individual spot. The protein spots were then 
normalised using the in-gel linked internal standard. The data from the first gel was 
XML formatted and exported into the Biological Variation Analysis (BVA) 
software for further analysis. This procedure was repeated for each gel in the 
experiment.  
 
2.8.2 Biological variation analysis (BVA) 
Once all gels from the experiment were loaded into the BVA module, the 
experiment design was set up and the images were assigned into three groups 
(standard, control and treated). The spots on the gels were then matched across all 
gels in the experiment.  
This module detects the consistency of the differences between samples across all 
the gels. The software standardises the relative spot intensity of the Cy5 image to 
that of the Cy3 image in the same gel. The standardised spot intensity was then 
averaged across the triplicate gels. The BVA module detected the consistency of the 
differences between samples across all the gels and applied statistics to associate a 
level of confidence for each of the differences. The protein spots with statistically 
significant protein expression changes were designated “proteins of interest” and 
placed in a pick list. 
 Preparative gels for spot picking with 400µg of protein/gel were focussed and run 
out on SDS-PAGE gels. The gels were then stained with colloidal coomassie 
(section 2.9). Spots that showed differential protein expression were picked with the 
ETTAN Spot Picker (section 2.10).  
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2.9 Brilliant blue G Colloidal Coomassie staining of preparative gels for 
spot picking  
After electrophoresis, the smaller lower plates with the gels attached were placed in 
the gel boxes containing fixing solution (7% (v/v) glacial acetic acid in 40% (v/v) 
methanol (Aldrich, 200-659-6)) for at least one hour. During this step a 1X working 
solution of Brilliant Blue G colloidal coomassie (Sigma, B2025) was prepared by 
adding 800ml UHP to the stock bottle. When the fixing step had nearly elapsed, a 
solution containing 4 parts of 1X working colloidal coomassie solution and 1 part 
methanol was made, mixed by vortexing for 30 seconds and then placed on top of 
the gels. The gels were left to stain for 2 hours. To destain, a solution containing 
10% acetic acid in 25% methanol was poured over the shaking gels for 60 seconds. 
The gels were then rinsed with 25% methanol for 30 seconds and then destained 
with 25% methanol for 24 hours. The glass surface was dried and two reference 
markers (Amersham) attached to the underside of the glass plate before scanning. 
The resulting image was imported into the ImageMaster software (Amersham) and 
the spots were detected, normalised and the reference markers selected. While 
keeping the shift key depressed, all spots of interest were manually selected. The 
resulting image was saved and exported into the Ettan Spot Picker software.  
 
2.10 Spot picking 
The stained gel was placed in the tray of the Ettan Spot Picker (Amersham, 18-
1145-28) with reference markers (Amersham, 18-1143-34) aligned appropriately 
and covered with UHP. The imported pick list was opened, the syringe primed and 
the system was set up for picking the spots from the pick list. The spots were 
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robotically picked and placed in 96-well plates, which were stored at 4oC until spot 
digestion. 
 
2.11 Spot digestion and identification with MALDI-TOF 
The 96-well plate was placed in the Ettan Digester (Amersham, 18-1142-68) to 
digest the protein as follows: Step 1 – the gel plugs were washed three times for 20 
minutes each with 50µl 50mM ammonium bicarbonate (Sigma, A6141) in 50% 
methanol. Step 2 – the gel plugs were washed twice for 15 minutes with 50µl 70% 
acetonitrile (Sigma, 34967). The gel plugs were left to dry for at least 60 minutes. 
After drying, the individual gel pieces were rehydrated in 10µl digestion buffer 
(12.5ng trypsin (Promega, V5111) per µl of 10% acetonitrile, 40mM ammonium 
bicarbonate). Exhaustive digestion was carried out overnight at 37oC. After 
digestion, the samples were transferred as follows: Step 1 – A volume of 40µl of 
0.1% trifluoroacetic acid (Sigma, 302031) in 50% acetonitrile was added to the 
wells, mixed and left for 20 minutes. A volume of 60µl of this solution was 
transferred to a fresh 96-well plate. Step 2 - A volume of 30µl of 0.1% 
trifluoroacetic acid in 50% acetonitrile was added to the wells, mixed and left for 20 
minutes. A volume of 50µl of this solution was transferred to the fresh 96-well 
plate. The liquid in the plate was vacuum-dried in a maxi dry plus. After drying, the 
96-well plate was placed in the Ettan Spotter (Amersham, 18-1142-67) for spotting 
onto the target plates. A volume of 3µl of 0.5% trifluoroacetic acid in 50% 
acetonitrile was added to the desiccated peptides and mixed 5 times. A volume of 
0.3µl of this mixture was spotted onto the target plate after which a volume of 0.3µl 
matrix solution [7.5mg/ml α-cyano-4-hydroxycinnamic acid (LaserBio labs, 28166-
41-8) in 0.1% trifluoroacetic acid in 50% acetonitrile].  
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The target plate was placed in the MADLI-ToF (Amersham, 11-0010-87) 
instrument. The system was set up as follows: the target plate was disengaged from 
the machine. A new empty run list was opened. In the acquisition mode of the 
“favorites icon, the “spectrum processes”, specifically PepMix 4 (LaserBio labs, 
C104) was picked, and “protein digest optimised” were successively selected and 
dragged to positions 1 and 2-24 respectively on the target slide. Within the 
identification section of favorites, “protein digest Homo sapiens IAA” was selected 
and dragged to positions 2-24 on the target slide. The run list for slide 1 was saved 
and associated to position 1 on the previously disengaged tray. Selecting process 
and play then started the MALDI.      
Mass spectra were recorded operating in the positive reflector mode at the 
following parameters: accelerating voltage 20 kV; and pulsed extraction: on (focus 
mass 2500). Internal and external calibration was performed using trypsin autolysis 
peaks at 842.509 m/z, 2211.104 m/z and PepMix 4 respectively. Calibration using 
Pep4 was performed as follows: Once two spectra were generated for the PepMix 4 
mix (position 1 on the slide), the acquisition of spectra was stopped. The first 
spectrum of sample one was selected and the calibrant peaks readjusted for 
accuracy. The five individual peaks cover the 500-3500 Da mass range and include 
bradykinin fragment 1-5 (573.315), angiotensin II human (1046.5424), neurotensin 
(1672.9176) and insulin B chain oxidised (3494.6514). Once calibration was 
completed it was saved as the new “system calibration”. The MALDI was then 
restarted. The mass spectra generated for each of the proteins were analyzed using 
MALDI evaluation software (Amersham Biosciences). Protein identification was 
achieved with the PMF Pro-Found search engine for peptide mass fingerprints. 
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2.12 Identification of proteins with LC–MS/MS 
Tryptic digest of proteins (for those which were more than 3 fold differentially 
expressed) were also analysed  by 1-D LC-MS using the Ettan™ MDLC system 
(GE Healthcare) in high-throughput configuration directly connected to a 
Finnigan™ LTQ™ (Thermo Electron). Samples were concentrated and desalted on 
RPC trap columns (Zorbax™ 300SB C18, 0.3 mm65 mm, Agilent Technologies) 
and the peptides were separated on a nano-RPC column (Zorbax 300SB C18, 0.075 
mm 6100 mm, Agilent Technologies) using a linear ACN gradient from 0 to 65% 
acetonitrile (Sigma, 34967) over 60 min. All buffers used for nano-LC separation 
contained 0.1% formic acid (Fluka, 94318) as the ion pairing reagent. Full scan 
mass spectra were recorded in profile mode and tandem mass spectra in centroid 
mode. A scan time of ~0.15 s (one microscan with a maximum ion injection time of 
10ms) over an m/z range of 300-2000 was used followed by MS/MS analysis of the 
3 most abundant peaks from each scan which were then excluded for the next 60 
seconds followed by MS/MS of the next three abundant peaks which in turn were 
excluded for 60 seconds and so on. A “collision energy” setting of 35% was applied 
for ion fragmentation and dynamic exclusion was used to discriminate against 
previously analysed ions (data dependent analysis).  
Protein identification search was performed using the Turbo-SEQUEST algorithm 
in the BioWorks 3.1 software package (Thermo Electron) and the Swiss-Prot 
human database (Swiss Institute of Bioinformatics, Geneva, Switzerland). The 
identified peptides were further evaluated using charge state versus cross-
correlation number (XCorr). The criteria for positive identification of peptides was 
XCorr > 1.5 for singly charged ions, XCorr > 2.0 for doubly charged ions, and 
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XCorr > 2.5 for triply charged ions. The distinct peptides with p-value ≤0.05 were 
considered for protein identification and also had at least 2 peptides. 
 
2.13 Western blot Analysis 
2.13.1 Gel electrophoresis 
Proteins for analysis by Western blotting were resolved using 12% NuPAGE Bis-
Tris Gels (Invitrogen, NP0341BOX) in XCell SureLock™ Mini-Cell (Invitrogen, 
EI0001) running instrument. Western blotting samples (2g/L) were prepared by 
diluting samples with water and then an equal volume of 2X loading buffer (Sigma, 
S3401). 10-40µg of protein and 5L of molecular weight marker (ISIS, P7708S) 
were loaded onto gels. The samples were electrophoretically separated at 200V and 
45mA using a MOPS/SDS buffer (MOPS 1M (Fluka, 69949), 1M Tris base (Sigma, 
T8404), 2% SDS (Sigma, 23771), 20mM EDTA, pH 7.7 (Fluka, 03609)), until the 
bromophenol blue dye reached the bottom of the gel. 
 
2.13.2 Western blotting 
Once electrophoresis had been completed, the gel was equilibrated in transfer buffer 
(25mM Tris (Sigma, T8404), 192mM glycine (Sigma, G-7126), pH 8.3-8.5) for 
approximately 30 minutes. Five sheets of Whatman 3mm filter paper (Whatman, 
1001824) were soaked in freshly prepared transfer buffer. These were then placed 
on the cathode plate of a semi-dry blotting apparatus (Bio-rad). Air pockets were 
then removed from between the filter paper. Nitrocellulose membrane (GE 
Healthcare, RPN3032D), which had been equilibrated in the same transfer buffer, 
was placed over the filter paper on the cathode plate. Air pockets were once again 
removed. The gels were then aligned onto the membrane. Five additional sheets of 
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transfer buffer-soaked filter paper were placed on top of the gel, all air pockets 
removed and excess transfer buffer removed from the cathode plate. The proteins 
were transferred from the gel to the membrane at a current of 34mA at 15V for 30-
40 minutes, until all colour markers had transferred. Following protein transfer, 
membranes were stained using Ponceau (Sigma, P7170) to ensure efficient protein 
transfer. The membranes were then blocked overnight using 1-5% Marvel 
(Cadburys; Marvel skimmed milk) in PBS at 4C. The membranes were washed 
with PBS prior to the addition of the primary antibody.  Membranes were incubated 
with primary antibody overnight at 4C. Antibodies were prepared in 1-5% Marvel 
in PBS at recommended dilutions. The membranes were then rinsed 3 times with 
PBS containing 0.5% Tween 20 (Sigma P1379) for a total of 15-30 minutes. 
Relevant secondary antibody (1/1000 dilution of anti-mouse (Dako Cytomation, 
P0260) or anti-rabbit (Dako Cytomation, P0448) or anti-goat (Santa Cruz 
Biotechnology, Sc2098) IgG peroxidase conjugate in 2-5% Marvel-TBS) was 
added for 1 hour at room temperature. The membranes were again washed three 
times thoroughly in TBS containing 0.5% Tween for 15 minutes. 
 
2.14 Enzyme-Linked Immunosorbent Assay (ELISA) 
The ELISAs performed for validation of lung cancer biomarker targets were 
sandwich ELISAs. These 96-well plates come with capture antibody precoated to 
the surface of the wells. Protein standards that come with the kit were prepared and 
along with serum samples at a kit specific dilution were added to the wells, with the 
standards in duplicate and a proportion of the serum samples in duplicate and 
triplicate. After incubation the plate was washed to remove any unbound antigen. 
An enzyme-linked detection antibody was added which binds specifically to the 
 103
antigen. After another incubation period the plate was washed to remove any 
unbound detection antibody. A substrate was added that is converted by the enzyme 
into a colour or fluorescent signal. This colour or fluorescence was measured at a 
wavelength recommended in the ELISA manual to determine the presence and 
quantity of the antigen. From the standard curve produced from the standards of 
known concentrations, the concentration of antigen present in the serum sample can 
be determined and comparisons can be made between the various types of samples. 
Standard protocols were followed for each ELISA. 
 
2.15 Biochemical Fluorometric Assays 
Biochemical assays involve a single reaction step. A standard curve was created to 
calculate concentrations in unknown samples. A reaction mix was created that 
contains assay buffer, a developer, and an enzyme mix, and was added to all 
standards and all unknown serum/plasma samples. These were then incubated in the 
dark (generally for a relatively short period e.g. 20-30min) and OD or fluorescence 
was measured in a microplate reader. Background is corrected by subtracting the 
zero standard/control from all sample readings. 
 
2.16 Pyruvate Kinase Activity Assay 
A pyruvate kinase assay kit from BioVision was used to measure the pyruvate 
kinase activity in serum samples. In the assay, phosphoenolpyruvate (PEP) and 
adenosine diphosphate (ADP) are catalysed by pyruvate kinase to generate pyruvate 
and adenosine triphosphate (ATP). The generated pyruvate is oxidised by pyruvate 
oxidase to produce a colour at 570nm and fluorescence at 535/587nm. Since the 
increase in colour or fluorescent intensity is proportional to the increase in pyruvate 
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amount, the pyruvate kinase activity can be accurately measured. One unit of 
pyruvate kinase activity is the amount of enzyme transfer of phosphate group from 
PEP to ADP, yielding 1.0 µmol of pyruvate per minute at 25ºC.  
 
2.17 Luminex Multiplex Bead-based Assays 
Cancer Panel 1, Cancer Panel 2, and the MMP Panel of biomarkers were performed 
according to Millipore Milliplex Map Kit protocol (Millipore). Serum/plasma 
samples were diluted as recommended with calibrator diluent. Initially, the 96-well 
filter bottom plate was prewet adding 200 µl assay buffer. The microparticles from 
a particular panel were pooled e.g. for discovery phase MMP-1, MMP-3, MMP-8, 
MMP-9, MMP-10, and MMP-13 were pooled together. 25µl of diluted 
microparticle solution and 25µl of sample and standards and controls were added to 
the necessary wells. 25µl assay buffer was added to all wells. Next the plate was 
incubated overnight at 4 ºC and next day washed three times with wash buffer. 
Afterwards, 50 µl of diluted biotin antibody was added to each well and incubated 
for 1 h. The plate was then washed as described above and 50µl of diluted 
Streptavidin-PE was added to each well and incubated for 30min. All incubations 
were performed at room temperature on an orbital shaker set at 15 g. Finally, the 
plate was washed again with 100 µl of Sheath Fluid. The median relative 
fluorescence units were measured using the Luminex 100 analyzer (Luminex, 
Austin, TX, USA).  
2.18 Immunodepletion and ProteoMiner 
Immunodepletion of serum was performed using ProteoPrep 20 Plasma 
Immunodepletion kit from Sigma. 8µl of serum was diluted to 100µl with 1x 
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Equilibration buffer and filtered through a Corning Spin-X centrifuge Tube Filter 
before being added to the immunodepletion column and following a standard 
protocol. 
ProteoMiner was performed using ProteoMiner Protein Enrichment Kits from Bio-
Rad. The small capacity kit was used in which 200µl of serum was added to the 
column. After following a standard protocol the elutions were pooled together. 
 
2.19 Label-Free Mass Spectrometry Sample Preparation 
20µg of protein (See Section 2.3) from the sample of interest was placed into an 
eppendorf. The 2D-Clean-up kit (Bio-rad) was used to precipitate the protein, which 
was then left overnight in acetone. The protein pellet was resuspended in 6M Urea, 
2M Thiourea, 10mM Tris, pH 8. The sample was sonicated and vortexed to make 
sure of complete suspension. A protein assay was performed on this sample and 
10ug of protein was transferred into a new eppendorf. 1ul of reduction buffer was 
added to the sample (5mM DTT in water), vortexed and incubated at 37ºC for 30 
minutes. 1µl of alkylation buffer was added to the sample (25mM Iodoacetamide in 
50mM Ammonium Bicarbonate), vortexed and incubated for 20 minutes at room 
temperature in the dark. Lys-C was added at a ratio of 1:50 (enzyme:protein, in this 
case 0.2ug of Lys-C) and incubated for 4 hours at 37ºC. Samples were diluted with 
4 volumes of 50mM Ammonium Bicarbonate. 
Trypsin was added at a ration of 1:25 (enzyme:protein, in this case 0.4ug of 
Trypsin) and incubated overnight at 37ºC. The following day, PepClean™ C-18 
Spin Columns from Thermo were used to purify the peptides. 3 parts sample was 
mixed with 1 part Sample Buffer (2% TFA in 20% ACN). The final sample 
contained 0.5% TFA in 5% ACN. The column was tapped to settle resin. Top and 
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bottom cap were removed. The column was placed into a receiver tube. 200 µl of 
Activation Solution (50% Acn) was added to rinse walls of the spin column and to 
wet resin and centrifuged at 1,500 x g for 1 minute. Flow-through was discarded 
and this step was repeated. 200ul Equilibration Solution (0.5% TFA in 5% ACN) 
was added. Centrifuge at 1,500 x g for 1 minute. Flow-through was discarded and 
this step was repeated. The sample was loaded on top of the resin bed. The column 
was placed into a receiver tube and centrifuged at 1,500 x g for 1 minute. To ensure 
complete binding, flow-through was recovered and step was repeated 3 times. The 
column was placed into a receiver tube. 200 ul Wash Solution (0.5% TFA in 5% 
ACN) was added to column and centrifuged at 1,500 x g for 1 minute. Flow-
through was discarded and this step was repeated four times. The column was 
placed in a new receiver tube. 20 ul of Elution Buffer (80% ACN) was added to the 
top of the resin bed and centrifuged at 1,500 x g for 1 minute. This was repeated 3 
times with same receiver tube. The sample was gently dried in a vacuum evaporator 
and the peptides were re-suspended in 50ul of 0.1% TFA in 2% Acn with vortexing 
and sonication. 5µl of this sample was taken up per LC run. 
Progenesis LC-MS software was used for statistical analysis of LC produced data. 
See section 7.3 for a more detailed description of the software. 
 
2.20 RNA interference (RNAi) 
RNAi using small interfering RNAs (siRNAs) was carried out to silence the 
hnRNPA2B1 gene. The siRNAs used were chemically synthesised (Ambion Inc). 
These siRNAs were 21-23 bps in length and were introduced to the cells via reverse 
transfection with the transfection agent siPORTTM NeoFXTM (Ambion Inc., 4511). 
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2.20.1   Transfection optimisation 
In order to determine the optimal conditions for siRNA transfection, optimisation 
with kinesin siRNA (Ambion Inc., 16704) was carried out for the DLKP-M cell 
line. 
 
Cell suspensions were prepared at 2.5 X 105, 1.5 X 105, 1 X 105, 0.75 X 105, and 
0.5 X 105 cells per well. Solutions of negative control and kinesin siRNAs at a final 
concentration of 30nM were prepared in optiMEM (GibcoTM, 31985047). NeoFX 
solutions at a range of concentrations were prepared in optiMEM in duplicate and 
incubated at room temperature for 10 minutes. After incubation, either negative 
control or kinesin siRNA solution was added to each neoFX concentration. These 
solutions were mixed well and incubated for a further 10 minutes at room 
temperature. 100μl of the siRNA/neoFX solutions were added to each well of a 6-
well plate. 1 ml of the relevant cell concentrations were added to each well. The 
plates were mixed gently and incubated at 37°C for 24 hours. After 24 hours, the 
transfection mixture was removed from the cells and the plates were fed with fresh 
medium. The plates were assayed for changes in proliferation at 72 hours using the 
acid phosphatase assay (Section 2.20.3). Optimal conditions for siRNA transfection 
were determined as the combination of conditions, which gave the greatest 
reduction in cell number after kinesin siRNA transfection and also the least cell kill 
in the presence of transfection reagent. Western blot analysis was used to establish 
the optimum conditions for a siRNA transfection. The optimised conditions for the 
cell lines are shown in Table 2.18.1. 
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Cell Line Seeding Density per 
6-Well Plate 
NeoFx Volume per 
6-Well Plate (µl) 
siRNA Volume per
6-Well Plate (µl) 
DLKP-M 0.5x105 1 0.2 
 
Table 2.18.1: - Optimised conditions for siRNA transfection 
 
2.20.2 siRNA functional analysis of hnRNPA2B1 in DLKP-M 
Two pre-designed siRNAs were chosen for the protein/gene targets and transfected 
into cells. Two siRNAs were sufficient if a validated siRNA was available. 
Validated siRNAs have been verified by real-time RT-PCR to reduce gene 
expression of >70% 48 hours post-transfection. For each set of siRNA transfections 
carried out, control, non-transfected cells and a scrambled (SCR) siRNA transfected 
control were used. Scrambled siRNA are sequences that do not have homology to 
any genomic sequence. The scrambled non-targeting siRNA used in this study is 
commercially produced, and guarantees siRNA with a sequence that does not target 
any gene product. It has also been functionally proven to have no significant effects 
on cell proliferation, morphology and viability. For each set of experiments 
investigating the effect of siRNA, the cells transfected with target-specific siRNAs 
were compared to cells transfected with scrambled siRNA. This took account of any 
effects due to the siRNA transfection procedure, reagents, and also any random 
effects of the scrambled siRNA. Kinesin was used as a control to assess the 
efficiency of the siRNA transfection. Kinesin plays an important role in cell 
division; facilitating cellular mitosis. Therefore, transfection of siRNA kinesin 
resulted in cell cycle arrest and confirmed efficient transfection. Western blots 
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(section 2.13) were used to determine if siRNA had an efficient knock-down effect 
at a Protein-Level. From Applied Biosystems, siRNAs s6713 and s6715 were used. 
 
2.20.3  Acid Phosphatase Assay 
Following the incubation period of 6-7 days, media was removed from the plates.  
Each well on the plate was washed twice with 100l PBS.  This was then removed 
and 100l of freshly prepared phosphatase substrate (10mM p-nitrophenol 
phosphate (Sigma 104-0) in 0.1M sodium acetate (Sigma, S8625), 0.1% (v/v) 
Triton X-100 (Sigma, X100), pH 5.5) was added to each well.  The plates were then 
incubated in the dark @ 37C for 2h. Colour development was monitored during 
this time. The enzymatic reaction was stopped by the addition of 50l of 1N NaOH.  
The plate was read in a dual beam plate reader at 405nm with a reference 
wavelength of 620nm. 
 
2.20.4  Proliferation assays on siRNA transfected cells 
As described in table 2.18.1, cells were seeded using 1μl NeoFX to transfect 30nM 
siRNA in a cell density of 0.5 X 105 per well of a 6-well plate. After 24 hrs, 
transfection medium was replaced with fresh media and cells were allowed to grow 
until they reached 80-90% confluency, a total of 5 days. Cell number was assessed 
using the acid phosphatase assay (section 2.20.3). All experiments were carried out 
independently at least three times. 
 
2.20.5  Invasion Assays 
Matrigel (Sigma, E-1270) was diluted to a working stock of 1 mg/ml in serum 
free DMEM. Aliquoted stocks were stored at -20C.  
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Invasion assays were set up using a Costar 24 well plate (Costar, 3524), 
containing 8.0m pore sized inserts (BD Biosciences, 353097). For invasion 
(but not motility) assays, a layer of Matrigel (BD Biosciences, 354234) was 
dispensed into the insert. Matrigel was diluted to 1mg/ml in serum-free DMEM 
medium. A volume of 100l of this Matrigel was dispensed into each insert, and 
the plate was incubated overnight at 4C. The following day, excess Matrigel 
was removed from the inserts. Cells were harvested at a concentration of 0.5 X 
106 cells/ml in media, and 100l was added to each insert, followed by another 
100l of media. A volume of 500l media was then added to each plate well. 
For DLKP-M, cells were incubated at 37C for 24h. 
Following this, the inner area of each insert was wiped with a cotton bud soaked 
in PBS, to remove any cells, while the outside of the insert was stained with 
0.25% crystal violet. Staining of the inserts was sustained for a period of 10 
minutes, followed by a gentle rinse, done in triplicate, in UHP and then allowed 
to dry. Quantification of the cells was achieved by doing a cell count per area 
per view at 20X magnification using a light microscope. 10 fields of view were 
counted per insert. A minimum of 2 inserts were used per sample tested.     
 
2.20.6  Motility Assays 
Motility assays were carried out in an identical manner to invasion assays, as 
described in section 2.20.5, with the exception that the inserts were not coated in 
Matrigel. 
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2.20.7  Invasion assays on siRNA transfected cells 
Using the optimised conditions in Table 2.18.1, each of the siRNAs was tested to 
see changes in invasion of the cells after transfection. Two-three separate siRNAs 
were used for each target gene (Appendix I, Table 5). All siRNAs were purchased 
from Ambion Inc. 
To assay for changes in invasive capacity, siRNA experiments in 6-well plates were 
set up using 2μl NeoFX to transfect 30nM siRNA at a cell density of 3 X 105 per 
well of a 6-well plate. Transfection medium was removed after 24 hours and 
replaced with fresh growth medium. The transfected cells were assayed for changes 
in invasion capacity at 48 hours using the in vitro invasion assay described in 
Section 2.5.2. All experiments were carried out independently at least three times. 
 
2.20.8  Motility assays on siRNA transfected cells 
Motility assays were carried out in an identical manner to invasion assays, as 
described in section 2.20.7, with the exception that the inserts were not coated in 
Matrigel. 
 
2.21 Immunohistochemistry 
Antibodies were optimised (starting with recommended dilution on product data 
sheet) for immunohistochemistry staining purposes prior to using commercial lung 
cancer tissue arrays. Antigen retrieval was performed using the Dako PT Link, with 
pH 6 buffer being the optimum pH buffer. Staining of the tissue slide was 
performed using the Dako AutoStainerPlus according to a standard protocol. 
Stained tissue slides were prepared for mounting by placing in 70% ethanol for two 
3 minute periods, followed by 90% ethanol for two 3 minute periods and then 100% 
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ethanol for two 3 minute periods. Next the slides were placed in xylene for two 5 
minute periods before adding Sigma DPX Mountant and covering with a glass slide. 
The slides could then be viewed under a microscope and scored by trained 
personnel. 
 
2.22 Metabolomics 
Serum samples (140μL) were shipped on dry-ice to Metabolon Inc. where the 
metabolomic profiling was performed. 
Metabolon incorporates three independent complementary analysis platforms to 
maximise the number of small molecules and metabolites that the combined 
systems can identify and measure. Two separate ultra-high performance liquid 
chromatography / tandem mass spectrometry (UHPLC/MS/MS2) injections (one 
optimised for basic compounds, and the other for acidic compounds) and one 
GC/MS injection per sample are performed. 
Firstly, small molecules were extracted from serum specimens using methanol to 
allow precipitation of proteins. The extract supernatant was then split into four 
equal aliquots; two for UHPLC/MS, one for GC/MS and one reserve aliquot. 
Aliquots were then dried overnight to remove solvent.  
For the UHPLC methods one aliquot was reconstituted in 50μL 0.1% formic acid, 
and the other in 50μL 6.5mM ammonium bicarbonate pH 8.0. For GC/MS analysis 
aliquots were derivatized using equal parts N,O-bistrimethylsilyltrifluoroacetamide 
and a solvent mixture of acetonitrile:dichloromethane:cyclohexane (5:4:1) with 5% 
triethylamine at 60ºC for 1 hour. All reconstitution solvents contained instrument 
internal standards used to monitor instrument performance.  
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UHPLC/MS was carried out using a Waters Acquity UHPLC coupled to an LTQ 
mass spectrometer equipped with an electrospray ionization source. Two separate 
UHPLC/MS injections were performed on each sample. The acidic injections were 
monitored for positive ions and the basic injections were monitored for negative 
ions. The derivatized samples for GC/MS were analyzed on a Thermo-Finnigan 
Trace DSQ fast-scanning single-quadrupole MS. 
The resulting MS/MS2 data was then searched against Metabolon’s reference 
standard library. This library was generated from 1500 standards and contains the 
retention time/index, mass to charge (m/z), and MS/MS spectral data for all 
molecules in the library, including their associated adducts, in-source fragments, 
and multimers. The library allows identification of experimentally detected 
metabolites based on a multi-parameter match basis. All identifications and 
quantifications were subjected to QC to verify the quality of the identification and 
peak integration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 114
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER THREE 
 
BIOMARKER DISCOVERY FROM THE CONDITIONED 
MEDIA OF LUNG CANCER CELL LINES 
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3.1 Background 
The secretion and leaking of proteins is commonly associated with cancer. The 
process of cancer initiation and progression, and the signalling pathways involved, 
are not confined to the cancer cell itself but extend to the tumour-host interface, a 
dynamic environment in which information passes between the tumour cells and the 
normal host tissue (Kulasingam and Diamandis 2007).  
 
It is conceivable these leaked and/or secreted proteins from the tumour and its 
microenvironment will ultimately make their way to the serum proteome, where 
their detection could create a proteomic fingerprint of the tumour of origin. Of all 
cellular proteins about 20-25% are secreted, so one can predict with confidence that 
proteins or their fragments originating from cancer cells or their microenvironment 
may eventually enter the circulation (Liotta, Ferrari et al. 2003). 
 
3.2 Lung Cancer Cell Line Model 
In this study lung cancer cell lines were used as a model. Lung cancer cell lines 
secrete and shed proteins into the surrounding media and this environment could 
have similarities with the tumour microenvironment or the serum proteome of a 
lung cancer patient. This media, without serum which can mask the secreted or shed 
proteins, is known as conditioned media. Conditioned media from sixteen lung 
cancer cell lines and a normal human bronchial epithelial cell line were prepared 
and used for 2D-DIGE experiments. The four main types of lung cancer can be 
broadly categorised as squamous cell carcinoma, adenocarcinoma, large cell 
carcinoma, and small cell carcinoma; four cell lines from each of these categories 
was used in this study. 
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Conditioned media samples were concentrated from 10ml to 200µl before 
undergoing a 2-D cleanup and resuspended in lysis buffer. Accurate protein 
quantification is essential before labelling with the CyDye DIGE fluor minimal 
dyes. In total thirty gels were ran, each with a Cy3 and a Cy5 labelled individual 
cell line as well as a Cy2 labelled pool of all cell lines for internal standardisation. 
All sixteen lung cancer cell lines and normal human bronchial epithelial cell line 
were examined in triplicate, with some of the cancer lines examined four or five 
times. 
 
3.3 Decyder analysis of 2D-DIGE conditioned media 
All gels were scanned on a Typhoon Variable Mode Imager. The use of appropriate 
emission filters and lasers allowed the scanning of the three dyes per gel. The 
images are then cropped and imported into DeCyder for analysis. As per Materials 
and Methods section the DeCyder software allows quantitation of the protein spots, 
using the Cy2 internal pool to standardise spot intensity across all gels. 
Protein spots are picked from Coomaisse stained preparative gels and identified via 
mass spectrometry, the subsequent identifications then entered into DeCyder where 
spots can be matched with confidence. DeCyder allows statistical comparison of all 
protein spots between all conceivable comparisons of each of the designated sample 
groups. Lists were generated of all interesting proteins with t-test and 1-WAY 
ANOVA scores of ≤ 0.1. The cut-off of 0.1 instead of the standard 0.05 was used 
due to potential inaccuracies of this discovery phase technique. Conditioned media 
itself is only a model for the tumour cell environment so can not be examined with 
full confidence. A total of 83 identifications were recorded in the DeCyder 
experiment, though a number of these were duplicate identifications. 
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Protein ID Fold Change ANOVA
Pyruvate kinase 3 4.88 0.0021
Stathmin 4.81 0.0049
KNP-I beta protein 4.1 0.0028
L-lactate dehydrogenase A chain 2.67 0.018
Fumarylacetoacetate hydrolase 2.59 0.0041
Ubiquitin carboxyl-terminal esterase L1 2.48 0.0013
Chain A; Cyclophilin B 2.37 0.028
Malate dehydrogenase; mitochondrial 2.27 0.049
Proteasome activator complex subunit 1 2.19 0.0082
Creatine kinase B-type 2.14 0.0091
Rho GDP dissociation inhibitor (GDI) alpha 1.99 0.0088
Fumarate hydratase 1.86 0.00092
Triosephosphate isomerase (TIM) 1.83 0.0002
Inorganic pyrophosphatase 1.78 0.054
WDR1 protein 1.65 0.039
Protein disulfide-isomerase A6 1.56 0.006
Proteasome subunit beta type-7 1.47 3.70E-05
Peroxiredoxin-2 1.43 0.0097
Acetyl-CoA acetyltransferase 1.35 0.0019
Phosphoglycerate kinase 1 1.29 0.046
Phosphatidylethanolamine-binding protein 1 1.28 0.014
TKT protein 1.22 0.022
Peroxiredoxin 1 1.09 0.0069
L-lactate dehydrogenase A chain 1.07 0.052
PARP1 protein 1.05 0.016
Pigment epithelium-derived factor 1.05 0.015
Malate dehydrogenase; cytoplasmic -1.01 0.018
Synaptic vesicle membrane protein VAT-1 homolog -1.2 0.015
Chain B; Human Platelet Profilin -1.43 0.015
Adenosylhomocysteinase -1.66 0.06
Aspartate aminotransferase; cytoplasmic -1.75 0.037
Heat shock protein beta-1 -3.4 0.0014
 
Table 3.3.1: Lung cancer versus Normal. Statistically significant proteins 
identified from the 2D-DIGE experiments on conditioned media. A positive fold 
change indicates an increase in lung cancer and a negative fold change indicates a 
decrease in lung cancer for this protein compared to normal. 
 
Protein ID Fold Change T-test
Pyruvate kinase 3 6.19 0.043
WDR1 protein 2.89 0.056
KNP-I beta protein 2.7 0.029
Hsc70-interacting protein 2.69 0.045
Inorganic pyrophosphatase 1.79 0.042
Heat shock protein beta-1 -2.48 0.017
 
Table 3.3.2: Large cell lung cancer versus Normal. Statistically significant 
proteins identified from the 2D-DIGE experiments on conditioned media. A 
positive fold change indicates an increase in large cell lung cancer and a negative 
fold change indicates a decrease in large cell carcinoma for this protein compared to 
normal. 
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Protein ID Fold Change T-test
Stathmin 6.55 0.04
Pyruvate kinase 3 4.82 0.015
KNP-I beta protein 4.19 0.0057
Hsc70-interacting protein 3.23 0.057
L-lactate dehydrogenase A chain 2.89 5.50E-05
Elongation factor 1-alpha 2 2.51 0.01
Triosephosphate isomerase (TIM) 2.18 2.90E-05
Protein DJ-1 1.95 0.049
Chain A; Crystal Structure Of Human Dj-1 1.81 0.0041
Chain L; Crystal Structure Of Human B Type Phosphoglycerate Mutase 1.77 0.047
Proteasome activator complex subunit 1 1.62 0.042
Phosphatidylethanolamine-binding protein 1 1.46 0.0014
Proteasome subunit beta type-7 1.28 0.045
Heat shock protein beta-1 -3.04 0.0039
 
Table 3.3.3: Adenocarcinoma versus Normal. Statistically significant proteins 
identified from the 2D-DIGE experiments on conditioned media. A positive fold 
change indicates an increase in adenocarcinoma and a negative fold change 
indicates a decrease in adenocarcinoma for this protein compared to normal. 
 
 
 
Protein ID Fold Change T-test
KNP-I beta protein 5.81 0.0068
Stathmin 5.54 2.10E-06
Chain A; Cyclophilin B; Chain A; Cyclophilin B 3.64 0.017
Hsc70-interacting protein 3.6 0.045
Pyruvate kinase 3 3.59 0.015
Rho GDP dissociation inhibitor (GDI) alpha 3.43 0.00046
hnRNP protein A2 2.78 0.051
Ubiquitin carboxy-terminal hydrolase L1 2.29 0.02
Triosephosphate isomerase (TIM) 2.24 0.027
Peroxiredoxin-2 1.96 0.098
Peroxiredoxin 6 1.79 0.038
Ubiquitin carboxyl-terminal esterase L1 1.39 0.067
Chain B; Human Platelet Profilin -2.47 0.015
Heat shock protein beta-1 -5.47 0.0057
 
Table 3.3.4: Small cell carcinoma versus Normal. Statistically significant 
proteins identified from the 2D-DIGE experiments on conditioned media. A 
positive fold change indicates an increase in small cell carcinoma and a negative 
fold change indicates a decrease in small cell carcinoma for this protein compared 
to normal. 
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Protein ID Fold Change T-test
Vimentin 7.56 6.70E-05
Pyruvate kinase 3 6.27 0.00015
Ubiquitin carboxyl-terminal esterase L1 5.04 0.011
KNP-I beta protein 3.8 0.015
hnRNP protein A2 3.58 0.0032
Elongation factor 1-alpha 2 3.54 0.011
Fumarylacetoacetate hydrolase 3.43 0.00043
Fumarate hydratase 3.39 0.04
Stathmin 3.27 0.014
L-lactate dehydrogenase A chain 3.16 0.052
Chaperonin 10 3.12 0.0065
Creatine kinase B-type 3.02 0.00078
Proteasome activator complex subunit 1 2.82 0.0099
Hsc70-interacting protein 2.79 0.015
Peroxiredoxin 3 isoform b 2.24 0.003
Chain L; Crystal Structure Of Human B Type Phosphoglycerate Mutase 2.12 0.012
Peroxiredoxin-1 2.03 0.0022
Inorganic pyrophosphatase 2.01 0.055
Proteasome subunit beta type-7 2 0.0029
Peroxiredoxin 6 1.83 0.022
Proteasome subunit alpha type-1 1.63 0.036
TKT protein 1.54 0.059
Triosephosphate isomerase (TIM) 1.39 0.013
Translin-associated protein X -1.69 0.055
Heat shock protein beta-1 -3.28 0.04
 
Table 3.3.5: Squamous cell carcinoma versus Normal. Statistically significant 
proteins identified from the 2D-DIGE experiments on conditioned media. A 
positive fold change indicates an increase in squamous cell carcinoma and a 
negative fold change indicates a decrease in squamous cell carcinoma for this 
protein compared to normal. 
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Protein ID Fold Change T-test
Ubiquitin carboxyl-terminal esterase L1 2.89 0.0042
Peroxiredoxin-2 2.46 0.012
Pigment epithelium-derived factor 2.31 0.02
vimentin 2.17 0.009
fumarate hydratase 2.17 0.0099
PARP1 protein; PARP1 protein 2.05 0.01
Peroxiredoxin-1 1.77 2.90E-06
Proteasome activator complex subunit 1 1.74 0.0099
Chaperonin 10 1.74 0.04
Inorganic pyrophosphatase 1.72 0.01
Chloride intracellular channel protein 1 1.65 0.0049
Protein disulfide-isomerase A6 1.65 0.011
Malate dehydrogenase; mitochondrial 1.56 0.016
Proteasome subunit beta type-7 1.55 0.00058
Creatine kinase B-type 1.55 0.011
Peptidylprolyl isomerase A 1.48 0.046
Fumarylacetoacetate hydrolase 1.43 0.02
Chain A; Human Cyclophilin A 1.42 0.034
Tropomyosin 3 1.4 0.028
Adenosylhomocysteinase 1.39 0.03
Pyruvate kinase 3 1.3 0.088
Tyrosine 3/tryptophan 5 -monooxygenase activation protein 1.26 0.057
Chain A; Human Cyclophilin A 1.25 0.079
Chain A; Crystal Structure Of Human Dj-1 -1.33 0.022
L-lactate dehydrogenase A chain -1.41 0.057
Phosphatidylethanolamine-binding protein 1 -1.46 0.00021
Peroxiredoxin 1 -1.5 0.059
Triosephosphate isomerase (TIM) -1.56 4.50E-06
Purine nucleoside phosphorylase -1.57 0.038
Creatine kinase B-type -1.69 0.023
NM23-H1 -2.19 0.067
Fructose-biphosphate aldolase A -2.81 0.0044
 
Table 3.3.6: Squamous cell carcinoma versus Adenocarcinoma. Statistically 
significant proteins identified from the 2D-DIGE experiments on conditioned 
media. A positive fold change indicates an increase in squamous cell carcinoma and 
a negative fold change indicates a decrease in squamous cell carcinoma for this 
protein compared to adenocarcinoma. 
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Protein ID Fold Change T-test
Pigment epithelium-derived factor 4.02 8.30E-05
Ubiquitin carboxyl-terminal esterase L1 3.61 0.00023
Fumarate hydratase 3.12 0.00033
Protein disulfide-isomerase A6 2.81 8.30E-05
TKT protein 2.52 9.20E-05
Proteasome activator complex subunit 1 2.38 0.00012
Acetyl-CoA acetyltransferase 2.13 0.0012
Aspartate aminotransferase; cytoplasmic 1.99 0.01
Fumarylacetoacetate hydrolase 1.97 0.0015
L-lactate dehydrogenase A chain 1.97 0.017
Uridine diphosphoglucose pyrophosphorylase 1.88 0.025
Creatine kinase B-type 1.85 0.0018
Chain B; Human Platelet Profilin 1.82 0.0014
Synaptic vesicle membrane protein VAT-1 homolog 1.78 0.008
Pyruvate kinase 3 1.75 0.0042
Proteasome subunit beta type-7 1.73 0.00029
Aspartate aminotransferase; mitochondrial 1.7 0.03
Phosphoglycerate kinase 1 1.65 0.0042
Tyrosine 3/tryptophan 5 -monooxygenase activation protein 1.64 0.0076
Malate dehydrogenase; mitochondrial 1.64 0.012
Chain F; Nucleoside Triphosphate 1.64 0.094
Actin-related protein 2 1.63 0.051
Adenosylhomocysteinase 1.61 0.0073
Chloride intracellular channel protein 1 1.57 0.02
Tropomyosin 3 1.54 0.013
Rhabdomyosarcoma antigen 1.54 0.038
UPF0568 protein C14orf166 1.51 0.023
Peptidylprolyl isomerase A 1.47 0.067
Malate dehydrogenase; cytoplasmic 1.45 0.011
ACTB protein; Isocitrate dehydrongenase [NADP] cytoplasmic 1.43 0.028
Chain A; Human Cyclophilin A 1.37 0.072
TAGLN2 protein 1.28 0.041
Chain L; Crystal Structure Of Human B Type Phosphoglycerate Mutase 1.23 0.099
Peroxiredoxin 1 -1.5 0.074
Triosephosphate isomerase (TIM) -1.61 0.025
Phosphatidylinositol transfer protein alpha isoform -1.64 0.015
Stathmin -1.69 0.0033
Chain A; Cyclophilin B -1.82 0.068
Rho GDP dissociation inhibitor (GDI) alpha -2.43 3.30E-05
HNRPA2B1 protein -9.37 0.00074
 
Table 3.3.7: Squamous cell carcinoma versus Small cell carcinoma. Statistically 
significant proteins identified from the 2D-DIGE experiments on conditioned 
media. A positive fold change indicates an increase in squamous cell carcinoma and 
a negative fold change indicates a decrease in squamous cell carcinoma for this 
protein compared to small cell carcinoma. 
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Protein ID Fold Change T-test
Chaperonin 10 3 0.00092
Ubiquitin carboxyl-terminal esterase L1 2.96 0.0055
Fumarate hydratase 2.41 0.011
Vimentin 2.39 0.0041
PARP1 protein 1.99 0.011
Malate dehydrogenase; mitochondrial 1.97 0.022
Creatine kinase B-type 1.62 0.0081
Pigment epithelium-derived factor 1.6 0.072
Proteasome subunit beta type-7 1.56 0.002
Glutathione S-transferase P 1.52 0.098
Malate dehydrogenase; cytoplasmic 1.49 0.02
Peroxiredoxin 3 isoform b 1.48 0.015
Tropomyosin 3 1.43 0.021
UPF0568 protein C14orf166 1.41 0.087
Peroxiredoxin-1 1.4 0.018
Chain A; Human Cyclophilin A 1.38 0.051
Proteasome subunit alpha type-1 1.35 0.049
Tyrosine 3/tryptophan 5 -monooxygenase activation protein 1.28 0.081
Triosephosphate isomerase (TIM) 1.28 0.096
Adenosylhomocysteinase 1.24 0.049
Heat shock protein beta-1 -1.32 0.071
Phosphoglycerate kinase 1 -1.63 0.037
Creatine kinase B-type -2.12 0.095
 
Table 3.3.8: Squamous cell carcinoma versus Large cell carcinoma. Statistically 
significant proteins identified from the 2D-DIGE experiments on conditioned 
media. A positive fold change indicates an increase in squamous cell carcinoma and 
a negative fold change indicates a decrease in squamous cell carcinoma for this 
protein compared to large cell carcinoma. 
 
Protein ID Fold Change T-test
NM23-H1 2.55 0.027
Triosephosphate isomerase (TIM) 1.99 0.0014
Malate dehydrogenase; cytoplasmic 1.98 0.06
Peroxiredoxin 1 1.92 0.0034
Glutathione S-transferase P 1.88 0.0066
Phosphatidylethanolamine-binding protein 1 1.78 0.0033
KNP-I beta protein 1.55 0.058
L-lactate dehydrogenase A chain 1.38 0.093
Chain A; Crystal Structure Of Human Dj-1 1.31 0.052
Inorganic pyrophosphatase -1.53 0.027
Peroxiredoxin-2 -2 0.098
WDR1 protein -2.61 0.043
 
Table 3.3.9: Adenocarcinoma versus Large cell carcinoma. Statistically 
significant proteins identified from the 2D-DIGE experiments on conditioned 
media. A positive fold change indicates an increase in adenocarcinoma and a 
negative fold change indicates a decrease adenocarcinoma for this protein compared 
to large cell carcinoma. 
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Protein ID Fold Change T-test
Fructose-biphosphate aldolase A 3.46 0.00056
NM23-H1 2.25 0.066
Chain B; Human Platelet Profilin 2.11 0.032
TKT protein 2.03 0.076
Acetyl-CoA acetyltransferase 1.97 0.004
Malate dehydrogenase; cytoplasmic 1.93 0.016
Synaptic vesicle membrane protein VAT-1 homolog 1.88 0.0098
L-lactate dehydrogenase A chain 1.8 0.013
Heat shock protein beta-1 1.8 0.0062
L-lactate dehydrogenase A chain 1.79 0.003
Protein disulfide-isomerase A6 1.71 0.078
Aspartate aminotransferase; mitochondrial 1.7 0.099
Phosphoglycerate kinase 1 1.61 0.021
Creatine kinase B-type 1.51 0.049
Fumarate hydratase 1.44 0.094
Proteasome activator complex subunit 1 1.37 0.026
Rho GDP dissociation inhibitor; Rho GDP dissociation inhibitor -1.29 0.097
Ubiquitin carboxy-terminal hydrolase L1 -1.43 0.051
Inorganic pyrophosphatase -1.86 0.093
PARP1 protein -1.93 0.021
Chain A; Cyclophilin B -1.95 0.065
Manganese-containing superoxide dismutase -2.1 0.095
Rho GDP dissociation inhibitor (GDI) alpha -2.39 0.0085
Peroxiredoxin-2 -2.87 7.90E-05
HNRPA2B1 protein -29.99 0.0031
 
Table 3.3.10: Adenocarcinoma versus Small cell carcinoma. Statistically 
significant proteins identified from the 2D-DIGE experiments on conditioned 
media. A positive fold change indicates an increase in adenocarcinoma and a 
negative fold change indicates a decrease in adenocarcinoma for this protein 
compared to small cell carcinoma. 
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Protein ID Fold Change T-test
HNRPA2B1 protein 48.53 0.00093
Chaperonin 10 2.87 0.035
Manganese-containing superoxide dismutase 2.29 0.092
Peroxiredoxin 3 2.23 0.095
KNP-I beta protein 2.15 0.015
Chain A; Cyclophilin B 2.12 0.03
Triosephosphate isomerase (TIM) 2.05 0.012
Phosphatidylethanolamine-binding protein 1 1.99 0.042
Peroxiredoxin 1 1.92 0.0051
PARP1 protein 1.88 0.045
Stathmin 1.68 0.0049
Ubiquitin carboxy-terminal hydrolase L1 1.58 0.011
Fumarylacetoacetate hydrolase -1.58 0.072
Synaptic vesicle membrane protein VAT-1 homolog -1.61 0.06
Aspartate aminotransferase; cytoplasmic -1.66 0.031
L-lactate dehydrogenase A chain -1.86 0.067
Fructose-biphosphate aldolase A -1.95 0.067
Chain B; Human Platelet Profilin -2.09 0.012
Heat shock protein beta-1 -2.21 0.0033
WDR1 protein -2.44 0.092
TKT protein -2.52 0.021
Acetyl-CoA acetyltransferase -2.6 0.004
Phosphoglycerate kinase 1 -2.76 0.017
Uridine diphosphoglucose pyrophosphorylase -2.88 0.025
 
Table 3.3.11: Small cell carcinoma versus Large cell carcinoma. Statistically 
significant proteins identified from the 2D-DIGE experiments on conditioned 
media. A positive fold change indicates an increase in small cell carcinoma and a 
negative fold change indicates a decrease in small cell carcinoma for this protein 
compared to large cell carcinoma. 
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Protein ID Fold Change 1-ANOVA
HNRPA2B1 protein 13.78 0.00025
Rho GDP dissociation inhibitor (GDI) alpha 2.08 0.0088
Chain A; Cyclophilin B 1.95 0.028
Peroxiredoxin 3 isoform b 1.72 0.088
KNP-I beta protein 1.64 0.0028
Peroxiredoxin-2 1.57 0.0097
Peroxiredoxin-1 1.50 0.096
Vimentin 1.48 0.059
chaperonin 10 1.47 0.033
PARP1 protein 1.45 0.016
Phosphatidylethanolamine-binding protein 1 1.44 0.014
Triosephosphate isomerase (TIM) 1.36 0.0002
Peroxiredoxin 1 1.35 0.0069
Inorganic pyrophosphatase 1.33 0.054
Ubiquitin carboxy-terminal hydrolase L1 1.25 0.076
Stathmin 1.22 0.0049
Malate dehydrogenase; mitochondrial -1.18 0.049
Chloride intracellular channel protein 1 -1.23 0.061
Elongation factor 1-alpha 2 -1.31 0.049
Proteasome subunit beta type-7 -1.36 3.70E-05
Adenosylhomocysteinase -1.37 0.06
Tyrosine 3/tryptophan 5 -monooxygenase activation protein -1.41 0.063
Creatine kinase B-type -1.42 0.0091
NM23-H1 -1.42 0.084
WDR1 protein -1.49 0.039
L-lactate dehydrogenase A chain -1.49 0.052
Malate dehydrogenase; cytoplasmic -1.54 0.018
Pyruvate kinase 3 -1.56 0.0021
Fumarylacetoacetate hydrolase -1.66 0.0041
Synaptic vesicle membrane protein VAT-1 homolog -1.77 0.015
Aspartate aminotransferase; cytoplasmic -1.85 0.037
Heat shock protein beta-1 -1.86 0.0014
L-lactate dehydrogenase A chain -1.89 0.018
Phosphoglycerate kinase 1 -1.94 0.046
Chain B; Human Platelet Profilin -2.01 0.015
Fumarate hydratase -2.06 0.00092
Ubiquitin carboxyl-terminal esterase L1 -2.07 0.0013
Fructose-biphosphate aldolase A -2.07 0.0035
Proteasome activator complex subunit 1 -2.18 0.0082
Acetyl-CoA acetyltransferase -2.20 0.0019
Protein disulfide-isomerase A6 -2.20 0.006
 
Table 3.3.12: Small cell carcinoma versus Non-Small Cell Lung Cancer. 
Statistically significant proteins identified from the 2D-DIGE experiments on 
conditioned media. A positive fold change indicates an increase in small cell 
carcinoma and a negative fold change indicates a decrease in small cell carcinoma 
for this protein compared to Non-Small Cell Lung Cancer. 
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Figure 3.3.13: Example of DeCyder data from three interesting proteins. (A) 
Pyruvate kinase 3 showed a 4.88 fold increase and ANOVA value of 0.0021 for 
cancer compared to normal (B) Hsc-70 interacting protein showed a 2.69 and a 3.23 
fold increase and ANOVA value of 0.045 and T-Test score of 0.057 for large cell 
carcinoma and adenocarcinoma respectively compared to normal (C) hnRNPA2B1 
showed a 13.78 fold increase and ANOVA value of 0.00025 for small cell 
carcinoma compared to non-small cell carcinoma. 
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Figure 3.3.14: Principal component analysis showing the clustering of multivariate 
data of eight interesting proteins from fifty-eight spot maps in the DeCyder 
software for adenocarcinoma (Green), squamous cell carcinoma (Yellow), large cell 
carcinoma (Black), small cell carcinoma (Blue), and the normal human bronchial 
epithelial cell line (Red). A cumulative variance of 90% was reached after 
component 2.  
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3.4 Validation of Targets from Conditioned Media Discovery Phase 
 
For biomarker discovery experiments to become clinically significant the targets of 
interest must be validated in biological fluids. Serum and plasma are commonly 
used due to their non-invasive nature. To examine the levels of a biomarker of 
interest in serum and/or plasma, kits such as enzyme-linked immunosorbent assays 
(ELISAs) or biochemical assays are commercially available, however due to the 
high cost of manufacturing these kits they are only available for a selection of 
proteins. The availability of these kits often determined which proteins of interest to 
validate, regardless of fold changes and statistical scores. 
 
The clinical validation of these proteins was restricted to available serum/plasma 
samples, for example at the initial stages only serum samples were available and 
there were no patients used that were diagnosed with large cell carcinoma. In fact, 
through all the validation stages large cell carcinoma was not examined due to 
unavailability of clinical samples. Also, initial serum validation was performed in 
unevenly distributed sample sets (e.g. 20 normal samples, 22 SCC samples, 20 AD, 
and 5 SCLC), whereas validation further down the line could be performed in 
evenly distributed sample sets (e.g. 20 normal, 20 SCC, 20 AD, and 20 SCLC).  
 
Benign lung disease (BLD) control samples were not available for validation 
performed on late stage lung cancer serum samples. Later, when certain biomarkers 
were examined in earlier stage lung cancer serum, a benign lung disease control 
group was used. When available, an autoimmune control group was used along with 
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the normal control and benign lung disease control. When examined, plasma 
included a benign lung disease control group. 
 
Validation results (ELISA/biochemical assay) are presented in bar chart and box-
and-whisker format. As the sample sets used were relatively small no standard cut-
off point was used (e.g. mean +/- two-times the standard deviation), though any 
results that were obvious standout anomalies were excluded, though this was rare. 
For this reason box-and-whisker plots were included along with the standard bar 
chart as they show a more accurate distribution of results. From the box-and-
whisker graphs the minimum, maximum, and median can be determined as well as 
the 25th and 75th percentile, giving a more accurate representation of where the 
overall results lie. Comparisons with T-test ≤ 0.05 are marked by a single asterisk 
(*) and ≤ 0.01 are marked by two asterisks (**). 
 
ROC (receiver operating characteristic) curve analysis was performed on the 
ELISA results of some of the proteins that showed statistically significant 
comparisons. Using MedCalc software the sensitivity and specificity of the ELISA 
was calculated as well as the area under the curve. The sensitivity percentage refers 
to the chances of the test correctly identifying those patients with the disease, and 
the specificity percentage refers to the chances of the test correctly identifying those 
patients without the disease. In some cases where the same serum/plasma samples 
were used the results were combined for logistic regression, a percentage score 
created to indicate the chances of a correct diagnosis (whether diagnosing healthy 
or cancer).   
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3.4.1 hnRNPA2B1, PKM2, and HSC70-interacting Protein (Hip) show 
potential as lung cancer biomarkers 
 
Figures 3.4.1 and 3.4.4 show an increase in hnRNPA2B1 in lung cancer serum 
when compared to hnRNPA2B1 levels in normal healthy serum. Both ELISAs (Fig. 
3.4.1 and Fig. 3.4.4) were performed on an identical set of serum samples using the 
USCN kit E90323Hu. Although levels of hnPNPA2B1 are increased in the serum of 
all lung cancer types compared to normal, the quantities and the comparative 
differences vary between the two assays. In Fig. 3.4.1 hnRNPA2B1 was barely 
detectable in normal control serum (in the discovery phase 2D-DIGE conditioned 
media experiment hnRNPA2B1 was detected in all lung cancer types but not found 
at all in the NHBE cell line) but showed relatively high levels of almost 100pg/ml 
in normal control serum in the subsequent repeat ELISA (Fig. 3.4.4). This increase 
was not seen in the lung cancer types, indeed in Fig. 3.4.4 there is a large decrease 
in squamous and adneocarcinoma quantity (in pg/ml), however small cell 
carcinoma stays relatively consistent (in pg/ml). SCLC also showed higher levels in 
relation to the NSCLC groups in comparison to the first ELISA, indeed showing a 
higher average result (179pg/ml) compared to AD (163pg/ml), however the median 
value for AD (149pg/ml) is higher than SCLC (130pg/ml). The median values for 
the first assay for normal, SCC, AD, and SCLC were 1.6pg/ml, 53pg/ml, 9.8pg/ml, 
and 54pg/ml, whereas for the 2nd assay were 81pg/ml, 178pg/ml, 149pg/ml, and 
129pg/ml respectively. As these assays were performed on an identical set of serum 
samples the differences seen could be attributed to the assay kit itself; perhaps to 
batch-to-batch variation. The trend however does not change and it was concluded 
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that hnRNPA2B1 is increased in lung cancer serum compared to normal healthy 
serum. 
Figure 3.4.5 shows an ELISA on hnRNPA2B1 performed in plasma samples. These 
plasma samples are from earlier stage lung cancer compared to the late stages of the 
cancer serum used in Figures 3.4.1 and 3.4.4. The hnRNPA2B1 protein shows 
higher levels in normal plasma compared to plasma of benign lung disease and lung 
cancer patients. The quantity of hnRNPA2B1 in normal plasma is more than double 
than that in normal serum (when compared to Fig. 3.4.4), whereas for the same two 
ELISAs the quantity of hnRNPA2B1 in cancer serum far exceeds the quantity in 
normal serum. However, because the cancer stages used in serum and plasma are 
different, a direct comparison can not be made.  
To address this, an ELISA (Fig. 3.4.6) was performed examining matching serum 
and plasma from the same patients, the cancer group being from early-stage cancer. 
Matching serum and plasma from normal patients was not included. This ELISA 
showed relatively similar levels of hnRNPA2B1 in plasma of both benign lung 
disease patients and lung cancer patients, a trend also seen in Fig. 3.4.5. The 
matching serum samples however showed lower quantities compared to the plasma 
samples for both the benign lung disease group and the lung cancer group. It was 
concluded that levels of hnRNPA2B1 may vary in serum and plasma of benign lung 
disease patients and lung cancer patients, a benign lung disease control group is 
essential in assays for potential lung cancer biomarkers, and hnRNPA2B1 has 
potential in serum as an indicator of advanced lung cancer and also for treatment 
monitoring. 
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Two serum ELISAs and two plasma ELISAs were performed on PKM2. There was 
also a biochemical assay measuring pyruvate kinase activity (of all pyruvate kinase 
not a particular isoform). One serum ELISA measured PKM2 in normal serum and 
late-stage SCC, AD, and SCLC (Fig. 3.4.7) and the other serum ELISA measured 
PKM2 in serum of normal, autoimmune, benign lung disease, and earlier-stage lung 
cancer (Fig. 3.4.8). Two plasma ELISAs were combined (Fig. 3.4.9) and compared 
normal, benign lung disease, NSCLC, and SCLC. The biochemical activity assay of 
PKM2 was performed on serum of normal and late-stage SCC, AD, and SCLC 
patients, though only 5 SCLC samples were available at the time. 
Pyruvate kinase has potential as a biomarker of lung cancer. Although the results of 
Fig. 3.4.7 were not statistically significant there is a clear increase of PKM2 in lung 
cancer types compared to normal and even in Fig. 3.4.8 using earlier stage lung 
cancer PKM2 is elevated in lung cancer serum. Interestingly in Fig. 3.4.8 it is 
higher in lung cancer compared to benign lung disease too with an excellent T-test 
score and even in plasma in Fig. 3.4.9 it is elevated in both NSCLC and SCLC 
compared to the normal and benign lung disease control groups, though only the 
comparisons between normal and NSCLC, and normal and SCLC, are statistically 
significant. The conclusion can be made that PKM2 is increased in lung cancer 
serum and plasma compared to controls, and in the case of serum increased in both 
early-stage and late-stage lung cancers. 
The biochemical assay measures pyruvate kinase activity by calculating the amount 
of pyruvate produced in a particular time-frame. Pyruvate kinase activity could be 
down in serum due to a lack of available substrate in the cancer serum. 
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An ELISA was performed for HSC70-interacting protein in serum (Fig. 3.4.11) 
comparing normal and late-stage SCC, AD, and SCLC. Although raised in all 
cancer serum compared to normal the biggest difference (and with a T-test less than 
0.01) was seen between normal and AD. The levels in AD were almost double that 
in normal; in normal the average was 554pg/ml and the median was 502pg/ml while 
in AD they were 1089pg/ml and 759pg/ml respectively. In normal the minimum 
quantity was 278pg/ml and the maximum 1007pg/ml, while in AD they were 
353pg/ml and 2496pg/ml respectively. Comparing the AD results to the normal 
results the ROC curve analysis showed sensitivity of 55.6% and specificity of 
90.0%. The t-test score for AD versus SCC was better than that for Normal versus 
SCC (0.097 compared to 0.208 respectively), and ROC curve analysis comparing 
AD and SCC showed sensitivity of 93.3% and specificity of 38.5%. Hip shows 
some potential as a lung cancer biomarker, though perhaps only useful for 
adenocarcinoma. 
 
Figure 3.4.12 shows how useful the three biomarkers (hnRNPA2B1, PKM2, Hip) 
would be when combined as a panel to determine normal serum from lung cancer 
serum. Although the combination of three can predict 81.58% of cases with an 
AUC value of 0.875 and a combination of just hnRNPA2B1 and PKM2 can predict 
78.48% with an AUC value of 0.831 it should be noted that the combination of the 
latter was performed in a much larger sample set i.e. 20 normal and 59 cancer, 
compared to 8 normal and 30 cancer. 
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                        Figure 3.4.1:  2D-DIGE experiment Master Gel showing the nine proteins brought forward to the validation phase;  
(1) Triosephosphate isomerise, (2) Pyruvate kinase M2, (3) Peroxiredoxin 3, (4) Peroxiredoin 2, (5) Peroxiredoxin 3, 
(6) Hsc70-interacting protein, (7) hnRNPA2B1, (8) Lactate dehydrogenase, and (9) Glyceraldehyde-3-phosphate. 
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Figure 3.4.1: hnRNPA2B1 ELISA: Bar chart and Box and Whisker Plot showing 
normal compared to each late-stage lung cancer type. For box and whisker the box 
represents the interquartile range, the horizontal line the median, and the whiskers 
the highest and lowest quartiles. Patient serum samples used for this experiment 
included 20 normal, 20 squamous, 20 adenocarcinoma, and 19 small cell 
carcinoma. T-test score; Normal v SCC (p value=0.006), Normal v AD (p 
value=0.01), and Normal v SCLC (p value=0.04).  
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Figure 3.4.2: ELISA performed on hnRNPA2B1 showing the distribution of every 
data point. Patient serum samples used for this experiment included 20 normal, 20 
squamous, 20 adenocarcinoma, and 19 small cell carcinoma. This is the same 
ELISA as seen in Figure 3.4.1. 
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Figure 3.4.3: hnRNPA2B1 ELISA ROC Curve with sensitivity, specificity, and 
cut-off value in brackets respectively for statistically significant comparisons (A) 
Squamous versus Normal (85.0%, 80.0%, 0.0051ng/ml) (B) Adenocarcinoma 
versus Normal (65.0%, 80.0%, 0.0051ng/ml) (C) Small cell carcinoma versus 
normal (63.2%, 95.0%, 0.0188ng/ml) (D) Lung cancer versus Normal (72.9%, 
80.0%, 0.0051ng/ml). X-axis refers to the true positive rate, the y-axis to the false 
positive rate. 
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Figure 3.4.4: hnRNPA2B1 ELISA: Bar chart and Box and Whisker Plot showing 
normal compared to each late-stage lung cancer type. For box and whisker the box 
represents the interquartile range, the horizontal line the median, and the whiskers 
the highest and lowest quartiles. Patient serum samples used for this experiment 
included 16 normal, 15 squamous, 26 adenocarcinoma, and 19 small cell 
carcinoma. T-test score; Normal v SCC (p value=0.002), Normal v AD (p 
value=0.0005), and Normal v SCLC (p value=0.001).   
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Figure 3.4.5: hnRNPA2B1 ELISA: Bar chart and Box and Whisker Plot for two 
ELISA’s combined. For box and whisker the box represents the interquartile range, 
the horizontal line the median, and the whiskers the highest and lowest quartiles. 
Patient plasma samples used for this experiment included 30 normal, 39 benign 
lung disease, 60 early-stage NSCLC, and 14 early-stage SCLC. T-test score; 
Normal v BLD (p value=3.8E-05), Normal v NSCLC (p value=0.001), Normal v 
SCLC (p value=0.01), BLD v NSCLC (p value=0.05). 
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Figure 3.4.6: hnRNPA2B1 ELISA: Bar chart and Box and Whisker Plot for 
matching early-stage cancer serum and early-stage cancer plasma from the same 
patients. For box and whisker the box represents the interquartile range, the 
horizontal line the median, and the whiskers the highest and lowest quartiles. 
Patient samples used for this experiment included 18 benign lung disease plasma, 
18 benign lung disease serum, 22 cancer plasma, and 22 cancer serum. 
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Figure 3.4.7: PKM2 ELISA: Bar chart and Box and Whisker Plot showing normal 
compared to late-stage lung cancer. For box and whisker the box represents the 
interquartile range, the horizontal line the median, and the whiskers the highest and 
lowest quartiles. Patient serum samples used for this experiment included 20 
normal, 20 squamous, 20 adenocarcinoma, and 20 small cell carcinoma.  
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Figure 3.4.8: PKM2 ELISA: Bar chart and Box and Whisker Plot for PKM2 
ELISA. For box and whisker the box represents the interquartile range, the 
horizontal line the median, and the whiskers the highest and lowest quartiles. 
Patient serum samples used for this experiment included 16 normal, 16 
autoimmune, 19 benign lung disease, and 25 early-stage lung cancer. T-test score; 
Normal v Lung Cancer (p value=0.001), BLD v Lung Cancer (p value=0.04). 
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Figure 3.4.9: PKM2 ELISA: Bar chart and Box and Whisker Plot for two ELISAs 
combined. For box and whisker the box represents the interquartile range, the 
horizontal line the median, and the whiskers the highest and lowest quartiles. 
Patient plasma samples used for this experiment included 30 normal, 29 benign 
lung disease, 60 early-stage NSCLC and 14 early-stage SCLC. T-test value; Normal 
v NSCLC (p value=0.01), Normal v SCLC (p value=0.03). 
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Figure 3.4.10: Pyruvate Kinase Biochemical Activity Assay: Bar chart and box and 
whisker showing normal compared to each late-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the median, 
and the whiskers the highest and lowest quartiles. Patient serum samples used for 
this experiment included 20 normal, 16 squamous, 17 adenocarcinoma, and 5 small 
cell carcinoma. T-test score; Normal v SCC (p value=6.6E-08), Normal v AD (p 
value=0.01), Normal v SCLC (p value=0.0005). 
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Figure 3.4.11: HSC70-interacting protein ELISA: Bar chart and box and whisker 
showing normal compared to late-stage lung cancer type. For box and whisker the 
box represents the interquartile range, the horizontal line the median, and the 
whiskers the highest and lowest quartiles.Patient serum samples used for this 
experiment included 20 normal, 16 squamous, 28 adenocarcinoma, and 16 small 
cell carcinoma. T-test score; Normal v AD (p value=0.006). 
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Figure 3.4.12:  Logistic regression performed on matching serum patient samples 
(A) combining ELISA results from hnRNPA2B1, HSC70-interacting protein, and 
PKM2 with 8 matching normal and 30 matching cancer samples, indicating 81.58% 
of cases would be correctly classified with an AUC value of 0.875, and (B) 
combining ELISA results from hnRNPA2B1 and PKM2 with 20 matching normal 
and 59 matching cancer samples, indicating 78.48% of cases would be correctly 
classified with an AUC value of 0.831. 
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3.4.2 Peroxiredoxins, Lactate Dehydrogenase, GAPDH, and 
Triosephosphate Isomerase show little potential as possible Lung Cancer 
Biomarkers 
 
Serum ELISAs were performed for Peroxiredoxins 1, 2, and 3 comparing normal to 
late-stage lung cancer. For Prx 2 (Fig. 3.4.14) there were 20 samples for each of the 
cancers, whereas there were only five SCLC for Prx 1 ELISA (Fig. 3.4.13) and 
eight SCLC for Prx 3 ELISA (Fig. 3.4.15). All three peroxiredoxins were decreased 
in cancer serum compared to normal, though for Prx 3 the differences were 
negligible. In the Prx 1 ELISA the difference between the normal group and both 
the SCC and AD group was statistically significant; however there were only five 
SCLC serum samples available at the time compared to 21 for SCC and 20 for AD 
so the small sample set would affect the statistical comparison of SCLC versus 
normal group of 19 samples. In the Prx 2 ELISA the difference between the normal 
group and both SCC and SCLC were statistically significant.  
Although peroxiredoxins often have elevated expression in lung cancer tissue 
compared to normal lung tissue perhaps the decrease of Prx 1 and Prx 2 in lung 
cancer serum has significance. If cancer serum has more reactive oxygen species 
than normal serum then any peroxiredoxins in the serum could be depleted as they 
attack these oxygen derived molecules. It could be interesting to examine the three 
peroxiredoxins in early-stage lung cancer serum because if their levels are elevated 
in this serum they could act as markers of disease progression. 
The LDH assay (Fig. 3.4.16) shows higher levels in cancer serum compared to 
normal serum. This result was expected as LDH is known to be raised in many 
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cancers. This lack of specificity throws doubt on its usefulness as a lung cancer 
biomarker. 
Both the GAPDH and triosephosphate isomerise serum assays (Fig. 3.4.17 and 
3.4.18 respectively) showed little to no change in lung cancer compared to normal. 
Triosephosphate isomerise shows no potential as a lung cancer biomarker while the 
GAPDH assay could be treated as a loading control, as it indicated similar protein 
content throughout all serum samples used in this assay. 
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Figure 3.4.13: Peroxiredoxin 1 ELISA: Bar chart and box and whisker showing 
normal compared to late-stage lung cancer type. For box and whisker the box 
represents the interquartile range, the horizontal line the median, and the whiskers 
the highest and lowest quartiles. Patient serum samples used for this experiment 
included 19 normal, 21 squamous, 20 adenocarcinoma, and 5 small cell carcinoma. 
T-test score; Normal v SCC (p value=0.0002), Normal v AD (p value=0.002). 
 151
Peroxiredoxin 2 Serum ELISA
0
100
200
300
400
500
600
700
800
900
1000
Normal Squamous Adeno Small cell
pg
/m
l
 
 
 
Peroxiredoxin 2 Serum ELISA
0
100
200
300
400
500
600
700
800
Normal Squamous Adeno Small cell
pg
/m
l
**
*
 
 
Figure 3.4.14: Peroxiredoxin 2 ELISA: Bar chart and box and whisker plot 
showing normal compared to late-stage lung cancer type. For box and whisker the 
box represents the interquartile range, the horizontal line the median, and the 
whiskers the highest and lowest quartiles. Patient serum samples used for this 
experiment included 19 normal, 20 squamous, 20 adenocarcinoma and 20 small cell 
carcinoma. T-test score; Normal v SCC (p value=0.01), Normal v SCLC (p 
value=0.02). 
 152
Peroxiredoxin 3 Serum ELISA
0
5
10
15
20
25
Normal Squamous Adeno Small cell
ng
/m
l
 
 
Peroxiredoxin 3 Serum ELISA
0
5
10
15
20
25
30
35
40
45
Normal Squamous Adeno Small cell
N
g/
m
l
 
 
Figure 3.4.15: Peroxiredoxin 3 ELISA: Bar chart and box and whisker plot 
showing normal compared to late-stage lung cancer type. For box and whisker the 
box represents the interquartile range, the horizontal line the median, and the 
whiskers the highest and lowest quartiles. Patient serum samples used for this 
experiment included 20 normal, 21 squamous, 24 adenocarcinoma and 8 small cell 
carcinoma. 
 153
Lactate Dehydrogenase Serum Assay
0
200
400
600
800
1000
1200
1400
1600
1800
Normal Squamous Adeno Small cell
IU
/L
 
 
Lactate Dehydrogenase Serum Assay
0
500
1000
1500
2000
2500
3000
Normal Squamous Adeno Small cell
IU
/L
*
**
**
 
Figure 3.4.16: Lactate dehydrogenase ELISA: Bar chart and box and whisker plot 
showing normal compared to late-stage lung cancer type. For box and whisker the 
box represents the interquartile range, the horizontal line the median, and the 
whiskers the highest and lowest quartiles. Patient serum samples used for this 
experiment included 20 normal, 19 squamous, 28 adenocarcinoma and 12 small cell 
carcinoma. T-test value; Normal v SCC (p value=0.03), Normal v AD (p 
value=0.01), Normal v SCLC (p value=5E-05).  
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Figure 3.4.17: Glyceraldehyde-3-phosphate dehydrogenase ELISA: Bar chart and 
box and whisker plot showing normal compared to late-stage lung cancer. For box 
and whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles.  Patient serum samples 
used for this experiment included 12 normal and 74 lung cancer samples.  
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Figure 3.4.18: Triosephosphate isomerase ELISA: Bar chart and box and whisker 
plot showing normal compared to late-stage lung cancer type. For box and whisker 
the box represents the interquartile range, the horizontal line the median, and the 
whiskers the highest and lowest quartiles.Patient serum samples used for this 
experiment included 19 normal, 18 squamous, 18 adenocarcinoma and 16 small cell 
carcinoma. 
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3.5 Immunohistochemistry Analysis of hnRNPA2B1, PKM2, and Hip 
 
Immunohistochemistry (IHC) was performed on tissue slides to examine the 
staining intensity level for some of the interesting proteins from the conditioned 
media study. IHC can be used in the routine diagnosis of lung cancer in order to 
identify biological markers. In cancer diagnostics IHC can provide information on 
protein expression on top of tissue morphology and can be used as criteria for 
verification or rejection of a tentative diagnosis. Quantitative evaluation of protein 
levels in tumour samples is challenging, with technical issues arising related to 
immunohistochemistry procedure and subjectivity of assessment. Due to the 
significant heterogeneity that can be seen in small amounts of lung cancer tumour 
specimens, such as those frequently obtained in advanced lung cancer, they may not 
be representative of the tumour itself (Taillade, Penault-Llorca et al. 2007).  
 
Immunohistochemistry was performed on Human Lung cancer Tissue slides using 
antibodies for hnRNPA2B1, HSC70-interacting protein, and pyruvate kinase M2. 
Optimisation determined antibody for hnRNPA2B1, Hip, and PKM2 should be 
diluted to 1:1600, 1:7500, and 1:50 respectively. Antibodies used were a mouse 
monoclonal to hnRNPA2B1 from Abcam (ab6102), a mouse monoclonal to Hip 
from Abcam (ab98960), and a rabbit polyclonal to PKM2 from Abcam (ab38237). 
The tissue slides contained tissue cores from adenocarcinoma, squamous cell 
carcinoma, small cell carcinoma, and normal lung tissue. 
 
A mixed tissue slide was also used for hnRNPA2B1 immunohistochemistry 
analysis. This mixed tissue slide contained tissue spots for lung, colon, breast, 
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prostate, and pancreas cancers, as well as respective normal tissue (and for some 
cancer adjacent to normal tissue). All five cancers show similar levels with the 
majority of staining either intensity 3 or 2. For example 88% of colon AD, 66.66% 
of breast invasive duct carcinoma, 79.16% of prostate AD, 84% of pancreas AD, 
100% of lung SCC and 93.33% of lung AD are scored as a 3 or a 2. 
 
An intensity score of 1, 2, or 3, relating to staining that is weak, intermediate, or 
strong respectively, was assigned to each spot by a qualified person. 
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Figure 3.5.1: hnRNPA2B1 immunohistochemistry performed on lung cancer tissue 
array slide. Representative images show staining of normal lung tissue samples (A-
C). Magnification, 40X. Scale Bar, 100µm. 
 
A.                                                                   B. 
         
 
Figure 3.5.2: Staining for negative control (primary antibody omitted): 
Immunohistochemistry performed on lung cancer tissue array slide. Representative 
images show Grade 4 small cell lung cancer tissue samples (A+B). Magnification, 
40X. Scale Bar, 100µm. 
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Figure 3.5.3: hnRNPA2B1 immunohistochemistry performed on lung cancer tissue 
array slide. Representative images show staining of squamous cell carcinoma lung 
cancer samples (A-E). Magnification, 40X. Scale Bar, 100µm. 
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Figure 3.5.4: hnRNPA2B1 immunohistochemistry performed on lung cancer tissue 
array slide. Representative images (A-E) show staining of adenocarcinoma lung 
cancer samples. Magnification, 40X. Scale Bar, 100µm. 
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Figure 3.5.5: hnRNPA2B1 immunohistochemistry performed on lung cancer tissue 
array slide. Representative images show staining of Grade 4 (A-E) small cell lung 
cancer samples. Magnification, 40X. Scale Bar, 100µm. 
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Table 3.5.1: Intensity Scoring for immunohistochemistry of hnRNPA2B1 on Lung 
Cancer Tissue Slide. Scoring of 1, 2, and 3 relates to weak staining, intermediate 
staining, and strong staining, respectively. An intensity score with a “V” means 
there was variation in the staining. The percentage of total tissue cores with that 
particular intensity score is shown in brackets. 
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A.                                                                  B. 
 
       
 
 
 
Figure 3.5.6: hnRNPA2B1 immunohistochemistry performed on mixed tissue array 
slide. Representative images show staining of normal colon tissue (A+B). 
Magnification, 40X. Scale Bar, 100µm. 
 
 
A.                                                                   B. 
 
         
 
 
 
 
Figure 3.5.7: hnRNPA2B1 immunohistochemistry performed on mixed tissue array 
slide. Representative images show staining of cancer tissue adjacent to normal 
colon tissue (A+B). Magnification, 40X. Scale Bar, 100µm. 
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A.                                                                    B. 
 
       
 
 
 
 
C.                                                                    D. 
 
        
 
 
 
Figure 3.5.8: hnRNPA2B1 immunohistochemistry performed on mixed tissue array 
slide. Representative images show staining of colon adenocarcinoma cancer tissue. 
(A) Grade 1 Stage II (B) Grade 1 Stage II (C) Grade 2 Stage II (D) Grade 3 Stage 
III Magnification, 40X. Scale Bar, 100µm. 
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A.                                                                     B. 
          
 
 
 
Figure 3.5.9: hnRNPA2B1 immunohistochemistry performed on mixed tissue array 
slide. Representative images show staining of normal breast tissue (A+B). 
Magnification, 40X. Scale Bar, 100µm. 
 
 
A.                                                                    B. 
          
 
 
 
 
Figure 3.5.10: hnRNPA2B1 immunohistochemistry performed on mixed tissue 
array slide. Representative images show staining of cancer tissue adjacent to normal 
breast tissue (A+B). Magnification, 40X. Scale Bar, 100µm. 
 
 
 
 166
A.                                                                    B. 
       
 
 
 
 
C.                                                                    D. 
 
       
 
 
 
Figure 3.5.11: hnRNPA2B1 immunohistochemistry performed on mixed tissue 
array slide. Representative images show staining of breast invasive ductal 
carcinoma cancer tissue. (A) Grade 1 Stage IIb (B) Grade 1 Stage IIa (C) Grade 2 
Stage IIa (D) Grade 3 Stage IIb Magnification, 40X. Scale Bar, 100µm. 
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A.                                                                   B. 
         
 
 
 
Figure 3.5.12: hnRNPA2B1 immunohistochemistry performed on mixed tissue 
array slide. Representative images show staining of normal prostate tissue (A+B). 
Magnification, 40X. Scale Bar, 100µm. 
 
 
 
 
A.                                                                    B. 
 
          
 
 
 
Figure 3.5.13: hnRNPA2B1 immunohistochemistry performed on mixed tissue 
array slide. Representative images show staining of cancer adjacent to normal 
prostate tissue (A+B). Magnification, 40X. Scale Bar, 100µm. 
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A.                                                                     B. 
          
 
 
 
 
C.                                                                    D. 
 
          
 
 
 
Figure 3.5.14: hnRNPA2B1 immunohistochemistry performed on mixed tissue 
array slide. Representative images show staining of prostate adenocarcinoma cancer 
tissue. (A) Grade 1 Stage II (B) Grade 2 Stage III (C) Grade 2 Stage II (D) Grade 3 
Stage IV Magnification, 40X. Scale Bar, 100µm. 
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A.                                                                  B. 
        
 
 
C.                                                                  D. 
 
        
 
 
 
 
Figure 3.5.15: hnRNPA2B1 immunohistochemistry performed on mixed tissue 
array slide. Representative images show staining of normal pancreas tissue (A-D). 
Magnification, 40X. Scale Bar, 100µm. 
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A.                                                                    B. 
 
       
 
 
 
 
C.                                                                    D. 
 
       
 
 
 
 
 
Figure 3.5.16: hnRNPA2B1 immunohistochemistry performed on mixed tissue 
array slide. Representative images show staining of pancreas duct adenocarcinoma 
cancer tissue. (A) Grade 1-2 Stage II (B) Grade 1-2 Stage II (C) Grade 2 Stage II 
(D) Grade 2-3 Stage I Magnification, 40X. Scale Bar, 100µm. 
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A.                                                                    B. 
       
 
 
 
 
C.                                                                    D. 
 
       
 
 
 
 
Figure 3.5.17: hnRNPA2B1 immunohistochemistry performed on mixed tissue 
array slide. Representative images show staining of normal lung tissue. (A) staining 
on tissue spot in benign cancer tissue (B) staining on tissue spot in benign cancer 
tissue (C) normal lung tissue with congestion (D) normal lung tissue with 
congestion. Magnification, 40X. Scale Bar, 100µm. 
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A.                                                                    B. 
       
 
 
 
 
C.                                                                    D. 
 
       
 
 
 
 
Figure 3.5.18: hnRNPA2B1 immunohistochemistry performed on mixed tissue 
array slide. Representative images show staining of lung adenocarcinoma cancer 
tissue. (A) Grade 1 Stage II (B) Grade 2 Stage I (C) Grade 1 Stage IIIa (D) Grade 2 
Stage IIIa. Magnification, 40X. Scale Bar, 100µm. 
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A.                                                                    B. 
       
 
 
 
 
C.                                                                     D. 
 
       
 
 
 
 
Figure 3.5.19: hnRNPA2B1 immunohistochemistry performed on mixed tissue 
array slide. Representative images show staining of lung squamous cell carcinoma 
tissue. (A) Grade 1 Stage I (B) Grade 1 Stage IIIb (C) Grade 2 Stage I (D) Grade 3 
Stage II. Magnification, 40X. Scale Bar, 100µm. 
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Table 3.5.2: Intensity Scoring for immunohistochemistry of hnRNPA2B1 on 
Mixed Tissue Array Slide. Scoring of 1, 2, and 3 relates to weak staining, 
intermediate staining, and strong staining, respectively. The percentage of total 
tissue cores with that particular intensity score is shown in brackets. 
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A.                                                                    B. 
       
 
 
 
 
C.                                                                    D. 
       
 
 
 
 
Figure 3.5.20: HSC70-interacting protein immunohistochemistry performed on 
lung tissue array slide. Representative images show staining of normal lung tissue 
(A-D). Magnification, 40X. Scale Bar, 200µm. 
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A.                                                                    B. 
       
 
 
 
C.                                                                    D. 
       
 
 
 
Figure 3.5.21: HSC70-interacting protein immunohistochemistry performed on 
lung tissue array slide. Representative images show staining of lung squamous cell 
carcinoma tissue. (A) Grade 1 (B) Grade 2 (C) Grade 3 (D) Grade 3. Magnification, 
40X. Scale Bar, 200µm. 
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A.                                                                    B. 
       
 
 
 
 
C.                                                                    D. 
       
 
 
       
 
Figure 3.5.22: HSC70-interacting protein immunohistochemistry performed on 
lung tissue array slide. Representative images show staining of lung 
adenocarcinoma tissue. (A) Grade 1 (B) Grade 2 (C) Grade 3 (D) Grade 3. 
Magnification, 40X. Scale Bar, 200µm. 
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A.                                                                    B. 
       
 
 
 
 
C.                                                                    D. 
       
 
 
 
 
Figure 3.5.23: HSC70-interacting protein immunohistochemistry performed on 
lung tissue array slide. Representative images show staining of Grade 4 small cell 
lung carcinoma (A-D). Magnification, 40X. Scale Bar, 200µm. 
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Table 3.5.3: Intensity Scoring for immunohistochemistry of HSC70-interacting 
Protein on Lung Cancer Tissue Slide. Scoring of 1, 2, and 3 relates to weak 
staining, intermediate staining, and strong staining, respectively. The percentage of 
total tissue cores with that particular intensity score is shown in brackets. 
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A.                                                                    B. 
          
 
Figure 3.5.24: PKM2 immunohistochemistry performed on lung tissue array slide. 
Representative images show staining of normal lung tissue (A+B). Magnification, 
40X. Scale Bar, 200µm. 
 
 
 
A.                                                                    B. 
       
 
 
Figure 3.5.25: PKM2 immunohistochemistry performed on lung tissue array slide. 
Representative images show staining of squamous cell carcinoma. (A) Grade 1 (B) 
Grade 3. Magnification, 40X. Scale Bar, 200µm. 
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A.                                                                    B. 
       
 
Figure 3.5.26: PKM2 immunohistochemistry performed on lung tissue array slide. 
Representative images show staining of Grade 3 adenocarcinoma (A+B). 
Magnification, 40X. Scale Bar, 200µm. 
 
 
 
A.                                                                    B. 
       
 
 
 
Figure 3.5.27: PKM2 immunohistochemistry performed on lung tissue array slide. 
Representative images show staining of Grade 4 small cell carcinoma (A+B). 
Magnification, 40X. Scale Bar, 200µm. 
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Table 3.5.4: Intensity Scoring for immunohistochemistry of PKM2 on Lung Cancer 
Tissue Slide. Scoring of 1, 2, and 3 relates to weak staining, intermediate staining, 
and strong staining, respectively. The percentage of total tissue cores with that 
particular intensity score is shown in brackets. 
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3.6 Functional Assays 
 
The results from the 2D-DIGE Decyder study on conditioned media, and the 
subsequent validation in biological fluids and tissue cores indicated the 
hnRNPA2B1 protein had potential as a marker for lung cancer; however these 
results give little indication of the role this protein may play in the progression of 
the cancer itself. The invasion and migration of neoplastic cells (normal cells will 
undergo apoptosis after detachment) allows these cells to enter lymphatic and blood 
vessels for dissemination into the circulation and subsequently undergo metastatic 
growth in distant organs. This formation of a metastasis is the main cause of death 
for cancer patients. 
 
Invasion and migration assays are used to show how a change to the cancer cells 
will affect their ability to behave in a metastatic manner. Invasion assays give an 
indication of how well the cancer cells, under particular conditions, would move 
through tissue boundaries, a trait that separates benign from malignant lesions. 
Matrigel is used in the Boyden chamber to resemble the complex extracellular 
environment found in many tissues. Migration assays are set up the same as 
invasion, the only difference being (apart from the optimised cell count) that 
matrigel is NOT added to the chamber, and measure the motility of cancer cells 
under particular conditions. 
 
In this case the effect of knocking down the protein of interest on invasion and 
migration of cancer cells was examined. The lung squamous cell carcinoma cell line 
DLKP-M was chosen. Small interfering RNAs (siRNA) are used to suppress gene 
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expression of hnRNPA2B1; these 20-25 nucleotide double-stranded RNAs reduce 
expression of its corresponding gene. This potent inhibition of gene expression is 
achieved by transfection of the siRNA, a method by which the siRNA are delivered 
into the cancer cells.  
 
As per Materials and Methods the transfection conditions were optimised before 
setting up invasion and migration assays. Control wells are used to show the effect, 
if any, of; (i) the experiment on untreated cells, (ii) transfection reagent on the cells, 
(iii) kinesin knockdown on the cells, and (iv) knocking down a random gene 
through the use of relative scrambled siRNA. Two siRNAs for hnRNPA2B1 were 
used to confirm the consistency of results. To assess whether any changes witnessed 
were caused by the proliferation of the cells and not as a result of gene knockdown, 
a proliferation assay was performed. Western blot analysis was performed to check 
if the knockdown was successful. 
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hnRNPA2B1 
  
α-tubulin 
 
 
 
 
Figure 3.6.1: Western blot analysis of whole cell lysates of DLKP-M transfected 
cells. A reduction in the levels of hnRNPA2B1 can be seen in the two knockdown 
siRNAs s6713 and s6715 when compared to the untreated control, NeoFx only and 
scrambled siRNA controls. (15µg protein loaded per lane). 
 
 
 
 
 
 
Control NeoFx Scr s6713 s6715 
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Figure 3.6.2: Proliferation assay performed on five conditions from invasion and 
migration assays. Proliferation of DLKP-M cells does not change under any of the 
conditions. 
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Figure 3.6.3: Histogram showing effect of hnRNPA2B1 knockdown on invasive 
behaviour of DLKP-M cells. Twenty-four hours post-transfection with 
hnRNPA2B1 siRNAs, invasion assays on DLKP-M were performed. Both siRNA 
#1 (s6713) and siRNA #2 (s6715) transfected cells show a significant decrease in 
invasion levels. T-test values; Scrambled versus siRNA#1 (p value = 4E-13), 
Scrambled versus siRNA#2 (p value = 6E-08). 
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A. Untreated Control                         B. NeoFx Only Control 
           
 
 
C. Scrambled siRNA Control 
 
  
 
 
D. hnRNPA2B1 siRNA #1                E. hnRNPA2B1 siRNA #2 
 
          
 
 
Figure 3.6.4: Representative photomicrographs showing invasion status of DLKP-
M cells following transfection of hnRNPA2B1 siRNAs. (A) Untreated control (B) 
NeoFx only control (C) Scrambled siRNA control (D) hnRNPA2B1 siRNA #1 (E) 
hnRNPA2B1 siRNA #2. Inhibition of invasion can be seen in D and E. 
Magnification 40X. Scale Bar, 500µm. 
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Figure 3.6.5: Histogram showing effect of hnRNPA2B1 knockdown on migration 
behaviour of DLKP-M cells. Twenty-four hours post-transfection with 
hnRNPA2B1 siRNAs, migration assays on DLKP-M were performed. Both siRNA 
#1 (s6713) and siRNA #2 (s6715) transfected cells show a decrease in migration 
levels. T-test score; Scrambled versus siRNA#1 (p value = 2E-06), Scrambled 
versus siRNA#2 (p value =  4E-08). 
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A. Untreated Control                                  B. NeoFx Only Control 
              
 
 
C. Scrambled siRNA Control 
 
 
 
 
D. hnRNPA2B1 siRNA #1                        E. hnRNPA2B1 siRNA #2 
 
             
 
Figure 3.6.6: Representative photomicrographs showing migration status of DLKP-
M cells following transfection of hnRNPA2B1 siRNAs. (A) Untreated control (B) 
NeoFx only control (C) Scrambled siRNA control (D) hnRNPA2B1 siRNA #1 (E) 
hnRNPA2B1 siRNA #2. Inhibition of migration can be seen in D and E, but also in 
the scrambled control C. Magnification 40X. Scale Bar, 500µm. 
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3.6.1 Effect of knockdown of hnRNPA2B1 on Invasion and Migration of 
DLKP-M lung Cancer Cells. 
 
Knockdown of the hnRNPA2B1 gene in lung cancer cell line DLKP-M using two 
separate siRNAs was successful (Fig. 3.6.1), and had little effect on proliferation of 
cancer cells (Fig. 3.6.2).  
The knockdown of hnRNPA2B1 had an effect on both invasion and migration. For 
the two siRNAs used, s6713 and s6715, it resulted in a 57% and a 44% decrease in 
invasion respectively when compared to the scrambled control (Fig. 3.6.3) and a 
32% and 39% decrease in migration respectively when compared to scrambled 
control (Fig. 3.6.5). 
hnRNPA2B1 certainly has a role to play in the migration and invasion of lung 
cancer cells further indicating its potential as a biomarker and also perhaps as a drug 
target to inhibit tumour growth.  
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CHAPTER FOUR 
 
LUNG CANCER BIOMARKER DISCOVERY FROM 2D-DIGE OF 
IMMUNODEPLETED SERUM 
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4.1 Background 
 
The 2D-DIGE analysis of conditioned media of lung cancer cell lines proved to be a 
relatively useful model for the discovery of lung cancer biomarkers. However, as 
this was just a model the ratio difference between abundance levels of proteins 
shown in the DyCyder software analysis between comparisons did not translate 
accurately to ELISA/biochemical assay analysis of clinical samples. This result was 
not unusual and was somewhat expected. Cell lines grown in culture will never 
secrete and/or leak proteins into the conditioned media in the same manner a 
tumour would into the microenvironment in vivo. Add to this the added complexity 
of serum compared to the conditioned media and it is understandable that potential 
biomarkers from in vitro models have no real significance until validated in 
biological samples or tumour tissue. 
 
Instead of depending on a model, examining the biological sample directly (in this 
case serum) may prove more useful for finding biomarkers that will validate later in 
larger cohorts of clinical samples. Instead of performing 2D-DIGE on conditioned 
media why not perform 2D-DIGE on serum directly? Unfortunately, however, 
serum has far more complex protein content than conditioned media. High abundant 
proteins such as albumin and transferrin in the serum will mask any low abundant 
markers and have to be removed. For this immunodepletion kits are used, such as 
ProteoPrep 20, which specifically removes 20 of the most abundant proteins from 
human serum or plasma using small recombinant immunoaffinity ligands and 
conventional antibodies. The immunodepletion kit is supposed to remove 97-98% 
of total protein mass in human serum 
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4.2 2D-DIGE of Immunodepleted Serum 
 
An initial 2D-DIGE experiment was performed on ten immunodepleted serum 
samples from adenocarcinoma patients and ten immunodepleted serum samples 
from normal healthy patients. Five normal and five adenocarcinoma samples were 
labelled with the Cy3 fluorophore and five normal and five adenocarcinoma 
samples were labelled with the Cy5 fluorophore to remove bias. Unfortunately the 
only proteins identified were high abundant proteins (See Table 4.2.1). A number of 
proteins were identified more than once, showing varying fold changes, for example 
alpha-1-antitrypsin, haptoglobin, leucine-rich alpha-2-glycoprotein, transferrin, and 
zinc-alpha-2-glycoprotein. This was an indication that a number of isoforms from 
the same protein had been identified. 
 
The most interesting result from Table 4.2.1 (following page) was that for the 
haptoglobin isoforms. The six isoforms of haptoglobin in adenocarcinoma serum 
showed higher fold changes when compared to their counterparts in normal serum. 
Interestingly the highest fold change was seen in the isoform of highest molecular 
weight, the second highest fold change in the isoform of second highest molecular 
weight, and so on for the six isoforms. Alpha-1-trypsin showed a similar trend but 
for only four isoforms. Transferrin also showed a trend for four isoforms though 
these were up-regulated in normal compared to adenocarcinoma. The haptoglobin 
isoforms were also the most statistically significant. 
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Table 4.2.1: 2D-DIGE Analysis of Immunodepleted Adenocarcinoma and Normal 
Serum. Multiple identifications for the same protein indicate multiple isoforms of 
that protein. A positive fold change indicates an increase in lung adenocarcinoma 
and a negative fold change indicates a decrease in adenocarcinoma for this protein, 
or its isoform, compared to normal control serum. 
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4.3 Analysis of Haptoglobin Isoforms in Raw Serum using Coomaisse 
Stained Gels 
 
The haptoglobin isoform pattern seen in Table 4.2.1 could possibly be used itself as 
a biomarker. 2D-DIGE and immunodepletion however are time-consuming and 
expensive so could not be applied routinely in a clinical setting. Ideally this pattern 
could be picked up in gels stained with Coomaisse blue, a far quicker and cheaper 
alternative to 2D-DIGE for protein staining/labelling. If diluted raw serum was used 
(10µl of serum diluted in 440µl of rehydration buffer) again it would be a quicker 
and cheaper alternative to using immunodepletion columns, the high dilution 
hopefully lessening the masking effects of the high abundant proteins. 
 
In total forty-eight 2D gels were stained with coomaisse before being scanned with 
the Typhoon and imported into the DeCyder software. The gels included eight 
normal, eight lung adenocarcinoma, eight lung squamous, eight breast cancer, and 
eight colorectal cancer serum samples. A table showing the fold change for the six 
isoforms in each cancer type compared to normal was created (Table 4.3.1). 
An ELISA was performed in serum on haptoglobin (Fig. 4.3.3). The average 
quantity of Hp in normal serum was 566 ug/ml whereas in lung cancer it was more 
than four times this quantity for each of the conditions; 2311ug/ml in SCC, 
2313ug/ml in AD, and 2662ug/ml in SCLC, while the median, min, and max results 
were significantly different, showing results of, respectively, 539ug/ml, 189ug/ml, 
and 1148ug/ml for normal, 1675ug/ml, 484ug/ml, and 8449ug/ml for SCC, 
2126ug/ml, 307ug/ml, and 5690ug/ml for AD, and 1711ug/ml, 806ug/ml, and 
9151ug/ml for SCLC. 
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Figure 4.3.1: Progenesis analysis of coomaisse-blue stained 2D gel of diluted raw 
serum highlighted the six isoforms of haptoglobin as identified by mass 
spectrometry. In order of isoform of highest molecular weight to lowest the six 
isoforms from 1-6 in order are spots #169, #201, #234, #268, #300, and #312. 
 
 
 
 
 
 
pH 3 pH 10
MW 200 kDa 
MW 20 kDa 
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To confirm the six isoforms of haptoglobin were glycosylated a glycostain was 
performed. Also an ELISA for haptoglobin was performed on normal serum and 
lung cancer serum for squamous, adenocarcinoma, and small cell carcinoma (Figure 
4.3.3). 
 
 
 
 
Figure 4.3.2: Glycostain of diluted raw serum sample ran on 2D-gel stained with 
Pierce Glycoprotein Staining Kit. Six haptoglobin isoforms circled in red indicating 
that they are glycosylated.  
 
 
 
 199
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3.1: Haptoglobin isoforms: Fold change for each haptoglobin isoform for 
each cancer type compared to normal healthy control for Coomaisse stained gels 
using diluted raw serum that had not been immunodepleted. P value is recorded in 
brackets. 
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Figure 4.3.3: Haptoglobin ELISA: Bar chart and Box and Whisker Plot for normal 
compared to each lung cancer type. For box and whisker the box represents the 
interquartile range, the horizontal line the median, and the whiskers the highest and 
lowest quartiles. Patient serum (not diluted or immunodepleted) samples used for 
this experiment included 20 normal, 21 squamous, 25 adenocarcinoma, and 8 small 
cell carcinoma. T-test scores; Normal v SCC (p value=0.0001), Normal v AD (p 
value=2E-06), Normal v SCLC (p value=0.002).  
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CHAPTER FIVE 
 
LUNG CANCER BIOMARKER DISCOVERY FROM LABEL-FREE MASS 
SPECTROMETRY ANALYSIS OF PROTEOMINER SERUM 
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5.1 Background 
 
Unlike immunodepletion, the ProteoMiner technique decreases the amount of high-
abundant proteins while preventing the loss of proteins bound to them. It enriches 
and concentrates low-abundance proteins by decreasing the dynamic range of the 
overall protein concentration. It uses a large library of hexapeptide ligands with a 
limited number of binding sites that act as unique binders for proteins. Whereas 
immunodepletion will indiscriminately remove the high abundant proteins and any 
smaller proteins bound to it, ProteoMiner attempts to equalise all proteins 
throughout the sample.  
 
In protein-labelling approaches different protein samples are combined together 
once labelling is finished and after sample preparation steps the pooled mixtures are 
analysed by a single LC-MS/MS experiment. In contrast, the label-free quantitative 
method involves preparing each sample separately and then running them 
individually by LC-MS/MS. 
Progenesis LC-MS software allows statistical analysis of the label-free data. Each 
peptide ion in the experiment is automatically detected and quantified, even in 
complex samples such as serum which will have overlapping peptide ions. Peptide 
ion outlines are automatically applied to all runs providing a complete data set for 
analysis. Peptide ions are automatically ranked by ANOVA value and can be 
grouped in multiple ways depending on the data set you want to examine. Using a 
multivariate statistical analysis tool allows confident data exploration and 
visualisation of differentially expressed peptide ions. The user can validate and 
select MS/MS spectra for searches in protein databases such as Mascot or 
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SEQUEST. The imported search results are displayed alongside the differential 
analysis results. Identifications can then be filtered in a number of ways. 
The software will provide a confidence score for the identified protein, as well as 
the number of peptides used for the identification. Proteins of interest can be tagged 
and exported as a group and a simple dropdown menu allows you to view each of 
your created comparison groups. The software shows the fold change between two 
groups and also indicates which group the fold change is increased or decreased in. 
 
5.2 Progenesis Analysis of Label-Free Spectrometry on ProteoMiner 
Serum 
 
The ProteoMiner technique was performed on ten serum samples for each of the 
following groups: normal, squamous cell carcinoma, adenocarcinoma, and small 
cell carcinoma. ProteoMiner samples underwent a 2D-clean-up to remove 
impurities followed by reduction, alkylation, digestion and a C-18 clean-up before 
being dried in speed vac and re-suspended in 40µl of 0.1% TFA in 2% Acn.  
The Progenesis software that analyses results from label-free mass spectrometry 
generates lists of any conceivable comparisons, providing details on protein 
description, fold change, ANOVA value, confidence scores and number of peptides 
identified.  
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Table 5.2.1: Progenesis Analysis of Label-Free Spectrometry on ProteoMiner serum samples showing Lung cancer versus Normal.  
For a particular protein the fold change indicates an increase to the sample set in the ‘Highest Mean’ column. 
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Table 5.2.2: Progenesis Analysis of Label-Free Spectrometry on ProteoMiner serum samples showing Squamous cell carcinoma  
versus Normal. For a particular protein the fold change indicates an increase to the sample set in the ‘Highest Mean’ column. 
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Table 5.2.3: Progenesis Analysis of Label-Free Spectrometry on ProteoMiner serum samples showing Adenocarcinoma   
versus Normal. For a particular protein the fold change indicates an increase to the sample set in the ‘Highest Mean’ column. 
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Table 5.2.4: Progenesis Analysis of Label-Free Spectrometry on ProteoMiner serum samples showing Small cell carcinoma versus  
Normal. For a particular protein the fold change indicates an increase to the sample set in the ‘Highest Mean’ column. 
 
 
 
Table 5.2.5: Progenesis Analysis of Label-Free Spectrometry on ProteoMiner serum samples showing Squamous cell carcinoma  
versus Adenocarcinoma. For a particular protein the fold change indicates an increase to the sample set in the ‘Highest Mean’ column. 
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Table 5.2.6: Progenesis Analysis of Label-Free Spectrometry on ProteoMiner serum samples showing Squamous cell carcinoma  
versus Small cell carcinoma. For a particular protein the fold change indicates an increase to the sample set in the ‘Highest Mean’ column. 
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Table 5.2.7: Progenesis Analysis of Label-Free Spectrometry on ProteoMiner serum samples showing Adenocarcinoma versus 
 Small cell carcinoma. For a particular protein the fold change indicates an increase to the sample set in the ‘Highest Mean’ column. 
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(C)                                                                 (D) 
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Figure 5.2.1: Label-Free Targets from Normal (pink) versus Lung Cancer (blue) 
comparison showing abundance levels of each peptide identified for a particular 
protein. (A) Complement C5 precursor, (B) complement c9 precursor, (C) 
serotransferrin, (D) histidine rich glycoprotein, and (E) Thrombospondin. 
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Figure 5.2.2: Label-Free Targets from Normal (pink) versus Small cell carcinoma 
(blue) comparison showing abundance levels of each peptide identified for a 
particular protein. (A) S100-A9, and (B) L-ficolin. 
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Figure 5.2.3: Label-Free Targets from Normal (pink) versus Adenocarcinoma 
(blue) comparison showing abundance levels of each peptide identified for a 
particular protein. (A) Clusterin precursor, and (B) Kininogen 1. 
 
(A) 
 
 
 
Figure 5.2.4: Label-Free Targets from Adenocarcinoma (pink) versus Squamous 
cell carcinoma (blue) comparison showing abundance levels of each peptide 
identified for a particular protein. (A) Lumican. 
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5.3 Pathway Studio Analysis of Targets from Label-Free Experiment 
 
Pathway Studio pathway analysis software is used to find relationships among 
genes, proteins, cell processes and diseases, to interpret gene expression and other 
high throughput data, to build, expand and analyse pathways, and to create 
diagrams showing the pathway interaction between your proteins of interest. 
Proteins identified from the label-free experiment were put into the Pathway 
Analysis software and of the 64 proteins identified 23 proteins were found to have 
no direct interactions with any other proteins. The remaining 41 proteins are listed 
in Table 5.3.1. 
 
Thrombospondin 1 (THBS1) and kininogen 1 (KNG1) were identified from 
Pathway Studio Analysis as ‘hubs’ of connectivity. In Figure 5.3.1 the diamond 
shape enclosing THBS1 and KNG1 denotes them as ligands, which can be 
described as signal triggering molecules. KNG1 is a constituent of the blood 
coagulation system and THBS1 plays a role in angiogenesis and tumourigenesis.  
A serum ELISA was performed on both THBS1 (Fig. 5.3.3) and KNG1 (Fig. 5.3.4). 
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Table 5.3.1: Protein Key for Pathway Studio Analysis of biomarker targets from 
Label-Free Spectrometry experiment on ProteoMiner serum. 
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Figure 5.3.1: Proteins identified from label-free experiment and their interactions. 
Two major ‘hubs’ of connectivity were identified at KNG1 and THBS1. 
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Figure 5.3.2: Cell Location of proteins identified from label-free experiment and 
their interactions. THBS1 and KNG1 are secreted proteins. 
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Figure 5.3.3: Thrombospondin 1 ELISA: Bar chart and Box and Whisker Plot 
showing normal compared to late-stage lung cancer types. For box and whisker the 
box represents the interquartile range, the horizontal line the median, and the 
whiskers the highest and lowest quartiles. Patient serum samples used for this 
experiment included 20 normal, 13 squamous, 18 adenocarcinoma, and 17 small 
cell lung cancer. 
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Figure 5.3.4: Kininogen 1 ELISA: Bar chart and Box and Whisker Plot showing 
normal compared to late-stage lung cancer types. For box and whisker the box 
represents the interquartile range, the horizontal line the median, and the whiskers 
the highest and lowest quartiles. Patient serum samples used for this experiment 
included 20 normal, 13 squamous, 18 adenocarcinoma, and 17 small cell lung 
cancer. 
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CHAPTER SIX 
 
LUMINEX MULTIPLEX PLATFORM FOR LUNG CANCER BIOMARKER 
DISCOVERY 
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6.1 Background 
 
Multiple potential biomarkers can be quantitatively measured at the same time in 
the same serum or plasma sample using multiplex assay platforms. The sensitivity 
of the instruments means very small quantities of serum/plasma, for example as 
little as 5µl, can be used in a single experiment, a single experiment that may 
examine up to one hundred analytes. Due to cross-reactivity however, only certain 
combinations of analytes can be used in a single experiment, the combinations 
themselves restricted to those panels produced by the manufacturer.  
Luminex multiplex uses coated microspheres, tiny colour-coded polystyrene beads 
with distinct proportions of coloured dyes, to capture and detect the specific analyte 
from a sample. To further validate the results, multiple readings are made on each 
bead set.  
 
6.2 Experimental Design 
 
Previous biomarker discovery techniques used, for example 2D-DIGE of 
conditioned media and immunodepleted serum, and label-free mass spectrometry of 
Proteominer serum, start off relatively blind; there is no way to know what proteins 
may show potential as lung cancer biomarkers, and due to their very nature as basic 
exploratory techniques the results could very well be different if the experiments 
were repeated. For multiplex assay platforms, because the markers are known, 
serum and plasma are used for discovery phase, meaning that those brought forward 
to be validated in larger sample sets can be done so with greater confidence that the 
results will be reproducible. 
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Initial discovery phase included cancer panel 1 with six proteins, cancer panel 2 
with twelve proteins, and the matrix-metalloproteinase (MMP) panel with six 
proteins. From cancer panel 2, epidermal growth factor did not provide results so is 
not included (i.e. no data generated). As the discovery phase was performed over 
multiple plates with multiple cancers, the normal healthy sample size was larger 
than the sample size for any of the lung cancer types (i.e. normal n = 20, SCC n = 9, 
AD n = 9, and SCLC n = 10). All normal samples were performed in duplicate. For 
the cancer samples the majority were run as single samples, only five cancer 
samples ran in duplicate. 
Interesting proteins were brought forward to be examined on the Luminex system in 
a larger cohort of samples. As well as investigating levels in serum, plasma was also 
looked at. Plasma assays include a benign lung disease group and in some serum 
assays performed on earlier stage lung cancer there is an autoimmune control as 
well as a benign lung disease control. 
 
The Luminex multiplex platform reduces cost when panels of a certain size are 
purchased, i.e. the larger the panel the greater the savings. In some cases it was 
cheaper to buy in a separate ELISA for proteins interesting from the discovery 
phase and run them separately, or if further validation was required this was the 
cheaper alternative (e.g. in the case of MMP-8, prolactin, and tenascin C). Also, 
where the possibility presented itself to perform a multiplex assay on a protein not 
present in the discovery phase, a full set of samples was run and results included in 
the validation phase (e.g. MMP-2 and MMP-7). Logistic regression was performed 
on panels of some of the interesting proteins for both serum and plasma, as well as 
on the known cancer biomarkers (e.g. CA-125, CA19-9, and CEA) for comparison. 
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6.3 Luminex Discovery Phase 
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Figure 6.3.1: Alpha-fetoprotein (AFP) and cancer antigen-125 from Cancer 
Panel 1. Bar chart showing normal compared to late-stage lung cancer type. 
Patient serum samples included 20 normal, 9 squamous, 9 adenocarcinoma and 
10 small cell carcinoma. Student’s t-test with p value less than 0.01 is indicated 
by two asterisks (**). 
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Figure 6.3.2: Cancer antigen 15-3 and cancer antigen 19-9 from Cancer Panel 1. 
Bar chart showing normal compared to late-stage lung cancer type. Patient 
serum samples included 20 normal, 9 squamous, 9 adenocarcinoma and 10 small 
cell carcinoma. Student’s t-test with p value less than 0.01 is indicated by two 
asterisks (**). 
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Figure 6.3.3: Carcinoembryonic antigen and prolactin from Cancer Panel 1. Bar 
chart showing normal compared to late-stage lung cancer type. Patient serum 
samples included 20 normal, 9 squamous, 9 adenocarcinoma and 10 small cell 
carcinoma. Student’s t-test with p value less than 0.05 is indicated by a single 
asterisk (*) and p value less than 0.01 is indicated by two asterisks (**). 
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Figure 6.3.4: Amphiregulin and betacellulin from Cancer Panel 2. Bar chart 
showing normal compared to late-stage lung cancer type. Patient serum samples 
included 20 normal, 9 squamous, 9 adenocarcinoma and 10 small cell 
carcinoma. Student’s t-test with p value less than 0.01 is indicated by two 
asterisks (**). 
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Figure 6.3.5: Epidermal growth factor receptor and epiregulin from Cancer 
Panel 2. Bar chart showing normal compared to late-stage lung cancer type. 
Patient serum samples included 20 normal, 9 squamous, 9 adenocarcinoma and 
10 small cell carcinoma. Student’s t-test with p value less than 0.01 is indicated 
by two asterisks (**). 
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Figure 6.3.6: Fibroblast growth factor-basic and heparin-binding epidermal 
growth factor from Cancer Panel 2. Bar chart showing normal compared to late-
stage lung cancer type. Patient serum samples included 20 normal, 9 squamous, 
9 adenocarcinoma and 10 small cell carcinoma. Student’s t-test with p value less 
than 0.05 is indicated by a single asterisk (*) and p value less than 0.01 is 
indicated by two asterisks (**). 
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Figure 6.3.7: Platelet-derived growth factor and placenta growth factor from 
Cancer Panel 2. Bar chart showing normal compared to late-stage lung cancer 
type. Patient serum samples included 20 normal, 9 squamous, 9 adenocarcinoma 
and 10 small cell carcinoma. Student’s t-test with p value less than 0.05 is 
indicated by a single asterisk (*) and p value less than 0.01 is indicated by two 
asterisks (**). 
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Figure 6.3.8: Tenascin C and transforming growth factor alpha from Cancer 
Panel 2. Bar chart showing normal compared to late-stage lung cancer type. 
Patient serum samples included 20 normal, 9 squamous, 9 adenocarcinoma and 
10 small cell carcinoma. Student’s t-test with p value less than 0.01 is indicated 
by two asterisks (**). 
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Figure 6.3.9: Vascular endothelial growth factor-alpha from Cancer Panel 2. 
Bar chart showing normal compared to late-stage lung cancer type. Patient 
serum samples included 20 normal, 9 squamous, 9 adenocarcinoma and 10 small 
cell carcinoma. Student’s t-test with p value less than 0.01 is indicated by two 
asterisks (**). 
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Figure 6.3.10: MMP-1 and MMP-3 from MMP Panel. Bar chart showing 
normal compared to late-stage lung cancer type. Patient serum samples included 
20 normal, 9 squamous, 9 adenocarcinoma and 10 small cell carcinoma. 
Student’s t-test with p value less than 0.05 is indicated by a single asterisk (*) 
and p value less than 0.01 is indicated by two asterisks (**). 
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Figure 6.3.11: MMP-8 and MMP-9 from MMP Panel. Bar chart showing 
normal compared to late-stage lung cancer type. Patient serum samples included 
20 normal, 9 squamous, 9 adenocarcinoma and 10 small cell carcinoma. 
Student’s t-test with p value less than 0.05 is indicated by a single asterisk (*) 
and p value less than 0.01 is indicated by two asterisks (**). 
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Figure 6.3.12: MMP-10 and MMP-13 from MMP Panel. Bar chart showing 
normal compared to late-stage lung cancer type. Patient serum samples included 
20 normal, 9 squamous, 9 adenocarcinoma and 10 small cell carcinoma. 
Student’s t-test with p value less than 0.05 is indicated by a single asterisk (*) 
and p value less than 0.01 is indicated by two asterisks (**). 
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6.4 Validation of targets from Luminex discovery phase: Cancer Panel 1 
 
Cancer Panel 1 from Millipore was ran on the Luminex Multiplex platform includes 
the six proteins alpha-fetoprotein, CA 19-9, CEA, CA-125, CA 15-3, and prolactin. 
These proteins are known tumour markers, in some cases used for lung cancer 
though mainly used for other cancers. In the case where they are used for lung 
cancer there are issues with specificity and sensitivity, and often their main use is as 
a biological marker in other cancers. 
 
Alpha-fetoprotein is a marker for hepatocellular carcinoma, a common type of liver 
cancer, and germ cell carcinoma. It is known to be elevated in normal pregnancy, 
benign liver diseases, as well as in cancer. It is less frequently elevated in 
bronchogenic cancers and rarely elevated in healthy patients. 
CA-125 is an antigen present on eighty percent of nonmucinous ovarian carcinomas 
and is often elevated in patients with ovarian cancer, where it is used as a marker 
for patient response to surgical resection or chemotherapy. It is elevated in other 
cancers such as endometrial, pancreatic, breast, colon, and also lung cancer. 
Elevated levels of CEA are found in many cancers such as colon, pancreatic, 
gastric, breast, and lung. However it is also detected in benign conditions such as 
pancreatitis, chronic lung disease, cirrhosis, and inflammatory bowel disease, as 
well as being found to be elevated in 19% of smokers and 3% of a healthy control 
population. 
CA 19-9 is a primary marker in 80% of cases of pancreatic carcinoma, with good 
correlation between serum levels and tumour size. CA 19-9 can be used as a 
secondary marker after CEA in biliary carcinomas, colorectal cancer, liver 
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metastases and gastric carcinoma. Increases in CA 19-9 are also reported in breast, 
ovarian, and lung cancer. 
CA 15-3 is the most widely used serum marker in breast cancer. It is used in pre-
clinically detecting recurrent breast cancer and monitoring the treatment of patients 
with advanced breast cancer. Its levels are rarely elevated in women with early 
stage breast cancer. Elevated levels of CA 15-3 are seen in colon and lung cancer 
and also in noncancerous conditions such as benign ovarian or breast disease, pelvic 
inflammatory disease and hepatitis. 
Prolactin has been mentioned as a possible marker for cancer of the cervix and also 
colorectal cancer. It has also been postulated that prolactin levels in plasma have a 
correlation to breast tumour size, though this has been refuted (Arslan, Serdar et al. 
2000). 
 
Although not specific for lung cancer, the inclusion of known cancer biomarkers is 
a useful benchmark for judging the overall effectiveness of the Luminex multiplex 
system. An expected result in these markers leads to confidence in the results of the 
less studied/new markers and vice versa.  
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Figure 6.4.1: CA19-9 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each late-stage lung cancer type. For box and whisker 
the box represents the interquartile range, the horizontal line the median, and the 
whiskers the highest and lowest quartiles. Patient serum samples used for this 
experiment included 20 normal, 16 squamous, 21 adenocarcinoma, and 18 small 
cell carcinoma. T-test score; Normal v SCC (p value=0.003), Normal v AD (p 
value=0.001), Normal v SCLC (p value=0.04).  
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Figure 6.4.2: CA19-9 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to benign lung disease and lung cancer. For box and 
whisker the box represents the interquartile range, the horizontal line the median, 
and the whiskers the highest and lowest quartiles.Patient plasma samples used for 
this experiment included 18 normal, 11 benign lung disease, and 35 lung cancer. T-
test score; Normal v Lung Cancer (p value=0.03). 
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Figure 6.4.3: Alpha-fetoprotein Luminex Assay: Bar chart showing normal 
compared to each lung cancer type. Patient serum samples used for this experiment 
included 20 normal, 16 squamous, 21 adenocarcinoma, and 18 small cell 
carcinoma. 
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Figure 6.4.4: CEA Luminex Assay: Bar chart and Box and Whisker Plot showing 
normal compared to each late-stage lung cancer type. For box and whisker the box 
represents the interquartile range, the horizontal line the median, and the whiskers 
the highest and lowest quartiles.Patient serum samples used for this experiment 
included 20 normal, 16 squamous, 21 adenocarcinoma, and 18 small cell 
carcinoma. T-test score; Normal v SCC (p value=0.008), Normal v AD (p 
value=0.005).  
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Figure 6.4.5: CEA Luminex Assay: Bar chart and Box and Whisker Plot showing 
normal compared to benign lung disease and early-stage lung cancer. For box and 
whisker the box represents the interquartile range, the horizontal line the median, 
and the whiskers the highest and lowest quartiles.Patient plasma samples used for 
this experiment included 18 normal, 11 benign lung disease, and 35 lung cancer. T-
test score; Normal v Lung Cancer (p value=0.003), BLD v Lung Cancer (p 
value=0.01). 
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Figure 6.4.6: CA-125 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each late-stage lung cancer type. For box and whisker 
the box represents the interquartile range, the horizontal line the median, and the 
whiskers the highest and lowest quartiles. Patient serum samples used for this 
experiment included 20 normal, 16 squamous, 21 adenocarcinoma, and 18 small 
cell carcinoma. T-test scores; Normal v SCC (p value=3E-05), Normal v AD (p 
value=0.001), Normal v SCLC (p value=0.004). 
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Figure 6.4.7: CA-125 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to benign lung disease and early-stage lung cancer. 
For box and whisker the box represents the interquartile range, the horizontal 
line the median, and the whiskers the highest and lowest quartiles.Patient plasma 
samples used for this experiment included 18 normal, 11 benign lung disease, 
and 35 lung cancer. T-test score; Normal v Lung Cancer (p value=0.02). 
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Figure 6.4.8: CA-153 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each late-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used for this experiment included 20 normal, 16 squamous, 21 
adenocarcinoma, and 18 small cell carcinoma. T-test score; Normal v SCC (p 
value=0.02), Normal v AD (p value=0.02), Normal v SCLC (p value=0.04).  
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Figure 6.4.9: CA 15-3 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to benign lung disease and early-stage lung cancer. 
For box and whisker the box represents the interquartile range, the horizontal 
line the median, and the whiskers the highest and lowest quartiles.Patient plasma 
samples used for this experiment included 18 normal, 11 benign lung disease, 
and 35 lung cancer. 
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Figure 6.4.10: Prolactin Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each latre-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used for this experiment included 20 normal, 16 squamous, 21 
adenocarcinoma, and 18 small cell carcinoma. T-test score; Normal v SCC (p 
value=0.02). 
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Figure 6.4.11: Prolactin ELISA: Bar chart and Box and Whisker Plot showing 
normal compared to each late-stage lung cancer type. For box and whisker the 
box represents the interquartile range, the horizontal line the median, and the 
whiskers the highest and lowest quartiles. Patient serum samples used for this 
experiment included 21 normal, 15 squamous, 23 adenocarcinoma, and 16 small 
cell carcinoma. T-test score; Normal v SCC (p value=0.0001), Normal v AD (p 
value=0.001), Normal v SCLC (p value=0.01).  
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Figure 6.4.12: Prolactin Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to benign lung disease and early-stage lung cancer. 
For box and whisker the box represents the interquartile range, the horizontal 
line the median, and the whiskers the highest and lowest quartiles. Patient 
plasma samples used for this experiment included 18 normal, 11 benign lung 
disease, and 35 lung cancer. 
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6.5 Validation of targets from Luminex discovery phase: Cancer Panel 2 
  
From Cancer Panel 2 six proteins were brought forward for validation in larger 
serum sample sets. This 6plex included epiregulin, heparin-binding epidermal 
growth factor, placenta growth factor, transforming growth factor alpha, vascular 
epithelial growth factor (VEGF-α), and tenascin C. From this 6plex Luminex 
experiment, tenascin C and VEGF-α showed the most promise and were validated 
further in serum and also in plasma. One VEGF-α experiment in serum (without a 
tenascin C equivalent) included an autoimmune control, a benign lung disease 
control, and earlier stage lung cancer. 
 
VEGF-α has a history of being linked to lung development and also lung cancer 
itself. It is known to play a role in lung development and maintenance of adult lung 
structure, and its effects on pulmonary endothelial cells are of importance in the 
pathology of lung diseases. Its potential as a lung cancer biomarker is well known, 
with high levels of VEGF in lung cancer serum associated with poor prognosis, and 
unfavourable survival and poor response to treatment with SCLC patients. 
 
Tenascin-C is an extracellular matrix glycoprotein that is expressed upon damage to 
tissue. It is also known to modulate cell migration and proliferation making it an 
ideal candidate as a cancer biomarker. It has been suggested its levels in serum 
could be a predictive marker of angiogenesis in NSCLC and its expression in breast 
cancer cells has been linked to their ability to metastasise to the lungs. 
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Figure 6.5.1: Epiregulin Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each late-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles.Patient serum samples 
used for this experiment included 20 normal, 16 squamous, 21 adenocarcinoma, 
and 18 small cell carcinoma.  
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Figure 6.5.2: Heparin-binding Epidermal Growth Factor Luminex Assay: Bar 
chart and Box and Whisker Plot showing normal compared to each late-stage 
lung cancer type. For box and whisker the box represents the interquartile range, 
the horizontal line the median, and the whiskers the highest and lowest quartiles. 
Patient serum samples used for this experiment included 20 normal, 16 
squamous, 21 adenocarcinoma, and 18 small cell carcinoma. T-test score; 
Normal v AD (p value=0.01). 
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Figure 6.5.3: Placenta Growth Factor Luminex Assay: Bar chart and Box and 
Whisker Plot showing normal compared to each late-stage lung cancer type. For 
box and whisker the box represents the interquartile range, the horizontal line 
the median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used for this experiment included 20 normal, 16 squamous, 21 
adenocarcinoma, and 18 small cell carcinoma.  
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Figure 6.5.4: Transforming Growth Factor Alpha Luminex Assay: Bar chart 
and Box and Whisker Plot showing normal compared to each late-stage lung 
cancer type. For box and whisker the box represents the interquartile range, the 
horizontal line the median, and the whiskers the highest and lowest quartiles. 
Patient serum samples used for this experiment included 20 normal, 16 
squamous, 21 adenocarcinoma, and 18 small cell carcinoma. T-test score; 
Normal v AD (p value=0.04). 
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Figure 6.5.5: Vascular endothelial growth factor-alpha Luminex Assay: Bar 
chart and Box and Whisker Plot showing normal compared to each late-stage 
lung cancer type. For box and whisker the box represents the interquartile range, 
the horizontal line the median, and the whiskers the highest and lowest quartiles. 
Patient serum samples used for this experiment included 20 normal, 16 
squamous, 21 adenocarcinoma, and 18 small cell carcinoma. T-test score; 
Normal v SCC (p value=0.0001), Normal v AD (p value=0.0003), Normal v 
SCLC (p value=0.0001). 
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Figure 6.5.6: Vascular endothelial growth factor-alpha Luminex Assay: Bar 
chart and Box and Whisker Plot showing normal compared to each late-stage 
lung cancer type. For box and whisker the box represents the interquartile range, 
the horizontal line the median, and the whiskers the highest and lowest quartiles. 
Patient serum samples used for this experiment included 20 normal, 14 
squamous, 21 adenocarcinoma, and 16 small cell carcinoma. T-test score; 
Normal v SCC (p value=4E-05), Normal v AD (p value=0.002), Normal v 
SCLC (p value=0.001). 
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Figure 6.5.7: Vascular endothelial growth factor-alpha Luminex Assay: Bar 
chart and Box and Whisker Plot showing normal compared to each early-stage 
lung cancer type. For box and whisker the box represents the interquartile range, 
the horizontal line the median, and the whiskers the highest and lowest quartiles. 
Patient serum samples used for this experiment included 16 normal, 16 
autoimmune, 22 benign lung disease, and 26 lung cancer. T-test value; Normal v 
Lung Cancer (p value=0.0008), Autoimmune v Lung Cancer (p value=0.02), 
BLD v Lung Cancer (p value=0.03).  
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Figure 6.5.8: Vascular endothelial growth factor-alpha Luminex Assay: Bar 
chart and Box and Whisker Plot showing normal compared to benign lung 
disease and early-stage lung cancer. For box and whisker the box represents the 
interquartile range, the horizontal line the median, and the whiskers the highest 
and lowest quartiles. Patient plasma samples used for this experiment included 
18 normal, 11 benign lung disease, and 35 lung cancer. 
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Figure 6.5.9: Tenascin C Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each late-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used for this experiment included 20 normal, 16 squamous, 21 
adenocarcinoma, and 18 small cell carcinoma. T-test score; Normal v SCC (p 
value=9E-06), Normal v AD (p value=2E-05), Normal v SCLC (p 
value=0.0002). 
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Figure 6.5.10: Tenascin C Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each late-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used for this experiment included 20 normal, 14 squamous, 21 
adenocarcinoma, and 16 small cell carcinoma. T-test score; Normal v SCC (p 
value=0.01), Normal v AD (p value=0.0001), Normal v SCLC (p 
value=0.0002). 
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Figure 6.5.11: Tenascin C Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to benign lung disease and early-stage lung cancer. 
For box and whisker the box represents the interquartile range, the horizontal 
line the median, and the whiskers the highest and lowest quartiles. Patient 
plasma samples used for this experiment included 18 normal, 11 benign lung 
disease, and 35 lung cancer. 
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6.6 Validation of targets from Luminex discovery phase: MMP Panel 
 
From the initial discovery phase of the MMP panel, which included MMPs -1, -3, -
8, -9, -10, and -13, three were brought forward for validation in larger sample sets. 
The levels of MMP-1, MMP-8, and MMP-9 showed the greatest increase in cancer 
serum compared to normal control serum. These three assays also showed 
significant statistical scores for all of the comparisons of normal versus lung cancer 
type. The two MMP’s -1 and -9 were most extensively studied, which included 
experiments in serum and plasma, and also in autoimmune serum, benign lung 
disease serum, and earlier stage lung cancer serum. MMP-8 validation was not 
performed on the Luminex system but on a commercial single-plex ELISA.  
MMPs -2, -7, -10, were examined in larger sample sets due to the availability of 
Luminex bead sets at the time. 
 
MMPs degrade all protein components of tissue extracellular matrices and basement 
membranes and are known to have roles in the late stage of tumour progression, 
invasion, and metastasis. They may also be involved in earlier tumourigenesis such 
as in malignant transformation, angiogenesis, and tumour growth both at the 
primary and metastatic sites.  
MMP-1 and MMP-8 are collagenases, enzymes that break down collagen, the main 
component of connective tissue. MMP-9 is a gelatinase enzyme that breaks down 
gelatine, a mixture of proteins and peptides produced by the hydrolysis of collagen. 
MMP-1 has been suggested as possible marker for hematogenous metastasis of 
colorectal cancer, MMP-8 as a marker for improved prognosis in colorectal cancer, 
and MMP-9 as a marker for Dukes’ B colorectal cancer.  
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Figure 6.6.1: MMP-1 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each late-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used included 20 normal, 16 squamous, 21 adenocarcinoma, and 18 
small cell carcinoma. T-test score; Normal v SCC (p value=0.002), Normal v 
AD (p value=0.005). 
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Figure 6.6.2: MMP-1 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each late-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used for this experiment included 20 normal, 14 squamous, 21 
adenocarcinoma, and 16 small cell carcinoma. T-test score; Normal v SCC (p 
value=0.001), Normal v AD (p value=0.003). 
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Figure 6.6.3: MMP-1 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each early-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used for this experiment included 16 normal, 16 autoimmune, 22 
benign lung disease, and 26 lung cancer. T-test score; Normal v Lung Cancer (p 
value=0.03), Autoimmune v Lung Cancer (p value=0.01).  
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Figure 6.6.4: MMP-1 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to benign lung disease and early-stage lung cancer. 
For box and whisker the box represents the interquartile range, the horizontal 
line the median, and the whiskers the highest and lowest quartiles. Patient 
plasma samples used for this experiment included 18 normal, 11 benign lung 
disease, and 35 lung cancer. T-test score; Normal v BLD (p value=0.01), 
Normal v Lung Cancer (p value=9.7E-06). 
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Figure 6.6.5: MMP-9 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each late-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used included 20 normal, 16 squamous, 21 adenocarcinoma, and 18 
small cell carcinoma. T-test score; Normal v SCC (p value=0.0007), Normal v 
AD (p value=0.001), Normal v SCLC (p value=5.5E-05). 
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Figure 6.6.6: MMP-9 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each late-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used for this experiment included 20 normal, 14 squamous, 21 
adenocarcinoma, and 16 small cell carcinoma. T-test score; Normal v SCC (p 
value=0.0008), Normal v AD (p value=4E-05), Normal v SCLC (p value=2.9E-
05). 
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Figure 6.6.7: MMP-9 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to benign lung disease and early-stage lung cancer. 
For box and whisker the box represents the interquartile range, the horizontal 
line the median, and the whiskers the highest and lowest quartiles. Patient 
plasma samples used for this experiment included 18 normal, 11 benign lung 
disease, and 35 lung cancer. T-test score; Normal v Lung Cancer (p 
value=0.004). 
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Figure 6.6.8: MMP-8 ELISA: Bar chart and Box and Whisker Plot showing 
normal compared to each late-stage lung cancer type. For box and whisker the 
box represents the interquartile range, the horizontal line the median, and the 
whiskers the highest and lowest quartiles. Patient serum samples used for this 
experiment included 22 normal, 16 squamous, 24 adenocarcinoma, and 18 small 
cell carcinoma. T-test score; Normal v SCC (p value=4E-06), normal v AD (p 
value=0.0002), Normal v SCLC (p value=3.5E-08). 
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Figure 6.6.9: MMP-8 serum ELISA ROC Curve with sensitivity, specificity, 
and cut-off value in brackets respectively for statistically significant comparison 
of normal and lung cancer (94.1%, 90.9%, 2877 pg/ml). Area under the curve: 
0.981. 
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Figure 6.6.10: MMP-2 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each early-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used for this experiment included 16 normal, 16 autoimmune, 22 
benign lung disease, and 26 lung cancer. T-test score; Normal v Autoimmune (p 
value=0.04), Normal v BLD (p value=0.007).  
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Figure 6.6.11: MMP-7 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each early-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used for this experiment included 16 normal, 16 autoimmune, 22 
benign lung disease, and 26 lung cancer. T-test score; Normal v BLD (p 
value=0.0001), Normal v Lung Cancer (p value=0.0005), Autoimmune v Lung 
Cancer (p value=0.001), Autoimmune v BLD (p value=0.0005). 
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Figure 6.6.12: MMP-10 Luminex Assay: Bar chart and Box and Whisker Plot 
showing normal compared to each early-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples used for this experiment included 16 normal, 16 autoimmune, 22 
benign lung disease, and 26 lung cancer.  
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6.7 Logistic Regression on Matching Clinical Samples 
 
 
A.                                                                B. 
 
  
 
 
 
 
Figure 6.7.1:  Logistic regression performed on matching serum patient samples 
(A) combining Luminex assay results from CA-125, CA 19-9, and CEA with 20 
matching normal and 56 matching cancer samples, indicating 86.84% of cases 
would be correctly classified, and (B) combining Luminex assay results from 
MMP-1, MMP-9, and tenascin-C with 20 matching normal and 44 matching 
cancer samples, indicating 96.87% of cases would be correctly classified. 
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A.                                                                   B. 
 
        
 
 
 
Figure 6.7.2:  Logistic regression performed on matching plasma patient 
samples (A) combining Luminex assay results from CA-125, CA 19-9, and CEA 
with 18 matching normal and 34 matching cancer samples, indicating 80.77% of 
cases would be correctly classified, and (B) combining Luminex assay results 
from MMP-1, CA-125, and tenascin-C with 18 matching normal and 34 
matching cancer samples, indicating 88.68% of cases would be correctly 
classified. 
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CHAPTER SEVEN 
 
METABOLOMIC SERUM PROFILING FOR LUNG CANCER BIOMARKER 
DISCOVERY 
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7.1 Background 
 
Metabolomics is the name given to the global quantitative assessment of 
endogenous metabolites within a biological system. Metabolites are the 
intermediates and products of metabolism and usually refer to small molecules, with 
primary metabolites directly involved in normal growth, development and 
reproduction. Much like proteins, metabolites present in the serum or plasma can be 
used as biomarkers for a particular cancer. Metabolomics could address the 
limitation associated with transcriptomics and proteomics where changes do not 
always result in altered biochemical phenotypes. The detection of these metabolites 
could lead to early cancer detection and diagnosis, and also for chemotherapy drug 
treatment monitoring.  
Metabolon are a global biochemical and diagnostics company and provide a service 
of profiling serum samples. Lung cancer samples for squamous cell carcinoma, 
adenocarcinoma, and small cell carcinoma, as well as normal controls were sent to 
Metabolon, who in turn provided an extensive profile of up- and down-regulated 
metabolites. Eight samples, four male and four female, for each condition were 
analysed. 
In total, information on over three hundred metabolites was provided. From this 
extensive list the most interesting ones were selected and from this a number were 
chosen for validation. The initial selection process was based on abundance levels 
of the metabolite in the lung cancer samples compared to the normal control. Those 
chosen to be brought forward for validation in larger sample sets were very much 
restricted by availability of commercial assays and in total four were chosen; 12-
HETE, glutamate, aspartate, and phenylalanine. 
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12 (S)-HETE was examined in serum (including autoimmune and benign lung 
disease) and plasma. Glutamate and phenylalanine were examined in serum and 
plasma, and aspartate in serum only. 
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7.2 Metabolomics Discovery Phase 
 
A.                                                                       B. 
                     
C.                                                                      D.   
                              
 
Figure 7.2.1: Box and whisker plots from metabolomic discovery phase 
showing (A) 3-hydroxybutyrate, (B) 12-HETE, (C) glutamate, and (D) 
phenylalanine. Serum samples on x-axis show normal (A_C ctrl), 
adenocarcinoma (A1), squamous cell carcinoma (A2), and small cell carcinoma 
(A3). 
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A.                                                                       B. 
                              
C.                                                                      D.   
                              
 
 
Figure 7.2.2: Box and whisker plots from metabolomic discovery phase 
showing (A) aspartate, (B) ornithine, (C) glycylvaline, and (D) 1,7-
dimethylurate. Serum samples on x-axis show normal (A_C ctrl), 
adenocarcinoma (A1), squamous cell carcinoma (A2), and small cell carcinoma 
(A3). 
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A.                                                                       B. 
                              
C.                                                                      D.   
                              
 
 
Figure 7.2.3: Box and whisker plots from metabolomic discovery phase showing 
(A) allantoin, (B) 10-nonadecenoate, (C) erythronate, and (D) phenylalanylleucine. 
Serum samples on x-axis show normal (A_C ctrl), adenocarcinoma (A1), squamous 
cell carcinoma (A2), and small cell carcinoma (A3). 
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7.3 Validation of Targets from Metabolomic Profiling of Serum 
12(S)-HETE Serum ELISA
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Figure 7.3.1: 12(S)-HETE ELISA: Bar chart and Box and Whisker Plot 
showing normal compared to each late stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples included 17 normal, 16 squamous, 17 adenocarcinoma, and 17 small 
cell carcinoma. T-test scores: Normal v SCC (p value=0.008), Normal v AD (p 
value=2E-06), Normal v SCLC (p value=0.0002). 
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Figure 7.3.2: 12 (S)-HETE serum assay ROC Curve with sensitivity, 
specificity, and cut-off value in brackets respectively for statistically significant 
comparison of normal and lung cancer (86.7%, 88.9%, 10.10 ng/ml). Area under 
the curve: 0.927. 
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Figure 7.3.3: 12(S)-HETE ELISA: Bar chart and Box and Whisker Plot 
showing normal compared to each late-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples included 20 normal, 16 squamous, 24 adenocarcinoma, and 18 small 
cell carcinoma. T-test scores: Normal v SCC (p value=0.004), Normal v AD (p 
value=0.004), Normal v SCLC (p value=0.0007). 
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Figure 7.3.4: 12(S)-HETE ELISA: Bar chart and Box and Whisker Plot 
showing normal compared to each early-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient serum 
samples included 16 normal, 14 autoimmune, 19 benign lung disease, and 24 
lung cancer. T-test score; Normal v Lung Cancer (p value=0.03), Autoimmune v 
Lung Cancer (p value=0.04).  
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Figure 7.3.5: 12(S)-HETE ELISA: Bar chart and Box and Whisker Plot 
showing normal compared to each early-stage lung cancer type. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient plasma 
samples included 18 normal, 14 benign lung disease, and 39 lung cancer. T-test 
score; Normal v BLD (p value=7E-05), Normal v Lung Cancer (p value=1E-10). 
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Figure 7.3.6: Glutamate serum ELISAs: Bar charts showing normal and autoimmune 
controls compared to each late-stage lung cancer type. For box and whisker the box 
represents the interquartile range, the horizontal line the median, and the whiskers the 
highest and lowest quartiles. Patient serum samples included 10 normal, 20 
autoimmune, 11 squamous, 23 adenocarcinoma, and 16 small cell carcinoma.  
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Figure 7.3.7: Glutamate plasma assay: Bar chart and Box and Whisker Plot 
showing two assays combined using early-stage cancer plasma. For box and 
whisker the box represents the interquartile range, the horizontal line the 
median, and the whiskers the highest and lowest quartiles. Patient plasma 
samples included 30 normal, 40 benign lung disease, and 90 early-stage lung 
cancer. T-test score; Normal v BLD (p value=1E-12), Normal v Lung Cancer (p 
value=7E-13), BLD v Lung Cancer (p value=0.002).  
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Figure 7.3.8: Phenylalanine serum assay: Bar chart and Box and Whisker Plot 
using late-stage cancer serum. For box and whisker the box represents the 
interquartile range, the horizontal line the median, and the whiskers the highest 
and lowest quartiles. Patient serum samples included 18 normal, 40 non-small 
cell lung cancer, and 16 small cell lung cancer. T-test score; Normal v NSCLC 
(p value=3E-09), NSCLC v SCLC (p value=8E-07).  
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Figure 7.3.9: Phenylalanine serum assay ROC Curve with sensitivity, 
specificity, and cut-off value in brackets respectively for statistically significant 
comparison of non-small cell lung cancer and small cell lung cancer samples 
(93.7%, 65.0%, 1.2206 pmol/ul). AUC value was 0.866. 
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Figure 7.3.10: Phenylalanine plasma assay: Bar chart and Box and Whisker Plot 
showing two assays combined. For box and whisker the box represents the 
interquartile range, the horizontal line the median, and the whiskers the highest 
and lowest quartiles. Patient serum samples included 30 normal, 40 benign lung 
disease, and 89 early-stage lung cancer. T-test score; Normal v BLD (p 
value=0.002), Normal v Lung Cancer (p value=0.005). 
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Figure 7.3.11: Aspartate serum assay: Bar chart and Box and Whisker Plot 
showing two assays combined. For box and whisker the box represents the 
interquartile range, the horizontal line the median, and the whiskers the highest 
and lowest quartiles. Patient serum samples included 20 normal, 40 
autoimmune, 22 squamous, 46 adenocarcinoma, and 32 small cell carcinoma. 
All cancer samples were late-stage. T-test score; Normal v Autoimmune (p 
value=3E-08), Normal v SCC (p value=0.0002), Normal v AD (p value=2E-07), 
Normal v SCLC (p value=0.004). 
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CHAPTER EIGHT 
 
AUSHON MULTIPLEX IMMUNOASSAY PLATFORM FOR LUNG CANCER 
BIOMARKER DISCOVERY 
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8.1 Background 
 
Aushon Cira immunoassay platform can be used for protein biomarker discovery by 
combining the sensitivity and reproducibility of a singleplex ELISA with the 
advantages of multiplex. Using the standard 96-well plate format the Cirascan from 
Aushon can analyse up to 12 analytes per well, the arrays printed precisely in a 
circular pattern, using quantitative chemiluminescence. Unlike the bead-based 
method of the Luminex multiplex where beads are mixed by the user before 
addition to the plate, the Aushon arrays are delivered with chosen analytes pre-
spotted. Imaging and analysis software allow the user to view the spots and adjust 
the standard curve (e.g. removal of outliers) if needed. 
 
Cytokines are regulatory proteins released by cells of the immune system where 
they act as intercellular mediators for the generation of an immune response. 
Chemokines are a low-molecular weight type of cytokine classified by their ability 
to induce chemotaxis or chemokinesis, whereby cells can direct their movements 
according to certain chemicals in their environment, through controlled or random 
mechanisms respectively. Chemokines can play a role in cancer through the 
stimulation of angiogenesis and tumour growth through direct or indirect 
recruitment of tumour-associated macrophages (Vicari and Caux 2002) and also in 
cancer treatment by the combination of chemokine receptor antagonists with 
traditional chemotoxic agents (Wu, Lee et al. 2009). 
 
Aushon biosystems provide an intensive catalogue of chemokines and cytokines to 
assay. Our experiment used a panel of nine chemokines; macrophage inflammatory 
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proteins alpha and beta (MIP1a and MIP1b, also known as chemokine (C-C motif 
ligand 3 and 4 respectively (CCL3 and CCL4))), monocyte chemotactic protein 1 
(MCP-1, also known as CCL2), Regulated on Activation, Normal T-cell Expressed 
and Secreted (RANTES, also known as CCL5), I309 (also known as CCL1), 
Thymus and activation-regulated chemokine (TARC, also known as CCL17), 
Eotaxin (also known as CCL11), macrophage-derived chemokine (MDC, also 
known as CCL22), and interleukin-8 (IL-8). 
CCL3 is involved in the acute inflammatory state in the recruitment and activation 
of polymorphonuclear leaukocytes, CCL4 acts as a chemoattractant for natural 
killer (NK) cells, monocytes and other immune cells, CCL2 recruits monocytes, 
memory T cells and dendritic cells to the sites of inflammation, CCL5 attracts T-
cells, eosinophils and basophils and recruits leukocytes to inflammatory sites, CCL1 
attracts monocytes, NK cells, immature B cells and dendritic cells, CCL17 binds 
and induces chemotaxis in T-cells, CCL11 selectively recruits eosinophils, CCL22 
displays chemotactic activity for monocytes, dendritic cells, NK cells, and 
chronically activated T lymphocytes, and IL-8 is known to be a potent promoter of 
angiogenesis. 
 
Due to an unavailability of assay wells only small cell lung cancer was used. In total 
nine normal serum samples were compared to nine small cell lung cancer serum 
samples. Although some chemokines showed potential as small cell lung cancer 
biomarkers in the discovery phase, no validation in larger cohorts of patient samples 
was performed. 
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8.2 Discovery Phase 
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Figure 8.2.1: Macrophage inflammatory protein alpha (A) and beta (B) serum assay. 
Bar chart showing normal compared to late-stage small cell carcinoma. Patient serum 
samples included 9 normal and 9 small cell lung carcinoma. Student’s t-test with p 
value less than 0.01 is indicated by two asterisks (**). 
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Figure 8.2.2: MCP1 (A) and RANTES (B) serum assay. Bar chart showing normal 
compared to late-stage small cell lung carcinoma. Patient serum samples included 9 
normal and 9 small cell carcinoma.  
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Figure 8.2.3: I309 (A) and TARC (B) serum assay. Bar chart showing normal 
compared to late-stage small cell carcinoma. Patient serum samples included 9 normal 
and 9 small cell lung carcinoma. Student’s t-test with p value less than 0.05 is 
indicated by one asterisk (*). 
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A. 
Eotaxin Serum ELISA
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Figure 8.2.4: Eotaxin (A) and macrophage-derived chemokine (B) serum assay. Bar 
chart showing normal compared to late-stage small cell carcinoma. Patient serum 
samples included 9 normal and 9 small cell lung carcinoma. Student’s t-test with p 
value less than 0.05 is indicated by one asterisk (*). 
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Figure 8.2.5: Interleukin-8 serum assay. Bar chart showing normal compared to late-
stage small cell lung carcinoma. Patient serum samples included 9 normal and 9 small 
cell carcinoma. Student’s t-test with p value less than 0.01 is indicated by two 
asterisks (**). 
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9.1 Introduction 
 
 
Lung cancer is the most common cause of cancer-related death in the world. In 
Ireland it is the biggest cause of cancer death in both men and women, overtaking 
breast cancer in women. In 2010 in Ireland 1708 people died from lung cancer, 
1006 of those men and 702 women. In the same period breast cancer deaths 
amounted to 634 (www.cancer.ie). 
The American Cancer Society has estimated that in 2013 in the United States there 
will be 228,190 new cases of lung cancer, of which 159,480 patients will die, 
accounting for 27% of all cancer deaths, more than the cancer deaths from colon, 
breast, and prostate cancers combined (www.cancer.org). 
The five-year survival rate of lung cancer in Ireland is 11% and though this is 
higher than England (8.4%), Scotland (8.2%), and Wales (10.4%) it is lower than 
many other European countries such as Germany (14.75%), Poland (14%), Sweden 
(14%) and the Netherlands (13%). In the US the five-year survival rate is 16.3%, 
however when it has metastasised to other organs it is only 3.5% (Wender, Fontham 
et al. 2013). 
 
The biggest cause of lung cancer is smoking, accounting for 80-90% of cases. Often 
it is diagnosed at quite a late stage, usually when the cancer has already spread to 
other organs and curative treatment is not an option. Approximately 75% of patients 
present with symptoms due to metastatic or advanced local disease that is not 
amenable to cure. Symptoms can take many years to develop, often doing so when 
the disease is in an advanced stage. These symptoms vary and can often be 
overlooked as pertaining to lung cancer, both by patients and by doctors; these 
include persistent or intense coughing, pain in the chest, shoulder, or back from 
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coughing, hoarseness of voice, difficulty breathing and swallowing, and chronic 
bronchitis or pneumonia. 
If lung cancer spreads, additional symptoms can present themselves in the newly 
affected area. For example if it spreads to the brain it can cause vertigo, headaches, 
or seizures. As it spreads and uses more of the body's energy patients can present 
additional symptoms that are often associated with other ailments; for example 
fever, fatigue, unexplained weight loss, joint pain, swelling in the neck or face, and 
general weakness. 
Cancer screening is used to identify asymptomatic patients with unrecognised 
symptoms and to identify those at increased risk. It goes without saying that the 
earlier a cancer is diagnosed the less likely it has spread to other organs and the 
more treatable it is. However for screening to be a viable process it must benefit 
patients by increasing life expectancy, improving quality of life, or increase the 
chances of ridding the body of cancer altogether. For a screening technique to be 
ideal it must show low rates of false-positive results (i.e. results that show cancer is 
present when in fact it is not), must leave a large fraction of those tested unharmed 
(i.e. low risk), and should be not overly expensive. 
Screening methods are covered in Section 1.2.4 though it has been shown that 
regular sputum examination and chest radiography programs did not effectively 
reduce lung cancer mortality, even though early detection of lung cancer was 
possible with these programs. Updated guidelines released by the American Cancer 
Society on lung cancer screening have indicated sufficient evidence for screening 
with low-dose computed tomography (LDCT) in certain high-risk individuals. An 
extensive study in the U.S. by an expert Lung Cancer Screening Panel 
recommended LDCT screening for select patients at high risk for lung cancer as 
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results from a large randomised national lung screening trial (NLST) show that lung 
cancer screening with LDCT can decrease lung cancer-specific mortality by 20% 
and even decrease all-cause mortality by 7%, though their findings do also indicate 
that 320 high-risk individuals must be screened with LDCT to prevent one death 
(Wood, Eapen et al.). Before this could be implemented large-scale the cost-
effectiveness of LDCT screening would need to be analysed; reduction in mortality 
must be weighed against the harms from positive screening results and over-
diagnosis, as well as the costs, which includes not only the screening examination 
but also the diagnostic follow-up and treatment, all of which will depend on how 
this screening method is implemented in particular with regard to the eligibility 
criteria, screening frequency, interpretation threshold, diagnostic follow-up, and 
treatment (Aberle, Adams et al.). 
No single screening method is efficient for effective lung cancer detection and the 
use of companion diagnostics could help with diagnosis. This can involve the use of 
molecular assays that measure the levels of proteins, genes, or specific mutations 
that could help confirm the results from standard screening methods. These assays 
can not only help with early detection but also help provide a specific therapy for a 
patient's condition (known as personalised medicine) by stratifying disease status, 
selecting the correct medication, and tailoring the dosages of that medication to a 
particular patient's needs. 
 
These molecular assays are designed by using biomarkers of a particular disease. A 
biomarker is a biological molecule that can be used to ascertain the disease state of 
a patient. By its very nature cancer changes the normal processes of the human 
body. By changing these processes different genes are affected and in turn the type 
 306
and level of proteins produced. The levels of these proteins therefore could indicate 
the presence of cancer and ideally the type of cancer and state of the cancer (e.g. 
whether it has contracted after treatment). Proteomic techniques can be used to find 
potential protein biomarkers that may help with the diagnosis and prognosis of lung 
cancer. As it stands no biomarker for lung cancer is in standard use, though some 
biomarkers (often more specific for other cancers) are used (See Section 1.5.1). 
Single biomarkers would never be sensitive or specific enough to accurately 
identify a disease state, so ideally a panel of biomarkers would be used to account 
for the heterogeneity of lung cancer. 
The less invasive the method of detection for these biomarkers the better, so their 
presence in biological fluids such as serum/plasma, saliva, and urine are often 
examined. Tissue markers can also be effective indicators of disease state but 
involve the use of biopsies so are therefore more invasive than the use of biological 
fluids. Finding biomarkers that may detect lung cancer at an early stage, determine 
the type of lung cancer involved, and/or play an effective role in determining the 
usefulness of particular lung cancer treatment regimes, could greatly benefit the 
overall survival of lung cancer sufferers. 
 
The aim of this thesis was to find potential lung cancer biomarkers using proteomic 
techniques and validate the most interesting candidates in biological fluids and/or 
tissue. The main focus was to validate biomarkers in serum and/or plasma, though 
initially serum was the biological fluid of choice. Serum however is very complex 
with many high abundant proteins that can mask the more interesting disease 
specific low abundant proteins. The removal of these high abundant proteins with 
techniques such as immunodepletion are insufficient to uncover the low abundant 
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proteins as often the column will become saturated and fail to remove a high 
enough percentage of high abundant proteins. An additional problem arises when 
the low abundant proteins bind to high abundant ones and are removed with them. 
Albumin alone constitutes over 50% of the protein content in serum and due to its 
'sticky' nature many small low abundant proteins can bind to it and be removed with 
it. In fact the main 22 proteins in serum account for 99% of all protein content and 
together disguise the many thousands of other more disease-specific proteins. 
 
9.2 2D-DIGE Analysis of Conditioned Media 
 
To potentially unearth these disease-specific proteins before validating in biological 
fluids in very expensive commercial assays a cell culture model was initially 
proposed. In order to detect these biomarkers in serum they would need to find their 
way into the bloodstream. Tumours will secrete or leak proteins that can find their 
way into the serum/plasma of patients giving a potential molecular fingerprint 
reflecting physiological conditions. This secretion and leaking of proteins is 
commonly associated with cancer. The process of cancer initiation and progression, 
and the signalling pathways involved, are not confined to the cancer cell itself but 
extend to the tumour-host interface, a dynamic environment in which information 
passes between the tumour cells and the normal host tissue. It is conceivable these 
secreted and/or leaked proteins from the tumour and its microenvironment will 
ultimately make their way to the serum proteome, where their detection could create 
a proteomic fingerprint of the tumour of origin. Secreted proteins account for 10-
15% of the proteins encoded by the human genome (Karagiannis, Pavlou et al. 
2010), so one can predict with confidence that proteins or their fragments 
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originating from cancer cells or their microenvironment may eventually enter the 
circulation. 
 
In this study lung cancer cell lines were used as a model. Lung cancer cell lines 
secrete and/or leaked proteins into the surrounding media and this environment 
could have similarities with the tumour microenvironment or the serum proteome of 
a lung cancer patient. This media, without serum which can mask the secreted or 
shed proteins, is known as conditioned media. The cell lines were initially grown in 
serum-containing media until healthy and ready to grow in serum-free media for 
24/48h. During this period the cancer cell lines will secrete/shed proteins into the 
media that could potentially be used as biomarkers. In order to discover these 
biomarkers the conditioned media was collected, concentrated, cleaned up (e.g. 
removal of impurities), and in this case fluorescently labelled to determine 
differences in protein content and/or abundance for each of the cell lines. The 
technique used here was 2D-DIGE and its accompanying analysis software 
DeCyder. This allowed statistical comparisons to be made between all cell lines. 
 
In total sixteen lung cancer cell lines were examined as well as a normal human 
bronchial epithelial cell line (NHBE). The four major lung cancer types were looked 
at; adenocarcinoma (AD), squamous cell carcinoma (SCC), large cell carcinoma 
(LCC), and small cell lung cancer (SCLC). Together AD, SCC, and LCC are classed 
as non-small cell lung cancer (NSCLC). For each of the four lung cell types four 
separate cell lines were examined. In the case of SCC this included two poorly 
differentiated squamous cell lines (DLKP and DLRP). 
2D-DIGE was performed on the conditioned media and the subsequent gels scanned 
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by the Typhoon Image Analyser and imported into DeCyder. Using the DIA and 
BVA tools DeCyder can compare and match spots among multiple gels by using the 
Cy2 pool as reference. Abundance differences (fold changes) between the same 
spots in different gels are extrapolated and assigned confidence scores in the form 
of t-test or 1-WAY ANOVA depending on the comparison. 
After the DeCyder analysis of the 2D-DIGE results the most interesting protein 
spots were chosen for mass spectrometry analysis and subsequent identification. 
After plugging these identifications into DeCyder tables were generated that 
showed statistically significant (p value cut-off of 0.1 was chosen) comparisons 
(See Tables 3.3.1 to 3.3.12). From these tables the proteins showing the biggest fold 
changes were selected for potential validation. 
In order to validate these proteins in serum, commercial assay kits are needed. This 
involves either an ELISA or a biochemical assay (See Section 1.8). These assays 
can quantify the levels of particular proteins in the serum/plasma of healthy and 
disease patients. Unfortunately commercial assay kits were not available for many 
of the interesting proteins and therefore the selection process was restricted to those 
proteins with commercially available kits. Although this meant that some of the 
proteins selected did not show big fold changes in any of the comparisons, the 
possibility was there that the fold changes in serum for these proteins might be more 
pronounced than the conditioned media experiment indicated. Although this throws 
up a potential invalidity to this method for lung cancer biomarker discovery phase it 
should be noted that a cell culture based method such as this will never accurately 
reflect the proteome fingerprint of biological fluids and should be seen as a 
relatively crude initial discovery phase. This is why regardless of the fold change 
and p value, any protein from these experiments could not be considered potential 
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lung cancer biomarkers until some sort of validation step in cancer serum/plasma or 
in cancer tissue was performed. 
 
From the DeCyder comparisons the following proteins were chosen for validation; 
hnRNPA2B1, pyruvate kinase 3 (also known as pyruvate kinase M2 or PKM2), 
HSC70-interacting protein (Hip), triosephosphate isomerase, GAPDH, lactate 
dehydrogenase, and peroxiredoxins 1, 2, and 3. Assays on serum of normal and lung 
cancer patients were performed on all these proteins. Lung cancer samples only 
included patients with squamous cell carcinoma, adenocarcinoma, and small cell 
carcinoma. There were insufficient large cell lung carcinoma serum/plasma samples 
to be included in any of the validation phases. 
Further serum and plasma assays were performed on the proteins that showed the 
greatest abundance differences in serum between normal and cancer i.e. 
hnRNPA2B1 and PKM2. For these two proteins, as well as Hip, IHC was 
performed on lung tissue slides. In the case of hnRNPA2B1, IHC was performed on 
a mixed tissue slide also. As hnRNPA2B1 showed the most promising results 
functional assays were performed for this protein, involving the transient 
knockdown of this protein in the DLKP-M lung cancer cell line to examine its 
effect, if any, on the invasion and migration of lung cancer cells in the body. 
 
9.3 Validation of Targets from 2D-DIGE Conditioned Media Experiment 
 
9.3.1 Peroxiredoxin (Prx) 
Reactive oxygen species (ROS) are derived from the metabolism of molecular 
oxygen (Halliwell 1999). They are formed and degraded by all aerobic organisms, 
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leading to either physiological concentrations required for normal cell function, or 
excessive quantities and the state called oxidative stress (Nordberg and Arner 2001). 
Oxygen derived species such as superoxide radical, hydrogen peroxide, singlet 
oxygen and hydroxyl radical are well known to be cytotoxic and have been 
implicated in the etiology of a wide array of human diseases, and as oxidative 
damage to cellular DNA can lead to mutations it may play an important role in the 
initiation and progression of multistage carcinogenesis (Waris and Ahsan 2006). 
Anti-oxidative enzymes, such as superoxide dismutase (SOD), catalase, and 
glutathione peroxidise (PGX), scavenge reactive oxygen species and in doing so 
protect cells against oxidative stress (Fujii and Ikeda 2002). ROS induces other 
signal transduction proteins and play a pivotal role in the genesis and invasiveness 
of tumours (Lavrovsky, Chatterjee et al. 2000). 
Superoxide anions are formed from the incomplete reduction of oxygen to water 
during respiration and are spontaneously or enzymatically converted to hyrdrogen 
peroxide (H2O2), which, though not very reactive, can be further reduced to the very 
damaging hydroxyl radicals (Rhee, Kang et al. 2001). Hydroxyl radicals can reduce 
disulfide bonds in proteins, specifically fibrinogen, resulting in their unfolding and 
scrambled refolding into abnormal spatial configurations, a consequence of which 
has been observed in cancer (Lipinski). To combat this all aerobic cells have H2O2-
removing enzymes which include catalase, glutathione peroxidise, haem-containing 
peroxidise, and peroxiredoxin. 
 
Peroxiredoxin (Prx) is a family of peroxidases present in all animals, with 
molecular weight ranging from 20-30kDa. Prx exists in multiple isoforms, with at 
least six isoforms in humans (Tripathi, Bhatt et al. 2009). Each isoform distribute 
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differently in organelles, undergo different reaction intermediates during catalysis, 
and exhibit different expression patterns during development, with some providing 
defence against oxidative damage and others appearing to participate in signalling 
by controlling H2O2 concentration (Rhee, Kang et al. 2001). Prx 1 and Prx 2 are 
cytoplasmic, though small amounts of both have been reported to exist within the 
nucleus, while Prx 3 is found only in the mitochondria. The six isoforms in humans 
show strong amino acid sequence similarities and commonly exhibit peroxidase 
activity, which is dependent on reduced forms of thioredoxin (Trx) and/or 
glutathione (GSH). All members have shown antioxidant activity in the protection 
of glutamate synthase from oxidation and their reduction of peroxides, with a high 
affinity for H2O2 common to all (Fujii and Ikeda 2002). 
Prxs have been implicated in regulating many cellular processes including cell 
proliferation, differentiation, and apoptosis. The continuous growth and 
proliferation of lung cancer and persistent exposure to carcinogens may produce 
large amounts of ROS, particularly H2O2 and because this is catalysed by Prx 
proteins it makes sense that they are overexpressed in many types of cancer, with 
one study suggesting the upregulation of Prx 1 and Prx 3 in lung cancer may 
represent an attempt by tumour cells to adjust to the tumour microenvironment in a 
way that is beneficial to proliferation and survival while maintaining their 
malignancy potential (Park, Kim et al. 2006). 
 
Peroxiredoxins have been found to be elevated in several human cancer cells and 
tissues and to influence diverse cellular processes including cell survival, 
proliferation, and apoptosis (Kim, Bogner et al. 2008). Peroxiredoxin 1 (Prx1) has 
been shown to be elevated in oral, esophageal, pancreatic, follicular thyroid, and 
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lung cancer (Yanagawa, Ishikawa et al. 1999, Yanagawa, Iwasa et al. 2000, Chang, 
Jeon et al. 2001, Qi, Chiu et al. 2005) and to be overexpressed in NSCLC tissue 
(Chang, Lee et al. 2005), and Prx 1 and peroxiredoxin 2 (Prx2) have both been 
found to be elevated in breast cancer and head and neck cancers (Noh, Ahn et al. 
2001, Karihtala, Mantyniemi et al. 2003). Prx 1 has also been found to be elevated 
in the serum of epithelial ovarian cancer versus normal/benign patients (Hoskins, 
Hood et al. 2011). 
 
Although our 2D-DIGE experiments on conditioned media of lung cancer cell lines 
found peroxiredoxins to be elevated in lung cancer our validation in serum showed 
the levels of three peroxiredoxins to be decreased in the serum of lung cancer 
patients compared to normal patients. Prx 1 (Fig. 3.4.13) and Prx 2 (Fig. 3.4.14) 
were found to be decreased in lung cancer samples compared to normal samples, 
and while Prx 3 (Fig. 3.4.15) was also decreased, the differences were negligible.  
Prx 3 did not show any potential as a lung cancer biomarker however the potential 
of Prx 1 and Prx 2 can not be dismissed. For example, lower levels of Prx 2 in 
colorectal tissue has been associated with poorer disease-free survival or poorer 
overall survival (Ji, Li et al.), and so in turn lower levels of Prx 1 and Prx 2 in lung 
cancer serum could act as an indicator of disease state. The lung cancer serum 
samples used for the Prx 1 and Prx 2 ELISAs were for late-stage disease. Though 
not performed for this Thesis, comparing the levels of Prx 1 and Prx 2 in early stage 
lung cancer serum to late stage lung cancer serum could prove to be very useful for 
treatment monitoring and disease staging. 
 
9.3.2 Triosephosphate Isomerase (TPI) 
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Triosephosphate isomerise is an enzyme involved in glycolysis, catalysing the 
reversible interconversion of the triose phosphate isomers dihydroxyacetone 
phosphate (DHAP; a ketose) and D-glyceraldehyde-3-phosphate (GAP; an aldose). 
TPI is also involved in other metabolic processes such as gluconeogenesis, the 
pentose phosphate shunt, and fatty acid biosynthesis. Glycolysis and its role in 
cancer are covered in greater detail in Section 9.3.6. TPI has been mentioned as a 
possible lung cancer biomarker and one study showed in serum that it could 
distinguish squamous cell carcinoma patients from healthy patients, their ROC 
curve analysis taken at a particular cut-off point showed their ELISA could 
correctly classify 65.6% of SCC patients and 84.7% of healthy patients (Zhang, 
Xiao et al. 2009). 
An ELISA was performed on TPI in serum (See Fig. 3.4.18). Although there was a 
slight increase in cancer serum compared to normal serum the results were not 
statistically significant and the Box-and-Whisker plot shows there were large 
differences between samples for the same condition. TPI as a possible lung cancer 
biomarker did not look promising and no further assays were performed. Our 
interest in TPI as a lung cancer biomarker ended with the results of this ELISA. 
 
9.3.3 Lactate Dehydrogenase (LDH) 
Lactate dehydrogenase catalyses the interconversion of pyruvate and lactate 
accompanied by interconversion of nicotinamide adenine dinucelotide (NADH) and 
NAD+. When oxygen is absent or in short supply it converts the final product of 
glycolysis (i.e pyruvate) to lactate. LDH is not a specific cancer marker and tends to 
be elevated in almost all types of cancer. It is widely used as a prognostic factor for 
many cancers. Elevated serum levels of LDH was identified as a prognostic factor 
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for poor survival in lung cancer (Bremnes, Sundstrom et al. 2003), renal carcinoma 
(Atzpodien, Royston et al. 2003), head and neck cancer (Brizel, Schroeder et al. 
2001), and prostate and colorectal cancer (Suh and Ahn 2007). It has also been 
described as an important indicator of in-hospital mortality for advanced cancer in 
general (Bozcuk, Bilge et al. 2004). High levels of LDH are an indicator of tissue 
damage and can be caused by illness or injury. Though high levels of LDH indicate 
cellular damage they are not specific enough to pin point the exact location of the 
damage or injury, therefore making it a useful prognosis marker and not diagnosis 
marker. Because LDH is involved in anaerobic glycolysis it can be assumed its 
levels will increase in cancer as the uncontrolled growth of cells will require more 
energy as postulated by the Warburg Effect (See Section 9.3.6). It has been 
suggested as a marker of airway inflammation (Faruqi, Wilmot et al.), so its 
usefulness as a lung cancer biomarker can be rightly questioned. 
 
An assay for LDH was performed (Fig. 3.4.16) measuring its activity in serum. As 
expected its levels were increased in lung cancer compared to normal serum. LDH 
was elevated in SCC, AD, and SCLC compared to normal and this elevation was 
statistically significant for all three comparisons. Small cell carcinoma versus 
normal had a sensitivity of 91.7% and a specificity of 85%, highlighting its 
trustworthiness as a marker for cancer. High serum levels of LDH are so well 
characterised as a marker for cancer that a result in this case indicating lower levels 
of activity in cancer compared to control would raise doubts about the quality of the 
assay itself. Due to the differences between cancer and normal being relatively 
small and more importantly due to the fact LDH is elevated in so many conditions 
and already used as a marker for cancer prognosis in many cancers no further assays 
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were performed on this protein. 
9.3.4 Glyceraldehyde-3-dehydrogenase (GAPDH) 
GAPDH is an important enzyme involved in cell energy metabolism. Proliferating 
cells like cancer cells tend to utilise aerobic glycolysis for energy metabolism. 
GAPDH catalyses the sixth step in the glycolysis process (See Fig. 9.1). It is often 
used as a loading control in Western Blots to confirm similar quantities were loaded 
on the gel for all the different samples because its levels usually remain stable from 
condition to condition. However it has recently been shown to have an involvement 
in cell death, transfer RNA transport, DNA repair, membrane trafficking, histone 
biosynthesis and other activities (Tristan, Shahani et al.). GAPDH has been 
suggested as a promising target for anticancer therapy as inactivation of its 
enzymatic activity via targeted agents can likely affect its pro-apoptotic activity too, 
both in cancer and normal cells, and the bonus of a glycolysis-based therapy is that 
it can be applied to many types of cancers (Krasnov, Dmitriev et al.). 
Although no comparisons of GAPDH from the conditioned media work were 
statistically significant and therefore not included in the DeCyder result Tables 3.3.1 
to 3.3.12, it did show ~4-fold difference between lung cancer and NHBE and there 
was an ELISA kit available.  
An ELISA was performed for GAPDH in serum samples (Fig. 3.4.17). The 
expected result was there would be no or little difference between cancer and 
normal samples but the result from the conditioned media work (data not shown) 
raised doubt in the certainty of this. As can be seen in Figure 3.4.17 there is 
practically no difference in the levels of GAPDH in normal serum compared to 
cancer serum, and the bigger spread in results in cancer can be attributed to the fact 
there were seventy-four cancer samples to 12 normal samples. It is unlikely 
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GAPDH could act as a biomarker for lung cancer or be used in lung cancer 
treatment monitoring. Taking GAPDH’s function as a loading control into account 
perhaps what can be taken from this ELISA is that there are similar protein levels in 
all the normal serum and cancer serum samples. This is more significant than might 
first appear. The serum samples are a combination from different hospitals and there 
is always a worry that serum will be collected differently between hospitals that 
may affect the levels of proteins in the serum samples. Differences can also arise 
not only from the sampling technique used but the time before proper storage in the 
hospital and also during delivery from the hospital until proper storage in the 
freezers in the NICB (see Section 4.1 for greater detail on the possible affects of the 
preanalytical phases). Although it can not be taken with certainty it can be assumed 
that the GAPDH ELISA result may indicate that the overall protein content of these 
serum samples has not been changed despite the likely differences undergone 
during the preanalytical phase. No further assays were performed on GAPDH. 
 
9.3.5 HSC70-interacting protein (Hip) 
Heat-shock proteins (HSPs), present in all organisms, are regarded as intracellular 
molecules with important chaperone and cytoprotective functions (Hightower 
1991). The expression of HSPs is induced by protein-damaging stresses and they 
have essential roles in protecting cells from the potentially lethal effects of stress 
and proteotoxicity (impairment of cell function due to misfolding of a protein). 
Conditions of environmental stress such as heat shock, oxidative stress, heavy 
metals, or pathologic conditions such as inflammation, tissue damage, infection and 
mutant proteins associated with genetic diseases, results in the expression of heat-
shock proteins that function as molecular chaperones or proteases (Jolly and 
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Morimoto 2000). During cell stress, folding intermediates can lead to misfolded or 
otherwise damaged molecules and to prevent this happening a class of proteins 
called molecular chaperones interact with diverse protein substrates to assist in their 
folding. Heat-shock proteins, as molecular chaperones repair damaged proteins, or 
as proteases degrade damaged proteins, to restore protein homeostatis and promote 
cell survival, helping cells recover from stress and restore balance (Jolly and 
Morimoto 2000). HSPs are also known to afford protection against protein 
aggregation and induce solubilisation of loose protein aggregates (Hartl 1996). 
HSPs make up 5-10% of the total protein content in a cell under healthy conditions. 
When protein-damaging stresses induce protein misfolding or aggregation, the 
affected proteins bind to chaperones and release heat shock factor (HSF) which acts 
as a transcription factor and binds to heat shock elements within the promoter of 
HSP genes, resulting in an increase, often two- to three-fold, of cellular Hsp 
concentration (Pockley 2003, Voellmy 2006, Soo, Yip et al. 2008). 
 
Hsp70, designated so because of a molecular weight of 70kDa, has been studied 
extensively and can be considered the Hsp most inducible by stress (Suzuki, Ito et 
al. 2006). It is involved in inflammatory diseases, and serum levels of Hsp70 have 
been directly linked to a patient’s inflammatory status (Njemini, Demanet et al. 
2004). Due to the function of HSPs it has been proposed that their overexpression 
could be a potential therapy for neurodegenerative diseases characterised by the 
accumulation or aggregation of abnormal proteins (Mansilla, Montalban et al.). 
Serum levels of Hsp70 were shown to be elevated in patients with NSCLC 
diagnosed at an early or at an advanced stage when compared with healthy control 
groups (Zimmermann, Nickl et al. 2012). Hsp 70 has been shown to bind to the p53 
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tumour suppressor protein, the mutation of which is one of the most common events 
in cancer development (Lane, Midgley et al. 1993), though there is no conclusive 
evidence that the increased HSP levels are necessary to inactivate tumour 
suppressor molecules for malignant transformation to take place (Hollstein, 
Sidransky et al. 1991). Hsp70 expression has been correlated with poor prognosis in 
breast, endometrial, uterine cervical and bladder carcinomas (Ciocca and 
Calderwood 2005). 
 
HSP70 and HSC70 are often used interchangeably to describe the heat shock 
protein 70 but in fact Hsc70 (also known as HSP73) is a constitutively expressed 
chaperone protein while HSP70 is a stress- and heat shock-induced protein. They 
are cytosolic isoforms of the heat shock protein family HSP70. HSC70-interacting 
protein (also described as HSP70-interacting protein or Hip) is a co-chaperone of 
the 70-kDa heat shock proteins HSC70/HSP70 encoded by the gene ST13 
(suppression of tumourigenicity 13), though its role in cancer development is not 
certain. The expression of ST13 has however been shown to decrease in colorectal 
cancer tissue compared to adjacent normal tissue (Wang, Zheng et al. 2005). Hip 
may facilitate the chaperone function of HSC70/HSP70 in protein folding and 
repair, and in controlling the activity of regulatory proteins such as steroid receptors 
and regulators of proliferation or apoptosis (Shi, Zhang et al. 2007). 
 
An ELISA was performed on HSC70-interacting protein in late-stage lung cancer 
serum (Fig. 3.4.11). There was an increase in quantity of Hip in serum for each of 
the three cancer types (SCC, AD, and SCLC) compared to normal serum. The only 
statistically significant comparison was normal compared to AD where 20 normal 
were compared to 28 AD samples. Though there is crossover in the results Hip 
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shows potential as a biomarker in serum for adenocarcinoma. Being able to 
differentiate adenocarcinoma from SCC is very useful for selecting appropriate 
chemotherapy for patients with advanced disease (Terry, Leung et al. 2010). The 
results from this ELISA are not overly impressive but the potential of Hip as a lung 
cancer biomarker remains. There are a number of other ELISAs that could be 
performed, perhaps one comparing a large cohort of SCC and AD samples only. 
Also there is a need to examine it in plasma samples and also in benign lung disease 
samples in both serum and plasma. 
 
Immunohistochemistry was also performed on HSC70-interacting protein (Section 
3.5). In Table 3.5.2 the intensity scores for the tissue cores is recorded. Tissue cores 
available were from SCC, AD, SCLC, alveolar cell carcinoma, and normal lung 
tissue. Alveolar cell carcinoma (ACC) is a primary neoplasm of relatively 
infrequent occurrence. When it is operable the tumour is typically peripheral and 
may involve a small area of pulmonary parenchyma or it may be extensive, 
involving all of a lung or an entire lobe, and tends to arise from the pulmonary 
parenchyma rather than from a major bronchus (Belgrad, Good et al. 1962). 
Alveolar cell carcinoma is now referred to as bronchioalveolar carcinoma (BAC), a 
variant of lung cancer that arises in the distal bronchioles or alveoli that initially 
exhibit a specific non-invasive pattern. BAC is a sub-group of adenocarcinoma, 
however the term bronchioalveolar carcinoma is no longer considered valid and has 
been re-categorised (Lee, Goo et al.). 
Table 3.5.3 shows that SCC, SCLC, and ACC showed the strongest staining, with 
61.54%, 65.22%, and 53.85% of cores respectively with an intensity score of 3. The 
scoring system covers; strong (designated 3), intermediate (2), weak (1), and 
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negative (neg) staining. For AD cores only 23.81% showed strong staining, with 
alveolar carcinoma showing staining intensity more similar to SCC and SCLC than 
AD. Staining overall was most intense in SCC, as the remaining 38.46% of cores 
were intensity 2. One third (33.33% exactly) of AD cores were intensity 1 while 0% 
of SCC cores and only 7.7% of ACC cores were scored the same. Staining was 
certainly less in normal lung tissue, with 30% at intensity 2 and 70% at intensity 1. 
No cores showed negative staining and with very strong staining in many cores it 
can be assumed that the antibody concentration was too high, despite the 
optimisation steps. This experiment would need to be repeated using a more dilute 
antibody concentration to give a more realistic representation of the staining 
patterns in lung cancer and normal lung tissue cores.  
The conclusion can be made that HSC70-interacting protein is more strongly 
expressed in lung cancer tissue than normal lung tissue. By acting as a chaperone 
protein for heat shock proteins it is not surprising that Hip levels are increased in 
cancer. Heat shock proteins are over-expressed in many cancers and implicated in 
tumour cell proliferation, differentiation, invasion, metastasis, death, and 
recognition by the immune system (Ciocca and Calderwood 2005) so it is not 
surprising that a protein needed for its proper folding would also be increased. 
 
9.3.6 Pyruvate Kinase M2 (PKM2) 
Pyruvate kinase is an enzyme that catalyses the last, rate-limiting step of glycolysis. 
Glycolysis, literally meaning the lysis of glucose, first requires the conversion of 
glucose to pyruvate and then to the waste product lactic acid. In most mammalian 
cells glycolysis is inhibited by the presence of oxygen, which allows mitochondria 
to oxidise pyruvate to CO2 and H2O. For maintenance of energy production 
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throughout a wide range of oxygen concentrations it is essential that mammalian 
cells have versatile metabolisms and conversion of glucose to lactic acid in the 
presence of oxygen is known as aerobic glycolysis, and when seen in cancer cells as 
the Warburg Effect (Gatenby and Gillies 2004). Warburg proposed in the 1920’s that 
cancer results from impaired mitochondria metabolism and although this hypothesis 
has been proven incorrect, increased glycolysis in tumours even in the presence of 
oxygen has been verified (Semenza, Artemov et al. 2001). 
 
Pyruvate kinase catalyses the transfer of a phosphate group from 
phosphphenolpyruvate (PEP) to ADP, yielding one molecule of pyruvate and one 
molecule of ATP. Four isoforms are present in mammals; L, R, M1, and M2. The L 
and R isotypes are encoded by the PKLR gene and their expression is tissue specific 
and regulated by different promoters (Tamada, Suematsu et al. 2012). The L isotype 
is expressed in the liver, kidney, and intestine, and the R isotype is expressed in red 
blood cells (Mazurek, Boschek et al. 2005, Clower, Chatterjee et al. 2010, Mazurek 
2011). On the other hand PKM1 and PKM2 are encoded by the PKM gene and are 
the products of 2 mutually exclusive alternatively spliced exons (exon 9 and exon 
10 respectively) (Noguchi, Inoue et al. 1986, David, Chen et al. 2010). 
 
In most adult differentiated tissue, such as brain and muscles, the M1 isoform is 
expressed, whereas M2 is expressed in embryonic cells, adult stem cells, and cancer 
cells (Mazurek, Boschek et al. 2005). However, the preference of cancer cells for 
the PKM2 isoform over PKM1 in tumourigenesis has been called into question, 
studies suggesting that an exchange in PKM1 to PKM2 isoform expression during 
cancer formation is not occurring, that the PKM2 isoform dominance in cancer is 
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not a result of a change in isoform expression since PKM2 was also the 
predominant PKM isoform in matched control tissues, in unaffected lung tissue for 
example PKM2 accounted for a minimum of 93% of total PKM (Bluemlein, 
Gruning et al. 2011). Linking PKM2 to tumour growth can not, however, be easily 
dismissed as it has been suggested the expression of this isoform is necessary, and 
indeed essential, for tumour growth (Christofk, Vander Heiden et al. 2008, Gupta 
and Bamezai 2010). Indeed it has been noted that the replacement of PKM2 with 
PKM1 reduces the capacity of human tumour cell lines to develop into a tumour, 
allowing for the notion that by a change in PK splicing, tumourigenesis can be 
induced through shifting cellular metabolism to aerobic glycolysis (Christofk, 
Vander Heiden et al. 2008).  
PKM2 is present in very few types of proliferating normal cells but is present at 
high levels in cancer cells, slowing the passage of metabolites through glycolysis 
and promoting the shuttling of these substrates through the pentose phosphate 
pathway and other alternative pathways so that large quantities of reduced NADPH 
and other macromolecules are produced, which in turn are required for 
macromolecule biosynthesis and redox balance maintenance that are needed to 
support the rapid cell division that is undergone within a tumour (Cairns, Harris et 
al.). It has been suggested that silencing PKM2 alone can retard tumour cell growth 
by inducing apoptosis and inhibiting proliferation both in vitro and in vivo, making 
it a desirable target for cancer therapy (Peng, Gong et al. 2011). Several small 
molecule PKM2 inhibitors and activators have been developed, however as nearly 
complete knockdown of PKM2 does not completely inhibit cancer cell 
proliferation, caution should be maintained on the utility of PKM2 inhibition in 
targeting cancer (Tamada, Suematsu et al. 2012).  
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One study has shown in their study that tumour M2-PK (pyruvate kinase M2 
tumour marker) had higher sensitivity (58%) in the detection of lung cancer than the 
CEA-Test (sensitivity 39%) or CYFRA 21-1 (sensitivity 48%) and generally 
showed a higher sensitivity for NSCLC (68%) (Schneider, Velcovsky et al. 2000). It 
has been shown that for colorectal cancer a combination of tumour M2-Pk with an 
appropriate first choice-marker (e.g. CEA + Tumour M2-PK) in plasma resulted in a 
remarkable increase in the sensitivities (Schulze 2000). One study found 
measurement of tumour M2-PK may be useful in patients with lung cancer as 78% 
of SCLC patients, 73% of AD patients, and 81% of NSCLC patients showed an 
increase of tumour M2-PK serum concentration, while its concentration in patients 
with non-malignant diseases (e.g. bronchitis or tuberculosis) was within normal 
limits (Oremek, Kukshaite et al. 2007). 
 
Pyruvate kinase has potential as a biomarker of lung cancer. Interestingly PKM2 is 
elevated in lung cancer serum, both late-stage and early stage, as well as lung 
cancer plasma compared to controls. Although the results of Fig. 3.4.7 were not 
statistically significant there is a clear increase of PKM2 in lung cancer types 
compared to normal and even in Fig. 3.4.8 using earlier stage lung cancer PKM2 is 
elevated in lung cancer serum. Interestingly in Fig. 3.4.8 it is higher in lung cancer 
compared to benign lung disease too with significant T-test scores and even in 
plasma in Fig. 3.4.9 it is elevated in both NSCLC and SCLC compared to the 
control groups (both normal and benign lung disease). This increase in PKM2 in 
cancer serum and plasma could be attributed to the cancer cells undergoing aerobic 
glycolysis, the preferred energy pathway for cancer cells which utilises the PKM2 
isoform.  
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It has been suggested that the PKM2 isoform plays an important role in the growth 
and metabolic reprogramming of cancer cells in conditions of stress and how upon 
glucose starvation or lack of glucose due to their proliferative behaviour PKM2 
activity is stimulated to alter cellular energy levels, glucose uptake, and lactate 
production in cancer cells (Keller, Tan et al.). PKM2 can regulate the proportions of 
glucose carbons that are channelled to synthetic processes (an inactive dimeric 
form) or used for glycolytic energy production (active tetrameric form) and the use 
of the dimeric form in tumour cells is always predominant, allowing tumour cells to 
survive in environments with varying oxygen and nutrient supply, which is 
invariably the sort of environment cancer cells will find themselves due to their 
unnatural behaviour and location (Mazurek, Boschek et al. 2005). 
 
The pyruvate kinase biochemical assay showed pyruvate kinase activity in serum to 
be decreased in cancer serum compared to normal serum. The pyruvate kinase 
biochemical assay calculates the rate at which pyruvate kinase is being used based 
on the amount of pyruvate being generated over a controlled time-point. A growing 
tumour will require more energy from the body and if pyruvate kinase is being 
produced in greater amounts then perhaps there is more than is required for the 
amount of PEP available for conversion to ADP. This could result in an increase of 
pyruvate kinase but a decrease of PEP finding its way into the serum of lung cancer 
patients. This could explain why pyruvate kinase levels in lung cancer serum are 
higher than normal serum, while at the same time PEP levels could be higher in 
normal serum compared to lung cancer serum meaning less pyruvate is being 
produced in lung cancer serum resulting in less pyruvate kinase activity.  
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Immunohistochemistry was performed on a lung tissue array slide for PKM2 
(Figures 3.5.24 to 3.5.27). The intensity scoring is presented in Table 3.5.4. The 
results suggest PKM2 would not make a useful tissue marker. Indeed, surprisingly, 
the expression of PKM2 is highest in normal lung tissue, a total of 40% of normal 
lung tissue showing strong staining, more than any of the cancers SCC, AD, SCLC, 
and ACC. In fact all normal lung tissue showed some degree of staining, whereas 
some of the cancer cores exhibited negative staining e.g. ~24% of AD cores. There 
are no significant differences between the cancer tissue types to separate them from 
one another. Considering the elevated levels of PKM2 in lung cancer compared to 
controls for late-stage lung cancer serum, early-stage lung cancer serum, and early-
stage lung cancer plasma, it was unexpected to see higher PKM2 expression in 
normal lung tissue than in the cancer tissue, however it is known that good serum 
markers do not necessarily make good tissue markers and vice versa. 
 
9.3.7 HnRNPA2B1 
 
hnRNPA2B1 belongs to the A/B subfamily of ubiquitously expressed heterogeneous 
nuclear ribonucleoproteins (hnRNPs) (Tauler, Zudaire et al.; Kamma, Horiguchi et 
al. 1999). A2 and B1 are produced by alternative splicing from a single copy gene 
(Kozu, Henrich et al. 1995), and differ from each other only by a 12-amino-acid 
insertion in the N-terminal RNA binding motif (RBD) of B1 (Burd, Swanson et al. 
1989). hnRNPs are RNA binding proteins (RBPs) that form complexes with 
heterogeneous nuclear RNA (Wen, Shen et al.) and play important roles in 
regulating gene expression at transcriptional and also at post-transcriptional levels 
(He and Smith 2009), as well DNA repair, telomere biogenesis and cell signalling 
(Krecic and Swanson 1999; Dreyfuss, Kim et al. 2002). They are among the most 
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abundant nuclear proteins in mammalian cells (Patry, Bouchard et al. 2003) and 
appear to influence pre-mRNA processing and other aspects of mRNA metabolism 
and transport (Weighardt, Biamonti et al. 1996), and can prevent folding of pre-
mRNA into secondary structures that may inhibit its interactions with other proteins 
(Golan-Gerstl, Cohen et al.). It has been noted that they are essential for RNA 
metabolism, coordinating post-transcriptional events (splicing, transport, cellular 
localisation, decay and translation of mRNA) by participating in an extensive 
network of RNA-RBP interactions (Boukakis, Patrinou-Georgoula et al.). 
 
More than 20 distinct hnRNP proteins have been identified in human cells, 
designated hnRNPs A to U in increasing molecular size from 32 to 110kDa. This 
family of abundant nuclear proteins include many that share common structural 
motifs, exhibiting multiple isoforms (products of alternative splicing, as well as of 
post-translational) and having the ability to shuttle between the nucleus and the 
cytoplasm (Dreyfuss, Matunis et al. 1993; Burd and Dreyfuss 1994). 
The hnRNP A/B subgroup includes members of 32-40kDa size range. They have in 
common two tandem N-terminal RNA-binding domains of the RRM/RBD type 
(RNA recognition motif/RNA binding domain) and a C-terminal auxiliary domain 
rich in glycine (Boukakis, Patrinou-Georgoula et al.). Along with hnRNPA2B1, 
hnRNPA1 and hnRNPA3 are the best characterised, all of which share a high degree 
of sequence homology and the presence of several isoforms originating mainly from 
alternative splicing (He, Brown et al. 2005). hnRNPA2B1 in particular refers to two 
isoforms, the major hnRNP A2 and the minor B1 form that results from the 
inclusion of an extra exon (Burd, Swanson et al. 1989). In both proteins and mRNA 
levels, their proportions vary in different cells and tissues, with B1 constituting 
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roughly 2-5% of A2 (Kozu, Henrich et al. 1995; Kamma, Horiguchi et al. 1999). 
The major nuclear function of hnRNPA2B1 is thought to be in splicing and in 
particular alternative splicing of mRNA which allows many gene products with 
different functions to be produced from a single coding sequence (Brett, Pospisil et 
al. 2002). hnRNPA2B1 has been shown to antagonise, in a concentration dependent 
manner, protein members of the splicing regulator (SR) group, notably ASF/SF2, 
and to influence the mode of splicing of mRNA target molecules (Hanamura, 
Caceres et al. 1998). 
Overall expression of the hnRNP A/B proteins is tightly regulated during 
development and known to be tissue and cell type specific (Kamma, Horiguchi et 
al. 1999). It has been shown in human and rodent tissues that high hnRNP A/B 
levels occur during embryonic development and drop dramatically in adult lung 
tissue (Montuenga, Zhou et al. 1998). The expression of hnRNPs in cancer cells has 
been associated with alterations in their protein levels (over-expression and down-
regulation), mRNA abundance, cellular localisation, isoform types and post-
translational modifications (such as phosphorylation) (Tockman, Mulshine et al. 
1997; Ostrowski and Bomsztyk 2003). 
hnRNPA2B1 has previously been found to be a potential early marker of lung 
epithelial transformation and carcinogenesis (Zhou, Mulshine et al. 1996), up-
regulated in bronchial lavage specimens (Fielding, Turnbull et al. 1999), a potential 
early marker for breast cancer (Zhou, Allred et al. 2001), overexpressed in human 
pancreatic cancer (Gu, Liu et al.), and a novel oncogene in glioblastoma and a 
potential new target for glioblastoma therapy (Golan-Gerstl, Cohen et al.). 
hnRNPA2B1 has also been shown to modulate epithelial-to-mesenchymal transition 
in lung cancer cell lines (Tauler, Zudaire et al.). 
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Two serum ELISAs were performed comparing normal serum to late-stage SCC, 
AD, and SCLC. In the first ELISA (fig. 3.4.1) comparing almost identical quantity 
of samples; normal (n=20), SCC (n=20), AD (n=20), and SCLC (n=19). 
HnRNPA2B1 was significantly increased in all lung cancer types compared to 
normal, where it was barely detectable. The results between NSCLC and SCLC 
overall were relatively similar with the median values for SCLC and SCC at 
54.2pg/ml and 53.4pg/ml respectively. Median value for normal controls was very 
low in comparison (1.6pg/ml) and interestingly hnRNPA2B1 was not detected at all 
in the NHBE cell line conditioned media.  
A few high results can obviously increase the average significantly, but by including 
a box and whisker plot alongside the bar chart that indicates q1, min, median, max, 
and q3 values then a more true understanding of the results can be deciphered. With 
such small sample sets being used it was not ideal to use strict cut-off points and by 
including both graphs to display data there is little chance of ambiguity when 
interpreting the trend. Figure 3.4.2 shows data distribution of every sample, 
indicating hnRNPA2B1 levels vary considerably in lung cancer serum.  
ROC curve analysis was performed for statistically significant comparisons (Fig. 
3.4.3), with normal versus SCC showing the best trade-off between sensitivity and 
specificity, 85% and 80% respectively. Even on its own hnRNPA2B1 showed 
potential as a lung cancer biomarker. 
 
In the second ELISA (Fig. 3.4.4) hnRNPA2B1 is again significantly elevated in 
SCC, AD, and SCLC compared to normal, however the normal serum samples 
showed higher levels than those from the first ELISA. In both ELISAs the SCC 
group showed the highest levels of hnRNPA2B1. Overall the second ELISA (Fig. 
 330
3.4.4) shows more consistency in results and perhaps can be taken with more merit 
than the first ELISA (Fig. 3.4.1). It can be concluded that hnRNPA2B1 levels are 
increased in late-stage lung cancer serum compared to normal serum. The samples 
used in the first assay are actually identical to the samples used in the second assay 
so it can be assumed the ELISA kits themselves showed varying degrees of 
specificity and sensitivity perhaps due to batch-to-batch variation, or insufficient 
QC. 
 
A plasma ELISA was performed on hnRNPA2B1 (Fig. 3.4.5) comparing normal, 
benign lung disease, NSCLC, and SCLC serum, though the number of samples for 
each group varied considerably (n=30, n=39, n=60, and n=14 respectively). Benign 
lung disease and SCLC show almost identical averages (74.1pg/ml and 74.6pg/ml 
respectively) and the higher average in NSCLC (114.6pg/ml) could be biased by the 
extra samples, especially in its comparison with SCLC. The average concentration 
in normal plasma is significantly higher (210ng/ml), its results statistically 
significant when compared to the other three groups. Interestingly, the benign 
versus NSCLC t-test was also significant but the benign versus SCLC was not 
(though of course this could be attributed to different sample sizes).  
These samples were earlier stage lung cancer compared to the serum samples in Fig. 
3.4.1 and Fig. 3.4.4 but levels of normal plasma and that of normal serum in Fig. 
3.4.4 should be comparable and there are higher concentrations of hnRNPA2B1 in 
normal plasma, a ~2.5 fold increase. In cancer serum the concentrations of NSCLC 
and SCLC are higher compared to plasma but the concentration in plasma could rise 
in late-stage lung cancer to similar levels in serum of late-stage.  
An ELISA was performed to investigate if the hnRNPA2B1 levels in early-stage 
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cancer serum are higher than those in early-stage cancer plasma (Fig. 3.4.6). The 
samples used were matching plasma and serum samples from the same patients. 
Interestingly, the levels of hnRNPA2B1 were higher in plasma than serum of early-
stage lung cancer patients. The average levels of hnRNPA2B1 in both benign lung 
disease plasma and lung cancer plasma are double that in lung cancer serum, indeed 
benign lung disease serum shows higher levels too. Because many of these samples 
were used in the plasma ELISA (Fig. 3.4.5) then, as in that assay, it can be assumed 
that hnRNPA2B1 levels in normal plasma are higher than two plasma controls and 
hence higher than all four conditions in Fig. 3.4.6.  This data further confirms that 
serum and plasma can not be treated as being the same biological fluid and assays 
must be run on both before any conclusions can be drawn. If, as expected, 
hnRNPA2B1 levels are lower than normal in early-stage lung cancer serum and far 
higher in late-stage lung cancer then this biomarker could be very beneficial for 
drug treatment monitoring. Ideally an assay would be run with many lung cancer 
samples diagnosed as different stages to elucidate any trend that relates tumour 
stage to hnRNPA2B1 serum levels. Also an assay should be run comparing 
hnRNPA2B1 levels in late-stage lung cancer to those in earlier-stage lung cancer, 
performed in the same run on the same plate. Normal and benign lung disease 
control groups would be essential also. 
 
Immunohistochemistry was performed on hnRNPA2B1 on two lung cancer tissue 
slides and also a mixed cancer tissue slide. hnRNPA2B1 expression was examined 
in tissue slides on a total of 100 cores; 14 SCC, 32 AD, 28 SCLC, 13 ACC, and 13 
normal lung tissue cores. The highest expression was seen in the SCLC tissue cores 
with a total of 50% of the cores either strong staining (42.86%) or strong staining 
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with variance (7.14%). A further 20% was intermediate staining or intermediate 
staining with variance and only 10% showed negative staining. SCC showed strong 
staining too (~36% strong or strong with variance). AD showed less staining than 
SCC and SCLC. There was significantly less staining in the normal lung tissue with 
over 61% of cores showing negative staining. Only 7.14% of SCC showed negative 
staining though this was higher in SCLC (10.71%) and AD (25%). hnRNPA2B1 
certainly has potential as a tissue marker. 
 
Immunohistochemistry was performed on a mixed tissue slide and scored (Table 
3.5.2). This slide contained colon adenocarcinoma, breast invasive ductal 
carcinoma, prostate adenocarcinoma, pancreas duct adenocarcinoma, and also lung 
SCC and AD cores. There was also normal colon, breast, prostate, pancreas and 
lung tissue, as well as cancer tissue adjacent to normal for colon and prostate. This 
was necessary to examine if hnRNPA2B1 tissue staining was specific to lung 
cancer. 
Table 3.5.2 shows that hnRNPA2B1 staining is present in all cancer types. Though 
intensity 3 is more likely in lung cancer it is still quite common to the other four 
cancers. However, though all the cancer tissues showed relatively similar levels of 
staining, the normal tissue did not. Interestingly there is far more negative staining 
in normal lung tissue compared to the other normal tissue, indeed some normal 
tissue showed quite intense staining; e.g. 75% of normal colon was intensity 1. On 
the other hand 80% of all normal lung tissue showed negative staining. This shows 
the potential of hnRNPA2B1 as a tissue marker of lung tumour mass and 
subsequently treatment monitoring. 
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Functional assays were performed for hnRNPA2B1. Invasion and migration assays 
were the assays of choice. By using small interfering RNA that 'interfere' with the 
expression of specific genes, the implications of effectively knocking down or 
reducing expression of a protein of interest can be examined in an assay of choice. 
As mentioned in Section 1.3 invasion and migration of cancer cells allow them to 
enter the blood or lymphatic system to grow at distant locations to the primary 
tumour in a process called metastasis. By 'knocking-down' expression of 
hnRNPA2B1 its role, if any, in migration and/or invasion of cancer cells can be 
elucidated.  
The effectiveness of the knockdown, performed using two separate siRNAs, was 
examined using western blot (Fig. 3.6.1). The expression of hnRNPA2B1 was 
effectively knocked down using the optimised conditions.  
Cells were seeded at 0.5x105 in all wells for all conditions (i.e. Untreated, NeoFx 
only, kinesin, scrambled siRNA, siRNA#1, siRNA#2). The effect of knocking down 
hnRNPA2B1 will be calculated by cell counts e.g.for invasion by counting the 
number of cells that pass through the matrix, however if the knockdown effects the 
rate at which the cancer cells grow (i.e. proliferation) then the differences in cell 
counts compared to the controls can not solely be attributed to an effect on the 
invasion and/or migration potential. A proliferation assay performed on the same 
cells under all conditions is used to examine if the knockdown had any effect on 
proliferation. Figure 3.6.2 shows there was negligible effect on proliferation caused 
by hnRNPA2B1 knockdown. 
 
The knockdown of hnRNPA2B1 had an effect on invasion and migration, having a 
bigger effect on the former. The knockdown was performed in the SCC cell line 
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DLKP-M. The effect can be measured by calculating percentage difference in cell 
counts between the scrambled control and both siRNA#1 and siRNA#2. For both 
invasion and migration both siRNAs had an effect. This was a transient knockdown, 
meaning the effect on expression is only temporary and not absolute. With this 
decrease in hnRNPA2B1 expression there was a 57% and a 44% knockdown in 
invasion for siRNA#1 and siRNA#2 respectively. For siRNA#1 and siRNA#2 there 
was a 32% and 39% decrease in migration. It can be concluded that hnRNPA2B1 
expression is necessary for effective invasion and migration of SCC cancer cells. 
Interestingly it appears to play a more important role in the ability of SCC cancer 
cells to pass through surrounding tissue than the actual movement of the cells. 
 
A number of functions of hnRNPA2B1 may explain why it has such a strong effect 
on invasion of SCC cells. The invasion of cancer cells is known to be initiated and 
maintained by signalling pathways that control cytoskeletal dynamics in tumour 
cells and the turnover of cell-matrix and cell-cell junctions, followed by cell 
migration into the adjacent tissue (Friedl and Alexander), and is associated with 
disorganisation and destruction of basement membranes (Lissitzky, Pourreau-
Schneider et al. 1985), so the role of hnRNPs in regulating gene expression, in cell 
signalling, and in preventing folding of pre-mRNA into secondary structures that 
inhibit its interactions with other proteins could all be important for efficient 
invasion of cancer cells. Also their role in coordinating post-translational events 
such as cellular localisation could be very important for the ability of cancer cells to 
invade adjacent tissue and subsequently metastasise to other locations. 
 
Logistic regression performed on hnRNPA2B1, PKM2, and Hip ELISAs (Fig. 
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3.4.12) show their potential as biomarkers of lung cancer. The results here are for 
normal versus lung cancer. However, hnRNPA2B1 and PKM2 combined appear to 
work just as well as the three markers together. It should be noted that in the 
classification table it shows the correct identification of patients with cancer at 90% 
for the combination of three and 89.83% for the combination of two, while the 
correct identification of patients that are healthy is 50% and 45% respectively. It is 
more important to correctly identify patients with cancer as having cancer than it is 
to lessen the chances of identifying healthy patients as having cancer when they 
don’t.  
 
9.4 2D-DIGE Analysis of Immunodepleted Serum 
 
As already mentioned the analysis of conditioned media from lung cancer cell lines 
grown in culture can only be used for discovery phase and it is the subsequent 
validation of any interesting proteins that will decide their potential as lung cancer 
biomarkers. Validation of conditioned media targets was performed in serum and it 
was found that for the most part the differences seen in serum between normal and 
lung cancer did not correspond to the fold changes extrapolated by DeCyder for the 
2D-DIGE experiments. Although conditioned media as a starting point showed 
potential, it was proposed that using serum in the discovery phase would increase 
the chances of targets subsequently validating in larger serum sets. As the 2D-DIGE 
experiments on conditioned media showed many potential biomarkers it was 
decided to use this technique again. 
Due to the complexity of serum (covered in greater detail in the Introduction and 
Section 9.1) the many proteins present in high abundance can mask the more 
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interesting disease-specific low abundant proteins. Therefore before serum could be 
used in a 2D-DIGE experiment some sort of fractionation was needed. 
Immunodepletion columns are designed to remove ~99% of all protein content from 
serum, in this case using antibodies for the 22 most abundant serum proteins. The 
initial experiment compared six normal and six adenocarcinoma serum samples. 
Instead of DeCyder for analysis new software known as Progenesis SameSpots was 
used. Progenesis SameSpots allows greater manipulation of results than the 
DeCyder software. 
 
This experiment failed to go as planned. After mass spectrometry identification of 
interesting spots, disease-specific low abundant proteins were not identified. Instead 
only high adundant proteins and their isoforms (See Table 4.2.1) were identified. 
This suggests the immunodepletion column could not remove all of the high 
abundant proteins and its antibodies may have become saturated. Although 
immunodepletion decreased overall protein content of the serum samples it did little 
to decrease the complexity of the sample and the small abundant proteins could not 
be detected. However, the results from Table 4.2.1 led to an unforeseen discovery. 
Table 4.2.1 showed multiple identifications for mutiple proteins. There were two 
IDs for zinc-alpha-2-glycoprotein, four IDs for alpha-1-antitrypsin, leucine-rich 
alpha-2-glycoprotein, and transferrin, and six IDs for haptoglobin. The assumption 
was made that these represented isoforms of the same protein. Haptoglobin proved 
to be the most interesting because each of the six isoforms in adenocarcinoma 
showed different fold changes compared to their compatriots in normal serum, as 
well as showing the most significant T-Test scores. Interestingly the highest fold 
change was seen in the isoform of highest molecular weight, the next highest fold 
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change in the isoform of next highest molecular weight and so on for the six 
isoforms (See Fig. 4.3.1). It was concluded that the six isoforms of haptoglobin 
could serve as a potential panel of biomarkers but further experiments were needed. 
 
9.4.1 Haptoglobin 
Haptoglobin is an acute phase protein (APP). Acute phase response is a systemic 
reaction of an organism to local or systemic disturbances in its homeostatis caused 
by infection, tissue injury, trauma or surgery, neoplastic growth or immunological 
disorders. During this response protein synthesis by the liver is drastically altered 
resulting in an increase of some blood proteins, known as the acute phase proteins 
(Gruys, Toussaint et al. 2005). APPs are plasma proteins involved in the restoration 
of homeostasis. The plasma level of some proteins, albumins for example, is 
decreased during the acute phase response. These are known as negative acute 
phase proteins. Positive acute phase proteins are those, like haptoglobin for 
example, where their plasma levels increase during the acute phase response. 
 
Haptoglobin (Hp) is a plasma glycoprotein composed of α1, α2 and ß polypeptide 
chains (around 9, 19 and 40kDa respectively), the three main phenotypes in humans 
designated Hp1-1, Hp2-2, and Hp2-1. Its main function is to bind haemoglobin 
(Hb) and prevent oxidative stress (Abdullah, Schultz et al. 2009). Hp binds free 
haemoglobin to protect against oxidative stress and to facilitate the uptake of Hb by 
Hb scavenger receptors (Kristiansen, Graversen et al. 2001), though some animals 
only synthesise haptoglobin in response to stress (Dobryszycka 1997). 
 
Glycosylation forms the sugar-amino acid linkage in the biosynthesis of the 
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carbohydrate units of glycoproteins and leads to a complex series of 
posttranslational enzymatic steps that lead to the formation of many protein-bound 
oligosaccharides with diverse biological functions (Spiro 2002). It is an enzymatic 
process that leads to the addition of glycans, either polysaccharides or 
oligosaccharides, to proteins, hence modifying the protein in some way. 
Glycosylation of proteins is an important post-translational modification that 
enhances the functional diversity of the proteins and influences their biological 
activity and each glycoprotein, such as haptoglobin, will have a mixture of 
glycosylated variants known as glycoforms (Marino, Bones et al.). 
A higher circulatory level of α haptoglobin has been reported in SCLC patients. 
Higher serum levels of α and ß haptoglobin isoforms have been observed in SCLC 
patient samples and also a ß chain variant (5kDa smaller than the full length) has 
been shown to be differentially expressed in SCLC serum (Shah, Singh et al.). 
 
Immunodepletion of serum followed by 2D-DIGE analysis is an expensive and 
time-consuming technique. For routine diagnostic tests of patient serum samples it 
is not a viable option. An alternative cheaper and less time-consuming method of 
detecting haptoglobin isoforms in serum was proposed. This involved running 
diluted raw serum directly on 2D gels and staining with coomaisse blue. Before this 
however a glycostain was run on a 2D gel to confirm the haptoglobin isoforms were 
in fact glycosylated. In Fig. 4.3.1 the six haptoglobin isoforms are highlighted in 
red, the stain confirming they are glycosylated. In the literature one study analysed 
which chain of Hp is closely related to lung cancers and found the Hp ß chain 
showed the most potential as a serum biomarker for lung cancer, it being increased 
4-fold in 190 lung adenocarcinoma patients versus 190 healthy controls while 
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showing levels in plasma of patients with other respiratory disease such as TB, 
idiopathic pulmonary fibrosis, and bronchial asthma were closer to those of healthy 
controls (Kang, Sung et al. 2011).  
Our experiments hoped to use the fold changes of the six isoforms or indeed the 
ratio differences between some of the isoforms as lung cancer biomarkers. Table 
4.2.1 showed for adenocarcinoma compared to normal serum fold changes, six 
isoforms from isoform with highest molecular weight to isoform with lowest 
molecular weight, of +7.74, +6.49, +6.00, +5.40, +4.59, and +3.73 respectively. 
This shows a decrease in fold change in tandem with a decrease in molecular weight 
for haptoglobin. Comparing isoform 1 to isoform 6 there is a ratio difference of 
~2fold. 
 
When running diluted raw serum, as well as examining lung cancer, colon cancer 
and breast cancer were also examined to investigate if the haptoglobin isoform 
pattern was cancer specific. In total forty-eight gels were stained (eight gels each for 
normal, SCC, AD, SCLC, colon cancer and breast cancer), scanned with the 
Typhoon Imaging System, and the isoforms quantified using Progenesis SameSpots 
Software. Table 4.3.1 shows the fold change for each haptoglobin isoform for each 
of the cancer types. The fold change seen from the immunodepleted serum was not 
repeated, with a lot less variance seen between each isoform. For AD for example 
there is a 1.4fold increase for isoform 1 and also a 1.4 fold increase for isoform 6, 
and very little difference (either 1.5 or 1.6 fold) for the other isoforms. SCC does 
show ~2-fold increase from isoform 1 to isoform 6 but shows such identical fold 
changes for isoforms 1-3 that no pattern from isoform of highest MW to lowest 
MW is discernible. The ~2fold increase for SCC isoforms 1-3 do however show 
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good p values so perhaps these three isoforms could be used for treatment 
monitoring of SCC patients.  
The fold changes for each isoform were relatively similar between AD, SCLC, and 
breast and colon cancer. AD and colon cancer for example show almost identical 
fold changes for each of the isoforms. The isoform pattern for these four cancers 
shows no specificity. 
 
There is no correlation between the haptoglobin isoform results from the 2D-DIGE 
immunodepleted serum experiment comparing AD and Normal (Table 4.2.1) and 
the same comparison in the subsequent Coomaisse experiments (Table 4.3.1). One 
explanation for this could be that the immunodepletion column exaggerated the 
results seen in the initial experiments. The adenocarcinoma serum samples may 
have saturated the haptoglobin binding sites in the column resulting in less 
percentage of total haptoglobin being removed in these samples compared to the 
normal samples, which could change a 2-fold increase to a 7-fold increase as seen 
for isoform 1. 
Another reason for such a difference in results could be the use of 2D-DIGE on the 
immunodepleted serum compared to using Coomassie blue to stain the proteins in 
the raw serum. 2D-DIGE uses an internal standard to normalise all gels in an 
experiment. By pooling various samples together, labelling with its own fluorescent 
tag (generally Cy2), and including it in every gel, the DeCyder Software can 
normalise all spots using a Master gel (generally the gel with the most spots). This 
greatly lessens the effect of gel-to-gel variation and means the abundance levels of 
each protein spot in a gel can be taken with confidence. Without an internal 
standard when comparing gels to one another as is the case when using Coomassie 
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stain, it is impossible to know how much of the variance seen can be attributed to 
gel-to-gel variation. 
Despite the disappointing results the use of haptoglobin isoforms as lung cancer 
biomarkers certainly has potential. Using abundance levels of specific haptoglobin 
isoforms could allow for improved classification of lung cancer subtype during 
diagnosis or perhaps as an indicator that tumour bulk is decreasing after treatment. 
Perhaps a different serum/plasma fractionation technique would allow for improved 
Hp isoform detection and result in a more accurate and consistent reading of the 
changes in the individual isoforms in cancer. Overall Hp levels would not be 
specific enough for early detection due to the fact it is a positive acute phase protein 
and its levels are raised in many disease states but evaluating a number of specific 
haptoglobin isoforms could improve specificity.  
Recent studies have indicated a possible correlation between specific haptoglobin 
glycosylation and particular disease conditions and found differentially expressed 
haptoglobin isoforms in sera of SCLC versus normal and sera of prostate cancer 
versus benign prostate or normal subjects (Fujimura, Shinohara et al. 2008, Shah, 
Singh et al. 2010). Haptoglobin ß chain has been put forward as being potentially 
useful as a supportive biomarker for lung cancers (Kang, Sung et al. 2011).  
 
An ELISA was performed in serum for haptoglobin comparing normal to SCC, AD, 
and SCLC (Fig. 4.3.2). Increased levels of Hp in serum has been seen for many 
cancers (Tabassum, Reddy et al. 2012) and it has been suggested that circulating Hp 
levels could be used as a prognostic indicator in patients with epithelial ovarian 
cancer as lower Hp levels in preoperative sera were associated with better survival 
outcome (Seal, Doe et al. 1978, Ye, Cramer et al. 2003, Zhao, Annamalai et al. 
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2007). Our ELISA results were as expected, with Hp increased in the sera of lung 
cancer types SCC, AD, and SCLC compared to normal control serum. All t-test 
scores for normal compared to a particular lung cancer type were all less than 0.01. 
Haptoglobin levels are vastly increased in lung cancer patients compared to normal, 
healthy patients. Measuring overall levels of haptoglobin could be used as a general 
biomarker for treatment/recovery response but lacks the specificity to be an early 
detection marker for a particular cancer due to its raised levels in sera of many 
different cancers and diseases. 
 
9.5 Label-free Mass Spectrometry of ProteoMiner Serum 
 
Unlike immunodepletion, the ProteoMiner method does not simply attempt to 
remove the high abundant proteins but instead tries to equalise all proteins in 
serum/plasma to relatively equal quantities so that no one protein or group of 
proteins in particular can mask the other proteins, while at the same time preventing 
the loss of proteins bound to high abundant proteins as is the case with 
immunodepletion (See Introduction and Materials and Methods). It effectively 
dilutes high abundant proteins while simultaneously concentrating low abundant 
proteins with the goal of making these low abundant proteins easier to detect. 
To analyse the ProteoMiner serum, label-free mass spectrometry was used. Label-
free spectrometry involves measurements of changes in chromatographic ion 
intensity such as peptide peak areas or peak heights, and also spectral counting of 
identified proteins (See Section 1.9.3.3). Shotgun isotope labelling methods label by 
using light and heavy stable isotopes, before combining control and cancer samples 
and analysing by LC-MS/MS, the subsequent quantification calculation based on 
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the intensity ratio of isotope-labelled peptide pairs. However in label-free mass 
spectrometry control and sample are subjected to individual LC-MS/MS analysis 
and quantification is based on the comparison of peak intensity of the same peptide 
or the spectral count of the same protein (Zhu, Smith et al.). 
Progenesis LC-MS software allows statistical analysis of the label-free data and 
generates lists of any conceivable comparisons, providing details on protein 
description, fold change, ANOVA value, confidence scores and number of peptides 
identified (See Section 5.1). 
 
ProteoMiner followed by label-free MS was performed on ten serum samples each 
for the following groups; normal, SCC, AD, and SCLC. Tables were generated for 
seven different comparisons (Table 5.2.1 to Table 5.2.7) and unfortunately there 
were very few novel low abundant proteins identified, the main proteins being 
precursors for high abundant proteins such as plasminogen, haptoglobin, 
apolipoprotein, prothrombin, vitronectin, and fibrinogen, as well as members of the 
albumin family (e.g. afamin) and proteins involved in blood clotting (e.g. 
antithrombin III). In total 111 identifications were made through Mascot, though 
this included many duplicate or similar identifications (e.g. apolipoprotein A, 
apolipoprotein A-IV, apolipoprotein A-V, apolipoprotein B and apolipoprotein L 
were all identified).  
After the conditioned media study in which some of the proteins chosen to be 
validated in serum did not validate at all, showed opposite trends, or vastly different 
fold changes, compared to the 2D-DIGE Decyder analysis results, a different 
approach was decided upon here. Instead of automatically choosing the proteins 
with the highest fold changes, it was decided to use a Pathway Studio tool known as 
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PathwayAssist, which comes with a database of molecular networks automatically 
assembled from scientific abstracts and contains more than 100,000 events of 
regulation, interaction, and modification between proteins, cell processes, and small 
molecules (Nikitin, Egorov et al. 2003). By inputting our list of proteins it was 
hoped some proteins would stand out as being central to a number of pathways, 
perhaps indicating their importance to the development of lung cancer. From the list 
of 111 proteins, only 65 were linked with lung cancer and brought forward to the 
next step. The 65 proteins were examined for any interactions between one another 
and it was found 24 of these proteins had no interactions with any of the other 
proteins, resulting in 41 proteins of interest (Table 5.3.1). PathwayAssist is based on 
the fact that genes (and proteins) do not work alone but behave in an intricate 
network of interactions. A pathway-base approach has been used to identify a 
smoking-associated 6-gene signature of lung cancer risk and survival (Guo and 
Wan 2012). 
 
From the resulting interaction analysis (Fig. 5.3.1) which displayed the relationships 
between the biological molecules, two proteins were identified as ‘hubs’ of 
connectivity. This interaction diagram does not show how these proteins react 
together in a biological system but rather the inter-connection of these proteins 
based on the literature. The two proteins chosen to bring forward for validation 
were kininogen 1 and thrombospondin 1, not only ‘hubs’ of connectivity but they 
also showed reasonable fold change differences in the label-free analysis. For 
example kininogen-1 precursor showed a 3.5 fold increase in normal serum 
compared to lung cancer serum and a 4.4 fold increase in normal compared to AD 
serum, and thrombospondin-1 showed a 2.3 fold increase in normal compared to 
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lung cancer serum. Peptide abundance levels recorded from label-free MS 
identification can be seen for thrombospondin normal versus lung cancer 
comparison (Fig. 5.2.1) and for kininogen-1 normal versus AD comparison (Fig. 
5.2.3). 
An ELISA was performed in serum for both thrombospondin-1 (Fig. 5.3.3) and 
kininogen-1 (Fig. 5.3.4). Both assays were performed on 20 normal, 13 SCC, 18 
AD, and 17 SCLC patient samples. For both ELISAs there was little to no 
difference in the levels of the protein in serum of healthy patients compared to the 
serum of SCC, AD, and SCLC. As regards being potential lung cancer biomarkers 
there is nothing significant or noteworthy about the ELISAs for thrombospondin-1 
and kininogen-1 and here our interest in these two proteins ended. Pathway Studio 
analysis clearly has its benefits but is perhaps not ideal when looking for cancer 
biomarkers that will need subsequent validation in a biological fluid. An importance 
in the progression and/or cause of lung cancer does not automatically translate into 
a good serum marker.  
 
As mentioned already the label-free analysis of ProteoMiner serum threw up over 
one hundred identifications. From this list there are many other proteins that could 
be brought forward to be validated in serum without the need for any further 
analysis (e.g. Pathway Studio). For example heat-shock protein 86 showed a 20-fold 
increase in lung cancer versus normal, s100-A9 showed ~5-fold increase in lung 
cancer versus normal, vimentin showed a large increase (recorded as ‘infinity’) in 
lung cancer versus normal, and histone H4 showed a 8.4-fold increase in AD versus 
normal. 
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It is difficult from these experiments to determine how useful ProteoMiner and 
label-free MS are for the discovery of lung cancer biomarkers as one technique is 
very much dependent on the other. If the ProteoMiner technique does not equalise 
serum protein content and many high abundant proteins still mask the low abundant 
proteins then there is nothing the LC/MS system can do to identify these proteins 
but if the ProteoMiner technique worked then perhaps the label-free MS technique 
was not sensitive enough to identify these proteins. Most likely the high abundant 
proteins in the serum prevented the LC/MS system from identifying the disease-
specific low abundant proteins and although MS instruments are now sensitive 
enough to identify the lowest abundant proteins the proper fractionation of serum 
remains the problem. 
 
9.6 Luminex Multiplex Platform for Lung Cancer Biomarker Discovery 
 
Multiplex platforms allow analyse of multiple analytes using the same serum 
sample. Single-plex ELISAs that examine serum/plasma levels of particular 
proteins are expensive and not only examine one protein at a time but also generally 
use 50-100ul of serum. With a dependency on the hospitals to provide enough 
serum samples in large enough volumes it is beneficial to be able to use small 
amounts of serum for large sets of proteins. For example our initial discovery phase 
on the Luminex system that examined 12 proteins in Cancer Panel 1 (Section 6.1), 
only 5ul of serum was required per sample. For 12 single-plex ELISAs the volume 
required could be as high as 1.2ml per sample, a 240-fold increase. Although the 
Luminex system is expensive, purchasing panels of biomarkers that can be 
examined together in the one experiment will be cost-efficient in the long run. 
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There is however a restriction on the analytes that be examined, based upon 
catalogues from the manufacturer, and only certain biomarkers can be examined 
together in the same panel. In previous experiments the discovery phase was 
performed using a particular proteomic method (e.g. 2D-DIGE, label-free MS) and 
interesting proteins validated in ELISAs, however both the discovery phase and 
validation phase are performed in an identical fashion using the same method, in 
this case utilising the Luminex platform. For discovery phase three panels were 
chosen based on their likelihood to be differentially expressed in cancer (namely 
Cancer Panel 1, Cancer Panel 2, and an MMP panel) and a small selection of lung 
cancer serum samples were ran alongside breast cancer and colon cancer samples 
for a colleague’s discovery phase. 
 
From these panels, a selection of proteins was chosen to be examined in a larger set 
of lung cancer serum samples. Cancer Panel 1 was treated differently. Cancer Panel 
1 consists of six proteins; alpha-fetoprotein, CA 19-9, CEA, CA-125, CA 15-3, and 
prolactin, which are known cancer biomarkers. In particular CA 19-9, CEA, CA-
125, and CA 15-3 are mentioned as possible lung cancer biomarkers (Section 1.5.1) 
but all six markers from Cancer Panel 1 are not specific to lung cancer (Section 
6.4). Due to their use already as cancer biomarkers it was useful to examine the 
levels of each in lung cancer (both serum and plasma) for comparative purposes. 
 
CA 19-9, CEA, CA-125, and CA 15-3 were examined in late-stage lung cancer 
serum and early-stage lung cancer plasma. CA 19-9 levels were increased in late-
stage SCC, AD, and SCLC compared to normal with all three comparisons 
statistically significant, and increased early-stage lung cancer plasma compared to 
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normal plasma. Although levels of CA 19-9 were higher in lung cancer plasma than 
BLD plasma, the comparison was not statistically significant (T-test; 0.29). 
CEA levels in late-stage lung cancer serum were higher in both NSCLC groups 
(SCC and AD) compared to the SCLC group. CEA levels in all three were raised 
compared to normal and although in SCLC this difference was less pronounced the 
T-test score was relatively significant (Normal versus SCLC T-test; 0.06). In early-
stage lung cancer plasma CEA levels were significantly increased in lung cancer 
compared to normal and BLD plasma. Indeed normal and benign showed similar 
levels. 
CA-125 levels in late-stage serum were significantly higher in SCC, AD, and SCLC 
compared to normal, though also higher in both NSCLC types compared to SCLC.  
In early-stage cancer plasma levels of CA-125 are higher in lung cancer compared 
to both normal and BLD. Normal and BLD show very similar levels. 
CA-153 levels are increased in all three lung cancer types compared to normal, 
more so in AD and SCLC than SCC. In plasma, the highest CA-153 levels are in 
early-stage cancer compared to normal and BLD. 
 
From Cancer Panel 2 six proteins were brought forward; epiregulin, heparin-
binding epidermal growth factor, placenta growth factor, transforming growth 
factor alpha (TGF-α), vascular epithelial growth factor (VEGF-α), and tenascin C. 
In total 20 normal, 16 SCC, 21 AD, and 18 SCLC were examined. Epiregulin is a 
member of the epidermal growth factor family and can function as a ligand for 
EGFR. It showed relatively similar levels in normal and each of the lung cancer 
types SCC, AD, and SCLC, and no statistically significant comparisons (Fig. 6.5.1). 
It was not brought forward for further validation.  
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Heparin-binding epidermal growth factor is also a member of the EGF family that 
bind to and activate the EGF receptor and has been reported to be a potential 
serological biomarker for ovarian cancer (Kasai, Kobayashi et al.).  The only 
statistically significant comparison was normal versus AD (Fig. 6.5.2). It was not 
brought forward for further validation.  
Placenta growth factor is a member of the VEGF subfamily and is an important 
molecule in angiogenesis and vasculogenesis, particularly during embryogenesis. 
Interestingly it has been suggested that higher expression of plcenta growth factor in 
tissue can contribute to differences between the progression of SCLC and NSCLC, 
especially in regard to the nature of SCLC metastasis (Woo, Park et al. 2004). 
Though our results showed an increase in lung cancer serum overall there was a 
relatively broad spread of results for all conditions and none of the comparisons 
were statistically significant (Fig. 6.5.3) and this protein was not brought forward 
for further validation.  
TGF-α is closely related to epidermal growth factor (which is known to stimulate 
cell growth, proliferation, and differentiation) and induces epithelial development 
and can bind to the EGF-receptor with similar effects to EGF. One study claims that 
TGF-α expression can not serve as an independent marker for lung cancer (Pecur, 
Kapitanovic et al. 1994) and our results (Fig. 6.5.4) showed it to have similar levels 
in SCC and SCLC compared to normal. TGF-α was not brought forward for further 
validation. 
 
Tenascin C and VEGF- α were the most interesting biomarkers from Cancer Panel 2 
and were further validated in serum and also plasma. They will be discussed in 
detail. 
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The extra-cellular matrix (ECM) is a network of secreted proteins and 
carbohydrates that fills the intercellular spaces, the spaces between cells. It is 
formed by macromolecules secreted locally by cells resident in the matrix, the two 
main classes being polysaccharide glycosaminoglycans and fibrous proteins. It 
helps to bind together and regulate a number of cellular functions such as adhesion, 
migration, proliferation, and differentiation (Teti 1992). The ECM is not an inert 
structure surrounding the cells but varies depending on the cell type; in epithelium 
and muscle tissue for example cells are bound tightly together so the spaces 
between cells containing the ECM are very narrow, whereas in connective tissue the 
ECM is very abundant, with cells distributed sparsely within it. The ability of 
cancer cells to migrate in the vascular stream and to recognise the ECM of a target 
organ plays a vital role in their ability to invade an organ and form metastases (Teti 
1992). Because the ECM provides a microenvironment for cells and its destruction 
is associated with cancer cell invasion, any proteins involved in its make-up become 
possible markers for cancer. 
 
9.6.1 Tenascin C 
Tenascin-C is an extracellular matrix glycoprotein that is expressed upon damage to 
tissue, playing a host of different roles that mediate both inflammatory and fibrotic 
processes that help in effective repair of the damaged tissue (Midwood, Hussenet et 
al. 2011). Low levels of tenascin-C is detected in healthy adult tissues though it is 
known to be re-expressed upon tissue injury, and down-regulated after completion 
of tissue repair (Midwood and Orend 2009). It is expressed in the developing brain, 
cartilage, and mesenchyme and re-expressed in tumours, wound healing, and 
inflammation (Jones and Jones 2000). It also modulates cell migration, proliferation 
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and cellular signalling through induction of pro-inflammatory cytokines and 
oncogenic signalling molecules, and given the causal role of inflammation in the 
progression of cancer perhaps tenascin-C regulates some mechanism common to 
both (Midwood and Orend 2009). One study postulated that a peptide derived from 
tenascin-C, termed TNIIIA2, stimulates cell adhesion to ECM through activation of 
membrane receptor ß1-integrin (regulated activation of integrins is critical for cell 
adhesion, motility and tissue homeostasis (Rantala, Pouwels et al. 2011)) and could 
not only enhance cell proliferation but also induce apoptotic cell death (Iyoda and 
Fukai). 
 
The first assay performed on a full set of serum samples (20 normal, 16 SCC, 21 
AD, and 18 SCLC) showed a significant increase in each of the cancer types 
compared to normal (Fig. 6.5.9). All comparisons of normal versus lung cancer type 
were statistically significant with T-test scores less than 0.01 and average results for 
SCC, AD, and SCLC were either more than double or more than triple those for 
normal serum patients.  
Another assay performed on a full set of serum samples (Fig. 6.5.10) was performed 
on 20 normal, 14 SCC, 21 AD, and 16 SCLC serum samples. The trend of being up 
in all lung cancer types compared to normal was repeated and again all comparisons 
of normal versus lung cancer type were statistically significant with T-test scores 
less than 0.01. The average results in pg/ml were higher than in the first assay (Fig. 
6.5.9) for all groups, which could be attributed to the new sample set (though many 
of the samples overlap with the first assay) but more likely can be attributed to a 
different standard curve and a different run being performed on the Luminex 
instrument. The excellent T-test scores in both assays, as well as results showing 
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similar trends, suggests the multiplex Luminex platform is reasonably consistent in 
its readings. As in the first assay the average results are lower in AD than for the 
other two lung cancer types, however the median values are very similar. The 
minimum and maximum concentrations in AD are also lower than their 
counterparts in SCC and SCLC.  
It can be concluded with certainty than levels of tenascin C are increased in the 
serum of lung cancer patients compared to normal healthy patients. There is 
however a need to perform the assay again using more control groups, in particular 
a benign lung disease control group is essential. Due to the fact it is expressed upon 
damage to tissue it is likely Tenascin C is elevated in serum of other cancers and 
inflammatory diseases but its potential as a lung cancer biomarker is evident from 
these results. 
 
Another assay was performed on a full set of plasma samples (Fig. 6.5.11). The 
plasma samples are from patients with an earlier stage lung cancer to those 
investigated in the serum assays. The groups investigated were categorised as 
normal (n=18), benign lung disease (n=11), and lung cancer (n=35). Though none 
of the comparisons were statistically significant tenascin C is elevated in lung 
cancer compared to normal, however it is also elevated in benign lung disease 
compared to normal though not to the same extent.  
 
Tenascin-C levels in serum has been suggested as a potential predictive marker of 
angiogenesis in NSCLC (Ishiwata, Takahashi et al. 2005), in endobronchial 
epitheilial-lining fluid (ELF) of NSCLC it was upregulated in cancer patients with 
adeoncarcinoma or squamous cell carcinoma (Kahn, Meister et al. 2012), its 
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expression in breast cancer cells has been linked to their ability to metastasise to the 
lungs (Oskarsson, Acharyya et al. 2011), and its degradation could be a reliable 
marker for recurrence potential of stage-1 NSCLC (Cai, Onoda et al. 2002).  
 
9.6.2 Vascular Endothelium Growth Factor alpha (VEGF-α)  
VEGF-α is a 34-42 kDa dimeric, disulfide-bound glycoprotein. The highest levels 
of VEGF-α mRNA are found in adult lung, heart, adrenal gland, and kidney. Lower, 
yet still detectable, levels occur in the liver and spleen. The actions of VEGF are 
known to affect lung development (Gerber, Hillan et al. 1999) and maintenance of 
adult lung structure (Tuder, Petrache et al. 2003).  
VEGF has vascular permeability and endothelial cell growth functions. Its actions 
as a prototypic growth factor for endothelial cells are well known and well 
researched, and its effects on pulmonary endothelial cells are of particular 
importance in the pathobiology of lung diseases (Voelkel, Vandivier et al. 2006). It 
has a strong affect on several functions of endothelial cells, functions relevant to 
lung function and pulmonary vascular properties, such as prostacyclin and nitric 
oxide (NO) synthesis. Endothelial cell NO synthase is activated by VEGF, which in 
turn mediates the proangiogenic and permeability effects of VEGF (Dimmeler and 
Zeiher 1999). VEGF synthesis is stimulated by a wide range of growth factors such 
as transforming growth factor – α and – ß, fibroblast growth factor, insulin growth 
factor-I, keratinocyte growth factor and platelet-derived growth factor (PDGF). The 
strong link between inflammation and angiogenesis is illustrated by the fact 
platelet-activating factor production is stimulated by VEGF (Jackson, Seed et al. 
1997). 
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Three assays with a full set of serum samples were performed on the Luminex 
system for VEGF-α, two for late-stage lung cancer and one for earlier stage lung 
cancer. The two late stage assays showed increases of VEGF-α level in SCC, AD, 
and SCLC compared to normal serum. In all cases the comparisons of cancer type 
versus normal were statistically significant with p values of less than 0.01. In both 
assays the average SCLC result is higher than both NSCLC types but not 
significantly so. The results for the three cancer types vary between the two assays 
but do remain 2-3 times more elevated compared to normal. It can be concluded 
that VEGF-α is consistently higher in lung cancer serum compared to normal. 
 
The other serum assay (Fig. 6.5.7) was performed on earlier stage lung cancer and 
examined a normal group (n=16), an autoimmune group (n=16), a benign lung 
disease group (n=22), and a lung cancer group (n=26). Using a control group with 
only normal, healthy people is not a sufficient comparison for the lung cancer 
group. Lung cancer patients will often go to their doctors due to the presentation of 
symptoms that they would not necessarily associate with lung cancer, and often 
inflammatory diseases and indeed benign lung diseases can present with many of 
the same symptoms. Being able to separate lung cancer patients from those with 
other diseases is essential for initial diagnosis. 
Interestingly VEGF-α is increased in lung cancer compared to all three controls, 
with each comparison being statistically significant. The average results of both the 
autoimmune and benign lung disease group are more than double the normal group, 
however the level in lung cancer is much higher again compared to normal. Due to 
insufficient diagnosis information the lung cancer category can not be divided into 
lung cancer type. It can be concluded that VEGF-α is elevated in patients with 
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early-stage lung cancer compared to healthy patients and also patients with a 
number of disease conditions such as diabetes and benign lung diseases. 
 
High levels of VEGF in lung cancer serum has been associated with poor prognosis 
(Kaya, Ciledag et al. 2004). A novel VEGF receptor antagonist has been shown to 
inhibit LC-6 growth, a human NSCLC cell line (Ueda, Yamagishi et al. 2004). 
Bevacizumab is an angiogenesis inhibitor and slows the growth of new blood 
vessels; it is an antibody to VEGF and its addition to paclitaxel plus carboplatin 
improves survival when compared to chemotherapy alone in patients with untreated 
metastatic non-squamous NSCLC (Subramanian, Morgensztern et al. 2010). High 
serum concentrations of VEGF has been associated with unfavourable survival and 
poor response to treatment with SCLC patients (Salven, Ruotsalainen et al. 1998).  
Another study showed that although VEGF serum levels was strongly associated 
with platelet and leukocyte counts in NSCLC patients it did not correlate with 
prognosis and tumour burden of the patients (Choi, Kim et al. 2001).  
One study used ELISAs to assess the clinical usefulness of circulating angiogenic 
factors as a predictor for tumour angiogenesis in primary lung cancer and found a 
significant increase in VEGF concentrations in both serum and plasma of cancer 
patients compared to the healthy control. This study also showed a strong 
correlation between microvessel density and VEGF levels in plasma, indicating 
plasma VEGF could be a useful indicator of tumour angiogenesis in patients with 
lung cancer (Tamura, Ohta et al. 2001). 
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9.6.3 Matrix Metalloproteinases (MMPs) 
From the MMP panel discovery phase that examined MMP’s -1, -3, -8, -9, -10, and 
-13, the MMP’s -1, -8, and -9 were brought forward for validation in larger samples 
sets. Due to availability of an MMP panel, assays with large sample sets were also 
performed on MMP’s -2 and -7 despite the fact two of these MMP’s (2 and 7) were 
not in the discovery phase and on MMP-10 despite the fact it was not initially 
brought forward from the discovery phase. 
 
As a group MMPs degrade all protein components of tissue extracellular matrices 
and basement membranes. They form a family of 23 endopeptidases which can be 
subdivided into five groups depending on their domain structure and substrate 
specificity; collagenases, gelatinases, stromelysins, matrilysins and membrane-type 
MMPs, and are known to participate in various physiological and pathological 
processes such as embryonic development, wound healing, arthritis, atherosclerosis 
and tumour progression (Decock, Thirkettle et al.). In general, the structure of the 
MMPs includes a signal peptide, a propeptide domain, a catalytic domain, and a 
zinc-binding motif.  
MMPs are involved in cell signalling and are capable of activating specific cell 
receptors and growth factors or liberating them from the extracellular matrix, 
thereby regulating various cell behaviours such as cell growth, differentiation, 
apoptosis, and migration (Overall and Lopez-Otin 2002, Hojilla, Wood et al. 2008). 
They are secreted as inactive zymogens (inactive enzyme precursors) and are 
converted into active enzymes by specific proteolytic cleavages on the cell surface 
or in the pericellular environment (area around the cell), providing spatial control of 
their function.  They are inhibited by their endogenous inhibitors, the tissue 
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inhibitors of MMPs (TIMPs), which have four family members in humans with 
characteristic expression patterns and properties (Baker, Edwards et al. 2002). 
 
MMPs are known to have roles in the late stage of tumour progression, invasion, 
and metastasis, and there is increasing evidence that they are also involved in earlier 
tumourigenesis such as in malignant transformation, angiogenesis, and tumour 
growth both at the primary and metastatic sites (Hua, Li et al.). Interactions between 
malignant and surrounding stromal cells (fibroblasts, endothelial cells, and 
inflammatory cell) may establish an environment in which tumour cells grow and 
metastasise and also the extracellular matrix (ECM) has a strong impact on tumour 
progression, the major components of which include structural proteins such as 
fibrillin, fibronectin, and laminin, as well as proteoglycans (Stetler-Stevenson, 
Aznavoorian et al. 1993). 
Due to their critical roles in inflammation and tumourigenesis, MMPs appear to be 
ideal drug targets, the development of MMP inhibitors seen as being very attractive 
(Hu, Van den Steen et al. 2007), but although many have shown promising effects 
in preclinical studies, the results from clinical trials with these agents appear to be 
disappointing in cancer treatment (Hua, Li et al.). 
MMP-1 and MMP-8 are collagenases, enzymes that break down collagen, the main 
component of connective tissue. MMP-9 is a gelatinase, enzymes that break down 
gelatine, a mixture of proteins and peptides produced by the hydrolysis of collagen. 
Increased expression of certain MMPs has been observed in many cancers, this 
over-expression often associated with poor survival (Egeblad and Werb 2002). 
Increased MMP-1 expression for example has been associated with the incidence or 
invasiveness of various types of cancer, including colorectal, esophageal, 
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pancreatic, gastric, breast, and malignant melanoma (Liu, Kato et al.). Also MMP-1 
expression in atypical ductal hyperplastic tissues may serve as a marker for 
predicting which patients will develop invasive breast cancer (Poola, DeWitty et al. 
2005). Elevated serum levels of MMP-8 in colorectal cancer (CRC) patients has 
suggested a role for MMP-8 in the course and progression of this cancer (Vayrynen, 
Vornanen et al.). In one study MMP-9 expression increased in lung cancer with 
tumour size and its expression was significantly higher in NSCLC cases with 
metastasis compared to those without metastasis, and also in lymph node metastasis 
compared to primary lesions, showing MMP-9 may play an important role in 
tumour growth and metastasis of NSCLC (Zheng, Chang et al. 2010). 
 
The three most interesting MMP’s were -1, -8, and -9 and further assays were 
performed on these three proteins. 
 
9.6.3.1 MMP-1 
In the first serum assay (Fig. 6.6.1) performed on MMP-1 normal (n=20) was 
compared to SCC (n=16), AD (n=21), and SCLC (n=18). The cancer samples were 
late-stage. There was a notable increase in the NSCLC types compared to normal, 
whereas in SCLC the levels were similar to the control. Both SCC and AD 
comparisons with normal were statistically significant. Concentrations of MMP-1 in 
normal and SCLC were 3.2ng/ml and 4.6ng/ml respectively, however in SCC and 
AD the levels were far higher, 11.2ng/ml and 8.9ng/ml respectively. Results for 
NSCLC were very different from SCLC, with this comparison showing a t-test 
score of 0.0357. 
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In the second serum assay (Fig. 6.6.2) again there was a large increase in the levels 
of MMP-1 in the NSCLC types SCC and AD compared to both normal and SCLC 
groups. In serum MMP-1 appears to be highly elevated in NSCLC but only slightly 
elevated in SCLC. A lung cancer marker takes on added significance if it can make 
a diagnosis between NSCLC and SCLC as their treatment method varies. For this 
assay the t-test score for NSCLC versus SCLC was 0.0377, indicating a result for 
this assay could be assigned as NSCLC or SCLC with a strong degree of 
confidence. This t-test score was very similar to that in the first MMP-1 serum 
assay for NSCLC versus SCLC. Again the comparisons of normal versus both SCC 
and AD are statistically significant with T-test scores less than 0.01.  
 
A serum assay was performed in earlier stage lung cancer and compared to three 
controls; normal, autoimmune, and benign lung disease (Fig. 6.6.3). The earlier-
stage lung cancer samples are not separated into NSCLC and SCLC due to lack of 
clinical data. MMP-1 is elevated in lung cancer compared to normal yet again but 
the difference is not as pronounced as seen in the late-stage cancer comparison. The 
autoimmune group showed similar levels to the normal group; however the benign 
lung disease group had MMP-levels similar to the lung cancer group. Often serum 
assays only compare normal to cancer and if this was the case here the result would 
appear to be more significant than it is. With the addition of a benign lung disease 
control group it gives a more accurate overview of the usefulness of MMP-1 levels 
as a biomarker for lung cancer. The average for benign lung disease and lung cancer 
were notably higher than the normal and autoimmune groups, however the box and 
whisker plot shows this difference is somewhat exaggerated by a few high results as 
the median values show, e.g. median for autoimmune is 11.6ng/ml and for benign 
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lung disease it is 14.9ng/ml. Many symptoms of benign lung disease are similar to 
symptoms of early onset of lung cancer; so because MMP-1 serum levels could not 
make a distinction between lung cancer and lung diseases it is more likely to be a 
marker of inflammation. A marker of general lung inflammation is no good for 
early detection of lung cancer.  
 
Interestingly, when MMP-1 levels were investigated in plasma for earlier-stage lung 
cancer a different trend was seen (Fig. 6.6.4). The plasma assay compared normal, 
benign lung disease, and lung cancer. The levels of MMP-1 in plasma were 
increased in normal plasma compared to both benign lung disease and lung cancer. 
Indeed these comparisons were also statistically significant. Levels of MMP-1 
benign lung disease and lung cancer were relatively similar and dramatically lower 
than those seen in normal plasma. Indeed the concentrations in plasma (though 
subject to variability when using a new kit and a performing a different run on the 
Luminex system) are far lower than those in serum, e.g. MMP-1 levels in normal 
serum in Fig. 6.6.3 is 12.9ng/ml but levels in normal plasma are only 0.36ng/ml. 
Serum and plasma clearly having varying protein/biomarker content and must be 
treated as two distinct biological fluids for biomarker discovery until both are 
examined for the levels of a biomarker of choice. The differences between serum 
and plasma will be discussed in greater detail later.  
 
9.6.3.2 MMP-9 
MMP-9 was validated in two serum assays and one plasma assay using a full set of 
samples. In the first serum assay (Fig. 6.6.5) MMP-9 is elevated in all cancer types 
compared to normal, the comparisons all statistically significant. Unlike the levels 
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of MMP-1 there is little difference between small cell and the two NSCLC types. 
There is such a big difference between the results for the cancers compared to 
normal that the minimum results for the cancer are the same as or higher than the 
median value for the normal e.g. minimum values for SCC, AD, and SCLC are 
32.6ng/ml, 51.9ng/ml, and 61.6ng/ml respectively, and the median value for normal 
is only 33ng/ml. 
In the second serum assay (Fig. 6.6.6) there is a dramatic increase in MMP-9 levels 
in the cancer types compared to normal again, and though not as pronounced as in 
the first serum assay (Fig. 6.6.5) the comparisons are still statistically significant. It 
is increased in NSCLC and SCLC, though again it is slightly up in the SCLC group. 
It can be concluded that in late-stage lung cancer serum MMP-9 is significantly 
elevated in lung cancer serum compared to normal serum. MMP-9 was not 
examined using an autoimmune or a benign lung disease control group so before 
any further conclusions can be drawn it would need to be repeated in an assay 
including more control groups, the benign lung disease group in particular.  
 
MMP-9 was also examined in plasma samples (Fig. 6.6.7) in earlier stage lung 
cancer. It was decreased in lung cancer compared to normal, as was MMP-1; 
however it was also decreased in lung compared to benign lung disease too. Levels 
in normal and benign were relatively similar and double that of lung cancer. The 
normal versus lung cancer comparison was statistically significant and even the 
benign lung disease versus lung cancer comparison showed a significant T-Test of 
0.08. An MMP-9 assay was not performed in serum for early-stage lung cancer but 
comparing the levels in the normal it can be seen that, as was the case with the 
MMP-1 assays, the level of MMP-9 in plasma is lower than the levels in serum as 
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can be seen with the normal control. MMP-9 in plasma can be considered a better 
biomarker than MMP-1 in plasma due to the fact levels in lung cancer differ to 
those in the benign lung disease group. 
 
9.6.3.3 MMP-8 
MMP-8 validation was not performed in an assay on the Luminex system but in a 
single-plex commercial ELISA, performed on normal, SCC, AD, and SCLC serum 
(Fig. 6.6.8). There is a significant increase in levels of MMP-8 in cancer serum 
compared to normal. Interestingly there was very little overlap in any of results 
from normal with those in any of the cancers; indeed the maximum value in normal 
was 4ng/ml which wasn’t much higher than the minimum value in SCC (1.3ng/ml), 
AD (2.1ng/ml), and SCLC (3.7ng/ml). It can be concluded that MMP-8 levels in 
lung cancer serum far exceed those in normal serum. 
With the results showing such large variance in cancer serum compared to normal a 
ROC curve analysis was performed for the MMP-8 ELISA results for normal versus 
lung cancer serum (Fig. 6.6.9). With sensitivity of 94.1% and specificity of 90.9% 
and an AUC value of 0.981 it further emphasises the disparity between MMP-8 
levels in normal serum compared to lung cancer serum. Though MMP-8 shows 
potential as a lung cancer biomarker, again further assays are required that will 
include more control groups and also examine it in plasma. 
 
The final three MMP serum assays will be examined together; those of MMP-2 
(Fig. 6.6.10), MMP-7 (Fig. 6.6.11), and MMP-10 (Fig. 6.6.12). MMP-2 levels in 
lung cancer are more similar to those in normal serum than are the autoimmune and 
benign lung disease group and for the MMP-10 assay the average levels are very 
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similar for normal, autoimmune, and lung cancer. The most statistically significant 
comparison is normal versus benign lung disease so it would appear from this assay 
that MMP-10 has more potential as an inflammatory marker than a lung cancer 
marker. MMP-7 showed similar levels in lung cancer serum and serum of benign 
lung disease both of which showed statistically higher levels compared to both the 
normal and autoimmune groups. MMP-7 showed greater potential as a lung cancer 
marker than either MMP-2 or MMP-10. 
 
9.6.4  Biomarker Panel from Luminex Multiplex Platform 
The Luminex system proved to be an effective method for biomarker discovery. It 
is simple to run and uses very little serum/plasma compared to commercial ELISAs. 
In assays that were repeated using many of the same samples the results were 
relatively consistent and the highly significant T-Test scores for the comparisons 
that showed variance indicates a consistency in the systems reading of the beads. By 
expanding the number of proteins available in their library for detection there is no 
reason this system will not remain relevant for years to come. It also has the added 
benefit of allowing discovery phase and validation phase to be performed in 
serum/plasma on the same system using the same method. By using serum/plasma 
in the initial discovery phase it can be determined straight away if your protein of 
interest is even detectable in these biological fluids and saves time and money on 
validation. 
 
As already mentioned Cancer Panel 1 includes many biomarkers already in clinical 
use. Though they are not specific for lung cancer they are often used in lung cancer 
and are a useful comparison for the new biomarkers. Excluding AFP, Cancer Panel 
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1 validated in serum reasonably effectively. CEA for example (Fig. 6.4.4) showed 
higher levels in NSCLC (AD in particular) compared to normal and SCLC and also 
showed statistically higher levels in lung cancer plasma compared to both normal 
and benign lung disease plasma (Fig. 6.4.5). CA-125 also showed higher levels in 
cancer serum compared to normal, with higher levels in NSCLC than SCLC, and 
also validated well in plasma showing an increase in lung cancer compared to both 
control groups (benign lung disease group versus lung cancer had a T-Test of 0.07). 
 
By performing logistic regression analysis on panels of three biomarkers from the 
Luminex results it was investigated in both serum and plasma if a combination of 
any three proteins would show improved sensitivity and/or specificity over a panel 
of three biomarkers from Cancer Panel 1. The logistic analysis combines the 
sensitivity and specificity results to give a percentage based on the classification of 
correct cases identified overall. For both serum and plasma the combination was 
examined for the known markers from Cancer Panel 1 and then any number of 
combinations (including those from Cancer Panel 1 and at least one from Cancer 
Panel 2 or the MMP panel) and the best comparisons are shown in Fig. 6.7.1 for 
serum and Fig. 6.7.2 for plasma. Only matching samples for the three biomarkers in 
each combination are used for calculating results. 
 
Interestingly it was found that a better combination of biomarkers in both serum and 
plasma included at least two not found in Cancer Panel 1. In fact in serum the best 
combination was for three biomarkers outside this panel. In serum a combination 
from Cancer Panel 1 of CA-125, CA 19-9, and CEA from a sample set of 76 could 
correctly predict 86.84% of cases with an AUC of 0.962 (Fig. 6.7.1 A), whereas a 
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combination of MMP-1, MMP-9, and tenascin C from a sample set of 64 could 
correctly predict 96.87% of cases with an AUC of 0.992 (Fig. 6.7.1 B) 
The best combination in plasma included one from Cancer Panel 1 and two from 
outside it; CA-125, CA 19-9, and CEA from a sample set of 52 could predict 
80.77% of cases with an AUC of 0.887 (Fig. 6.7.2 A), whereas a combination of 
MMP-1, CA-125, and Tenascin C from a sample set of 53 could predict 88.68% of 
cases with an AUC of 0.932 (Fig. 6.7.2 B). 
 
9.7 Metabolomic Serum Profiling for Lung Cancer Biomarker Discovery 
 
As the metabolism of cancer cells is different from that of normal cells it is not 
surprising that metabolites themselves can be biomarkers of lung cancer. 
Metabolites are intermediates and products of metabolism and are often involved 
cell growth, development, and reproduction (See Sections 1.10 and 7.1). There are 
many assays available to quantify metabolites in biological fluids. The study of 
metabolites in these biological fluids involves a quite technical discovery phase. A 
diagnostic company called Metabolon provides a service that globally analyses 
complex biological samples for the discovery of metabolic markers.  
From the resulting discovery phase performed on eight samples of normal, SCC, 
AD, and SCLC serum that produced over 300 metabolites of interest a number of 
the most interesting were brought forward for validation in larger serum and/or 
plasma sets. These metabolites were 12-HETE, phenylalanine, glutamate, and 
aspartate (See Figures 7.2.1 and 7.2.2 for Metabolon results).  
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9.7.1  12-HETE 
12-HETE was examined in serum in three assays, two for late-stage and one for 
earlier stage lung cancer, and in plasma in one assay.  
The lipoxygenase (LOX) pathway leads to the formation of leukotrienes and also 
catalyses the conversion of arachidonic acid (AA) to hydroperoxyeicosatetraenoic 
acids that are then reduced to hydroxyeicosatetraenoic acids (HETE) by glutathione 
peroxidase. Arachidonic acid is a polyunsaturated fatty acid regarded as structural 
components of cell membranes whose main function is to regulate membrane 
permeability. There are four mammalian LOXs that produce 5-, 8-, 12- and 15-
HETE, respectively (5-LOX produces 5-HETE, 12-LOX produces 12-HETE etc), 
12-HETE being generated when cytochrome P-450 isozymes metabolise AA by bis-
allylic oxidation (lipoxygenase-like reaction). The production of LOX metabolites 
has been observed in several tissues and cells, including epithelial cells, vascular 
smooth muscle cells, endothelial cells, monocytes and leukocytes. HETEs have 
important physiological and pathological functions that modulate ion transport, 
renal and pulmonary functions, vascular tone and reactivity, and inflammatory and 
growth responses. HETEs have also been observed to have a role in apoptosis, 
angiogenesis, and the proliferation and metastasis of cancer cells (Moreno 2009). 
12(S)-HETE is the predominant enantiomer and is mainly produced by platelets and 
leukocytes. 
 
Platelets metabolise AA through the lipoxygenase pathway producing 12(S)-HETE 
(Moncada and Higgs 1986). After intravasation, tumour cells interact with platelets 
and induce platelet aggregation and also synthesis of platelet 12(S)-HETE, 
indicating platelets can be a contributor of 12(S)-HETE to facilitate tumour cell 
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interaction with endothelial cells and subendothelial matrix. It has been previously 
shown that exogenous 12(S)-HETE increases tumour cell adhesion to endothelium, 
induces large vessel and mircovessel endothelial retraction, and stimulates tumour 
cell spreading on matrix (Chen, Duniec et al. 1994). Pretreatment of tumour cells 
with exogenous 12(S)-HETE enhances their adhesion to and spreading on 
fibronectin, which is mediated exclusively by integrin αIIbß3 receptors and in a 
cytoskeleton-dependent manner (Timar, Chen et al. 1992), and this pretreatment 
also stimulates tumour cell motility and release of cathepsin B, a proteinase linked 
to tumour cell invasiveness (Chen, Duniec et al. 1994). 
 
The first 12-HETE serum ELISA (Fig. 7.3.1) showed 12-HETE to be significantly 
increased in SCC, AD, and SCLC compared to normal. All these comparisons were 
statistically significant; indeed the T-test for normal versus AD was 0.00000218. 
There was a large spread of results in each of the lung cancer types; for example 
minimum and maximum values for SCC, AD, and SCLC were respectively 1.2ngml 
and 1867ng/ml, 8.6ng/ml and 1485ng/ml, and 3.1ng/ml and 1214ng/ml, however 
the maximum concentration in normal serum was only 15ng/ml. ROC Curve 
analysis of these results showed high sensitivity and specificity for the comparison 
of normal versus lung cancer, 86.7% and 88.9% respectively, and a high AUC value 
of 0.927. As a marker for lung cancer the potential of 12-HETE was clear. 
Another ELISA was performed in late-stage cancer serum (Fig. 7.3.3) and again a 
clear trend is present. 12-HETE is elevated in SCC, AD, and SCLC significantly 
compared to normal serum. In this assay 12-HETE was highly elevated in a few of 
the normal samples but the median value is a good indicator of how the results lie 
overall and median values for normal, SCC, AD, and SCLC were 2.3ng/ml, 
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311ng/ml, 119ng/ml, and 261ng/ml respectively, indicating big differences in the 
spread of results. Indeed the minimum values for each of the cancer types were 
significantly greater than the median of normal. All cancers compared to normal are 
statistically significant. 
 
The third serum ELISA (Fig. 7.3.4) was performed in early-stage lung cancer and 
included an autoimmune and a benign lung disease control as well as the normal 
control group. Interestingly the levels of 12-HETE in earlier stage lung cancer is far 
lower than those in the normal control. The average in normal serum is 241ng/ml 
(similar level is seen in autoimmune controls) and in lung cancer it is 67ng/ml. The 
benign lung cancer group shows lower levels than the other two controls but higher 
than lung cancer. Although not directly comparable it is interesting to note that 
average 12-HETE serum levels in the two assays in serum of late-stage lung cancer 
are very high compared to early-stage. 12-HETE therefore shows potential as a 
marker for lung cancer staging and also for lung cancer treatment monitoring.  
 
In plasma (Fig. 7.3.5) 12-HETE levels are significantly lower in lung cancer plasma 
and also benign lung disease plasma compared to normal plasma. As this was 
performed in early-stage lung cancer it makes sense to compare these results to Fig. 
7.3.4 as this serum assay was performed in early-stage lung cancer too. The average 
benign lung disease result of 21.5ng/ml is similar to the lung cancer average of 
16.2ng/ml, both being significantly lower than average of 361ng/ml in normal 
plasma. The difference between early-stage cancer serum and normal serum is not 
as big. Ideally an ELISA would be performed in plasma of late-stage lung cancer 
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patients to see if the difference shown in late-stage and earlier stage cancer serum 
transfers to plasma too.  
 
9.7.2  Phenylalanine 
A serum assay and a plasma assay were performed on phenylalanine. Phenylalanine 
is the precursor of tyrosine, an important amino acid for the biosynthesis of 
neurotransmitters like L-DOPA (L-3,4-dihydroxyphenylalanine) and 
catecholamines dopamine, epinephrine, and norepinephrine. Catecholamines are 
hormones produced by the adrenal glands, found on top of the kidneys, and are 
released into blood during times of physical or emotional stress. For enzymatic 
hydroxylation of phenylalanine to tyrosine by phenylalanine-4-hydroxylase (PAH), 
the cofactor 5,6,7,8-tetrahydrobiopterin (BH4), the reduced form of biopterin, is 
needed as a hydrogen donator (Shintaku 2002). Levels of phenylalanine in the 
blood are increased in consuming diseases such as HIV-1 infection, trauma, sepsis, 
burn, and malignancy, and though this increase is unexplained the clinical 
conditions mentioned are known to be linked with inflammation and immune 
activation and with increased concentrations of immune activation markers such as 
serum soluble 74kDa tumour necrosis factor-α (sTNF-R75) and neopterin 
(Neurauter, Grahmann et al. 2008). Subnormal enzymatic conversion of 
phenylalanine by PAH might explain the accumulation of phenylalanine in patients 
(Shintaku 2002). 
 
In parallel to neopterin and sTNF-R75 formation, macrophages and other cells 
stimulated with IFN-γ produce reactive oxygen species (ROS) at a high rate, which 
may wipe out antioxidant defence systems and therefore help in oxidative stress 
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development. BH4 is very sensitive to oxidation so if BH4 is destroyed the 
conversion rate of phenylalanine to tyrosine by PAH is reduced, which is reflected 
by an increased phenylalanine to tyrosine ratio (phe/tyr) (Widner, Fuchs et al. 
2001). Oxidative stress due to chronic immune activation and inflammation 
therefore could be involved in the increase of serum phenylalanine concentrations 
in patients, and a correlation between phe/tyr and neopterin concentrations in 
patients with multiple traumas has been described (Ploder, Neurauter et al. 2008).  
Depressive mood disorders may develop in cancer patients with increased 
phenylalanine concentrations, maybe due to an impaired hydroxylation of 
phenylalanine (Hoekstra, van den Broek et al. 2001). One study showed correlations 
between increased sTNF-R75 and neopterin concentrations, and phenylalanine, 
phe/tyr, and 8-isoprostane in patients with ovarian cancer (Neurauter, Grahmann et 
al. 2008). 
 
The serum assay for phenylalanine was performed in late-stage lung cancer (Fig. 
7.3.8). Levels of phenylalanine are decreased in NSCLC compared to both normal 
serum and SCLC serum. Interestingly the comparison of normal versus NSCLC and 
NSCLC versus SCLC are statistically significant. This shows potential of 
phenylalanine as a marker to distinguish NSCLC from SCLC and a ROC curve 
performed for NSCLC versus SCLC (Fig. 7.3.9) showing a sensitivity of 73.7% and 
specificity of 65.0% with an AUC of 0.886. This shows phenylalanine may be 
useful for distinguishing patients with NSCLC and those with SCLC. 
The plasma assay (Fig. 7.3.10) was performed in earlier stage lung cancer and 
compared to benign lung disease and normal plasma. Normal versus benign lung 
disease and normal versus lung cancer results were statistically significant. Average 
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concentration for normal, benign lung disease, and lung cancer were 155pmol/ul, 
112pmol/ul, and 122pmol/ul respectively. When lung cancer plasma is divided into 
NSCLC and SCLC the average results were 128pmol/ul for eighty-nine NSCLC 
samples and 118pmol/ul for only fourteen SCLC (data not shown), and though 
different to that seen in late-stage lung serum there are too many variables for a 
trustworthy comparison. In the serum assay there were forty NSCLC versus sixteen 
SCLC. It is difficult to compare serum and plasma in this instant as the number of 
samples is different and the stage of lung cancer is different. The most interesting 
result is that in serum of late-stage lung cancer levels of phenylalanine has potential 
to differentiate between NSCLC and SCLC.  
 
9.8 Aushon Multiplex Immunoassay Platform For Lung Cancer 
Biomarker Discovery 
 
The Aushon Cira immunoassay platform can be using for multiplex analysis of up 
to 12 analytes of interest. Unlike the bead based system where the user mixes and 
adds the beads before addition to plate, the analytes of interest are pre-spotted on 
the array. Our discovery phase examined nine chemokines; low-molecular weight 
type of cytokine classified by their ability to induce chemotaxis or chemokinesis. 
Cytokines are regulatory proteins released by cells of the immune system where 
they act as intercellular mediators for the generation of an immune response. 
Chemokines stimulate angiogenesis and tumour growth by recruiting tumour-
associated macrophages. 
A single discovery phase was performed using normal and SCLC serum samples 
only. Nine samples of each were used for comparison. No further validation was 
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performed though some of the chemokines showed potential as SCLC biomarkers. 
The results are in Section 8.2. 
 
MIP1a and MCP1 showed increased levels in SCLC compared to normal yet the 
results were not statistically significant (p value of 0.08 and 0.07 respectively). 
Considering the small sample set used however, these results are of potential 
interest. Both of these chemokines are involved in the inflammatory response.  
MIP1b, TARC, Eotaxin, and IL-8 showed increased levels in SCLC compared to 
normal, the comparisons all statistically significant. The roles of four chemokines 
are explained in Section 8.1. Of the nine chemokines examined only three showed 
no potential as potential SCLC markers. 
 
As this was only discovery phase using small sample sets for one control and one 
lung cancer type there is little to be said about the six interesting chemokines other 
than they show some potential as SCLC serum markers. A large sample set 
comparing normal, benign lung disease, SCC, AD, and SCLC is required for each 
of the six potential markers before any conclusions can be drawn. The Aushon 
system worked extremely well; used very little sample, was easy to use, and was 
fast and reliable. As an alternative multiplex platform to Luminex it shows potential 
and with a large catalogue of human analytes e.g. angiogenesis factors, chemokines, 
cytokines, growth factors, and MMPs, it is a very useful platform for biomarker 
discovery in serum. 
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CONCLUSIONS 
 
1. hnRNPA2B1 is a possible lung cancer biomarker in tissue and serum/plasma 
and has a role in invasion and migration of lung cancer cells. 
 
2. Pyruvate kinase M2, Hsc70-interacting protein, tenascin C, VEGF-α, MMP-1, 
MMP-8, MMP-9, 12-HETE, and phenylalanine show potential as lung cancer 
biomarkers. 
 
3. Haptoglobin isoforms have potential to differentiate lung cancer from healthy 
patients.  
 
4. A good biomarker in serum does not necessarily make a good biomarker in 
plasma. 
 
5. For lung cancer biomarker validation a benign lung disease control group is 
essential. 
 
6. Intensive validation of candidate biomarkers is essential before conclusions on 
its validity as a biomarker can be made. 
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FUTURE WORK 
 
1. To examine interesting biomarkers in late-stage and early-stage lung cancer 
samples (both serum and plasma) on the same array. 
 
2. To validate more proteins from the discovery phases in serum and plasma in a 
larger cohort of patients. 
 
3. To compare the proteome of patients who responded favourably, and those 
who did not, to drug treatment. 
 
4. To perform an ELISA on Hsc70-interacting protein in plasma samples. 
 
5. To perform siRNA knockdown of hnRNPA2B1 in more lung cancer cell lines. 
 
6. To perform siRNA knockdown of other candidate biomarkers in lung cancer 
cell lines to examine their effect on migration and invasion of lung cancer. 
 
7. To perform assays on interesting chemokines from Auschon multiplex 
experiments on non-small cell lung cancer samples as well as benign lung 
disease samples. 
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Figure A1: Mass Spectrometry Identifications for Conditioned Media 2D-DIGE Experiments: MALDI TOF/TOF data shows protein 
score (> 60 is a score of high confidence), peptide count, and protein score (% chance of a correct identification). MALDI TOF data 
shows percentage of sequence covered and confidence score (with 0 showing the highest degree of confidence). 
 
 
 
 416
 
 
 
 
 
 
Figure A2: Mass Spectrometry Identifications for 2D-DIGE Analysis of Immunodepleted Serum Experiments: MALDI TOF/TOF 
data shows protein score (> 60 is a score of high confidence), peptide count, and protein score (% chance of a correct identification). 
 
